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Improved surgical trial design and conduct is sought both to enhance the 
likelihood of main trial success and to reduce research waste. Surgical trials face 
unique and complex challenges that often hinder and obstruct their successful 
completion. Pilot and feasibility studies (PFS) are increasingly acknowledged as a 
methodological solution by presenting an opportunity to explore and address 
uncertainties around conducting a future main trial. Little research, however, has 
explored the optimal design, conduct and necessity of PFS for surgical trials. This 
work sought to provide a detailed understanding of the potential for PFS to 
optimise future surgical trials and provide clear recommendations for surgeons 
and study teams. 
The thesis comprises three phases of work: a targeted review and systematic 
analysis of NIHR funded surgical PFS protocols; a qualitative interview study 
exploring the perceptions, views and experiences of key stakeholders involved in 
designing and conducting surgical PFS and; a synthesis and interpretation of 
findings from the first two phases, to produce recommendations for the 
optimisation of PFS in surgery. 
The findings indicate a cyclical model of sub-optimisation, in which 
misunderstanding leads to sub-optimal design, conduct, reporting and 
consequent devaluation of PFS amongst the surgical research community. 
Confounding factors further preventing optimisation include cultural challenges 
historically inherent to the surgical community, and a lack of targeted and 
accessible guidance. 
A set of recommendations have been produced for all key stakeholders for 
optimising the design and conduct of PFS to inform main trials in surgery. To 
operationalise and apply these recommendations, a brief set of practical top tips 
have also been developed targeted specifically at surgeons involved in designing 
and conducting surgical PFS. A key recommendation includes a proposal to 
develop and seek endorsement for formal, consensus-based accessible guidance 
for surgeons on the design and conduct of surgical PFS. Additional 
recommendations focus on improving cross-disciplinary collaboration within the 
surgical trials community, the reporting and dissemination of PFS, and the 
research funding infrastructure. Future implementation of these 
recommendations will enhance the quality of definitive surgical trials, strengthen 
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Why it is necessary to optimise 
surgical trials  
1.1 Introduction 
This chapter will describe the historical development of surgical trials and why 
they need to be optimised. The multiple challenges specifically facing surgical 
trials will be discussed and explained including those in relation to recruitment, 
surgical interventions, outcomes and surgical culture. Some identified solutions 
to these challenges will also be discussed, and pilot and feasibility studies 
presented as one such potentially important solution for optimising future 
surgical trials. 
1.2 The importance of evidence to inform health 
policy and change clinical practice 
Clinical decision-making, health policy and best clinical practice guidelines are 
informed by evidence from research. Evidence based medicine was first 
introduced as a concept in the early 1990’s when clinicians began to evaluate the 
evidence from clinical research to inform the practice and treatment of patients, 
rather than relying on experience and theory taught from basic science principles 
alone 1. To assist clinicians with this new way of practising, hierarchical 
pyramids of evidence were described based on study design (Figure 1a). These 
range from expert opinion and case series as the weakest forms of evidence at the 
bottom of the pyramid, to randomised controlled trials (RCTs), systematic 
reviews and meta-analyses, as the strongest forms of evidence at the top. Whilst 
such systems are helpful, they can also be misleading.  
 2 
  
Figure 1a The evidence pyramid. 
 
Systematic reviews and meta-analyses are only as good as the studies they 
include: if you put poor quality evidence in, you get poor quality evidence out.  
Therefore, the evidence from a large pragmatic RCT may be less biased 
(internally valid), and more generalisable (externally valid), than a meta-analysis 
of multiple small, underpowered poorly designed RCTs. This has led others to 
challenge the traditional pyramidal hierarchy of evidence, most recently by 
suggesting that systematic reviews and meta analyses are a lens through which 
other forms of evidence should be viewed 2. Others have suggested that evidence 
based medicine is ‘in crisis’ 3, and has perhaps been misinterpreted to result in a 
plethora of guidelines and protocols which are too restrictive on real world 
practice. Consequently, it is advocated that a return to patient centred shared 
decision making is needed. To acquire more valuable and relevant evidence to 










that are important to patients and clinicians are vital. However, RCTs can be 
difficult, time consuming and expensive to perform. 
Improved trial design, conduct and evaluation is sought to enhance the 
likelihood of main trial success, therefore avoiding trial failure and reducing 
research waste. When trials fail, it is a significant waste of time, effort and 
resources. Trial failure can also result in loss of morale and momentum within 
research teams and even disappointment from patients that their involvement 
has not been worthwhile. Improved trials will generate the best evidence to 
inform practice and improve outcomes for patients in the future. Trials in 
surgery, however, face unique challenges not encountered in trials in other 
clinical areas, and therefore need special consideration. 
1.3 Challenges and some solutions in designing 
and conducting surgical trials 
 
“…I should like to shame [surgeons] out of the comic opera performances which they 
suppose are statistics of operations.”  
Major Greenwood, 1923 4. 
 
“…moving from slapstick to symphonies, and it’s symphonies that we are after today.”  
Jane Blazeby, 2016 5. 
 
It is more than 20 years since Richard Horton published his commentary in the 
Lancet on poor quality of surgical research in general, the lack of RCTs and a 
preponderance to case series as evidence for efficacy 4.  In this commentary, some 
challenges to conducting RCTs in surgery were identified. Those challenges 
identified include the potential difficulties of multicentre collaborative research, 
complexities in the standardisation of surgical techniques and the difficulties of 
selecting appropriate study outcomes and acceptable study designs. The surgical 
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community replied vociferously in their own defence 6, and in doing so, perhaps 
overlooked these valuable insights as to why surgical research was indeed 
challenging.  
A decade on, a group of methodologists and surgeons met and formed the Balliol 
Collaboration, through taking part in three conferences concerning surgical 
innovation and evaluation at Balliol College, Oxford University. In 2009, the 
Balliol Collaboration published three seminal papers in The Lancet 7-9 describing 
the process of surgical innovation (termed the IDEAL paradigm or framework) 7, 
the challenges facing the evaluation of surgical innovation 8 and 
recommendations for the design and conduct of future surgical research 9. The 
IDEAL recommendations propose different study designs and methods of 
reporting for each stage of surgical innovation. These stages span from the initial 
‘Idea’ (Stage 1), to ‘Development’ (Stage 2a), ‘Exploration’ (Stage 2b), 
‘Assessment’ (Stage 3), and ‘Long-term monitoring’ (Stage 4), with different 
study designs recommended at each stage. The purpose of setting out the IDEAL 
recommendations was to improve the quality of research in surgery and ensure 
that there was ‘no surgical innovation without evaluation’9. 
The challenges of designing, conducting and evaluating surgical research, 
beyond those typical of any RCT, have been well documented in the literature by 
several authors 8, 10-12. Surgical research is challenging fundamentally, because 
surgery is a complex intervention, meaning simply that it consists of multiple 
interacting components acting both independently and interdependently 13. 
Complex interventions are widely used throughout the health service and 
include interventions from primary care and public health to surgery. What 
makes an intervention complex rather than simple is not well defined and it may, 
therefore, be more helpful to consider all interventions as having different levels 
of complexity 13. The evaluation of complex interventions presents numerous 
methodological and practical challenges. Many of these are pertinent to the 
assessment of all complex, non-pharmacological interventions, but unique to 
surgery is the fact that multiple challenges often coincide 8. 
 5 
A surgical intervention has been defined by others in the literature, but at the 
start of this work, there was no universally accepted definition of exactly what a 
surgical intervention constituted. Others had defined surgical interventions in 
the literature 12, 14, 15, but these definitions are limited with regard to the scope of 
modern surgical practice. For the purposes of this thesis it was therefore 
necessary to define a surgical intervention. A definition was created with more 
relevance to modern day surgical practice inclusive of a range of techniques, 
procedures and delivering personnel. Explanation of development detail and the 
parameters of this definition are discussed in Chapter three, section 3.3.2. In 
brief, a surgical intervention is defined for this thesis as: A diagnostic, therapeutic 
or adjunctive invasive intervention performed by a trained clinician, using hands, 
instruments and/or devices. 
Trials of surgical interventions may, therefore, be considered as trials of complex 
interventions, but with distinct challenges. Broadly these challenges may be 
considered as being related to methodological and cultural issues, though these 
may overlap and interact. Methodological difficulties may include for example, 
those with recruitment, intervention stability and standardisation, and outcome 
selection and/or measurement. The cultural challenges of surgical research and 
practice may be separate or intertwined with these methodological challenges, 
for example a lack of equipoise amongst surgeons, or inexperience of recruiting 
to RCTs and working collaboratively. These challenges are discussed in detail 
below.  
1.3.1 Challenges relating to recruitment 
Clinicians must be able to portray equipoise (even if they are not in equipoise) in 
order to explain to patients that there will be no advantage or disadvantage to a 
patient taking part in a trial and that the lack of evidence means they are unable 
to make a decision about which treatment to offer 16. Whether surgeons are in 
equipoise will depend on what the intervention is and how different this is to the 
comparators. Surgeons have traditionally not worked in a highly evidence-based 
field and are more used to making treatment decisions based mostly on their 
 6 
own preferences. They may not even be aware of their own equipoise, or lack of, 
and how this relates to community equipoise, which may contribute to 
difficulties recruiting and randomising patients in the context of a trial 17-19.  
Surgeons may also have limited appreciation of the methodological flaws of data 
derived from non-randomised studies and the possibilities of pragmatic trial 
designs 20, which will also limit their appreciation of the role of RCTs in surgery. 
Surgical procedures are very emotive for patients and patients too may exercise 
preference for a certain surgical treatment, which can make randomisation even 
more challenging 21.   
For example, the QUEST (quality of life after mastectomy and breast 
reconstruction) feasibility trials considered the impact of the type and timing of 
latissimus dorsi breast reconstruction on health-related quality of life when post 
mastectomy radiotherapy was unlikely (QUEST A) or highly probable (QUEST 
B). The primary outcome was to demonstrate acceptable randomisation rates of 
at least 25% of patients screened. Both feasibility trials closed early because of 
poor recruitment with the authors citing patient preferences and non-acceptance 
of randomisation as the major reasons for failure. Issues with clinical equipoise of 
the recruiting surgeons were also reported as well as clinician biases with the 
concept of randomisation itself 22.  The ESTEeM Trial (Endocrine +/- Surgical 
Therapy for Elderly women with Mammary cancer) was also stopped as it failed 
to recruit. Again, the authors cited patient preferences and non-acceptance of 
randomisation as the major reason for poor recruitment, but also stated that 
clinician preference and the influence of family and friends may have played a 
part 23. Both these trials demonstrate that patient and surgeon preferences may 
be co-influential as a challenge to trial recruitment. 
Many of the issues described above around recruitment are specific to RCTs. 
Work over the last two decades has led to the development of qualitative 
methods to improve recruitment to RCTs 24, 25. These methods have been highly 
effective and successful in improving patient recruitment to surgical trials by 
surgeons, through identifying opportunities for training and improving 
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recruiting practices 26. It is advocated that such methodology is integrated in the 
pilot/feasibility stage of the trial when work can be done to consider both patient 
and recruiter views and/or beliefs about the trial. In addition, because RCTs are 
not always required, possible or practical in surgery, there is a growing body of 
work and evidence regarding incorporating a wider range of study types for the 
evaluation of surgery 7-9. These include, for example, using surgical registries for 
real world evaluation of surgical devices and implants 27, 28 
1.3.2 Challenges relating to interventions 
Buxton’s law stated in 1987 that: ‘It’s always too early (for rigorous evaluation), 
until unfortunately it’s suddenly too late’ 29. The phenomenon explained by this 
law is a process where evaluating interventions whilst they are developing and 
changing is difficult, meaning interventions progress seamlessly to becoming 
stable. At this point, the delivering clinicians become so convinced of the benefit 
of the intervention, that they lack equipoise and would not accept randomised 
evaluation in the context of an RCT.  The IDEAL recommendations describe the 
study designs which may be appropriate at different stages in the development 
of an intervention so that there is ‘no innovation without evaluation’ 9.  The 
appropriate evaluation of surgical devices and techniques before widespread 
adoption has become even more topical following evidence of emerging harm 
with some surgical implants. These implants include Poly Implant Prothesis 
(PIP) breast implants 30, metal on metal hip replacements 31, and transvaginal 
mesh 32. Knowing what study design is appropriate and possible at different 
stages in the development of surgical interventions is key, so that the chance for 
randomised evaluation is not missed.  
Because surgical interventions are invasive, they also present unique questions 
on ethical issues such as when to introduce a new intervention to clinical practice 
and how to obtain informed consent from patients who are undergoing novel 
surgical procedures 33. These issues in turn may present distinct difficulties in 
terms of gaining ethical approval for proposed research on surgical 
interventions.  
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Trials in surgery may be hindered by a lack of standardisation of the surgical 
procedure and difficulties in recognising when a surgeon has significantly 
deviated from the intended procedure. Surgeons often adopt procedural 
variations to best suit their personal skills, the skills and experience of the team, 
the facilities of the local clinical environment and the needs of individual 
patients. Surgical interventions are therefore dependent on the expertise and 
actions of many operators, including the surgeon, anaesthetist, operating 
department practitioners and theatre nurses. Whilst all health care professionals 
are increasingly aware of the need for quality assurance in the NHS in general 34, 
there are many challenges as to how this should be achieved. In surgery, there is 
also recognition that quality assurance should not be interpreted as simply 
ranking the ‘best’ surgeons 35. Instead, quality assurance should constitute clear 
protocols for surgical interventions so that outcomes can be measured, compared 
and monitored. The complexity in achieving this lies in deciding which elements 
of surgical procedures should be standardised, and protocolised in the context of 
trials, and which outcomes are key in the assessment of benefit. Extensive 
methodological work has been done to develop a framework to standardise 
surgical interventions in the context of RCTs 36.  Work is ongoing to extend this 
framework to include co-interventions, and the identification of factors which 
may influence the extent of standardisation required.   
The intervention may be altered by a surgeon’s capability of learning new 
procedures, the so-called ‘surgical learning curve’, and by individual surgical 
aptitude 12, 37. A learning curve can simply be defined as improvement of a 
surgeon’s performance over time 37. In the conduct of trials of novel 
interventions, a learning curve can impact significantly on the results, as the 
intervention may be prone to more complications whilst evolving 38, 39. 
Two approaches to address the issue of the surgical learning curve in the context 
of RCTs have been described 12, 37.  The design approach involves stipulating 
entry level criteria for operators in terms of the number of procedures performed 
and a minimum professional level.  This ‘expertise’ approach may mean that the 
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results of the RCT are less externally valid. In contrast, the analysis approach 
uses statistical methods to quantify the impact of a learning curve on outcomes.  
The latter approach has a high data requirement and may therefore only be 
practical in very large trials 12. The use of a questionnaire to elicit information 
from surgeons participating in a trial about their current practice, experience and 
beliefs about learning curves, has been advocated to aid the interpretation and 
generalisability of trial results 40. Limitations to this approach include that 
personal beliefs and attitudes will influence the responses to the questionnaire. 
One way of dealing with the challenges and complexities of standardising 
surgical practice, is to perform large pragmatic surgical trials. Unlike 
pharmaceutical trials where patients can be guaranteed to receive the same drug, 
no two surgical treatments are the same leading to complexity with intervention 
implementation, standardisation and fidelity 8, 14. Surgeons will never all practice 
in exactly the same way and care surrounding the surgical procedure will not 
necessarily be provided in the same way. The methodological arrangement of 
pragmatic trials allows for this, meaning the results may be more generalisable to 
practice in the ‘real world’.  Challenges with this approach, include the extent to 
which a trial is pragmatic; for example, how rigid should the trial protocol be, 
which elements should be standardised and how should co- comitant 
interventions be considered.  
Consideration of co-interventions are therefore of particular relevance to the 
design of trials of surgical interventions. There are many which have the 
potential to impact on outcomes such as pre-optimisation programmes, the type 
and duration of anaesthetic given, what perioperative care is received (for 
example, high dependency, intensive care or ward care), and enhanced recovery 
programmes.  Whilst the potential impact of such co-interventions is recognised 
by those with expertise in surgical trials methodology 14, consideration has not 
yet appeared in guidelines seeking to standardise the reporting of interventions 
such as the TIDieR (Template for Intervention Description and Replication) 
checklist 41. The purpose of the TIDieR checklist is to encourage authors to 
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describe interventions in sufficient detail to allow for their replication.  The 
checklist is an extension of both the CONSORT (CONsolidated Standards Of 
Reporting Trials) 2010 statement 42 and the SPIRIT (Standard Protocol Items: 
Recommendations for Interventional Trials) 2013 statement 43.  
Randomised controlled trials are designed specifically to avoid biased results. 
Despite randomisation, different forms of bias can still occur, such as through 
missing data, an imbalance in baseline prognostic variables, or in not performing 
an intention to treat analysis 44. Blinding of both providers and recipients of 
healthcare interventions and those assessing the primary outcomes is desirable to 
avoid biasing the results. However, it is often difficult to blind any members of a 
surgical team to the intervention received by a patient as they are typically all 
intricately involved in providing that intervention 45.  
The different methods of blinding available for non-pharmacological 
interventions have been reviewed and classified 46, and include the use of sham 
and/or placebo procedures and blinding participants or assessors to the study 
hypothesis. It is unknown whether complex blinding procedures translate into 
improvements in the quality of evidence, but work is underway to consider this 
in general and abdominal surgery 47. It is important to consider the effects of 
blinding or not blinding members of the trial team, and how challenges may be 
overcome, and effects modified. Pilot and feasibility work may be well placed to 
trial novel or complex blinding procedures 48. 
1.3.3 Challenges relating to outcomes 
The selection and measurement of outcomes is less clear in surgical trials, and if 
not well thought out can lead to less meaningful results. Traditionally outcomes 
from surgery have focussed on short term clinical measures, for example 
mortality and morbidity.  The Dutch TIME trial (traditional invasive versus 
minimally invasive esophagectomy), for example, compared two or three phase 
oesophagectomy with totally minimally invasive oesophagectomy. Short term 
outcomes were reported of a lower incidence of in-hospital pulmonary infection 
with minimally invasive oesophagectomy (12% versus 34%) and a shorter 
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hospital stay (median 11 days versus 14 days) when compared to open surgery 
49.  The publication of this paper concluded that minimally invasive surgery was 
advantageous, but was met with criticism from the surgical community who 
argued that had various components of the surgery been different, the results 
would have been altered 50-53.   
An additional challenge is that the definitions of clinical outcomes are both 
numerous and not standardised. The sheer volume of outcome definitions and 
their heterogeneity, therefore, makes comparison between studies and 
institutions difficult. For example, in 2001, a National Institute for Health 
Research (NIHR) funded review was published on the measurement and 
monitoring of surgical adverse events 54. A total of 41 different definitions and 13 
grading scales of surgical wound infection were identified from 82 studies. 
Similarly, 56 definitions of anastomotic leak were found from 107 studies of 
upper gastrointestinal, hepatopancreaticobiliary and lower gastrointestinal 
surgery. In terms of mortality, although the review found the definition to be 
relatively consistent, most systems reported in-hospital mortality only and few 
had the potential to link deaths to national registers 54. The recording of 
outcomes in national registries has been shown to be important for transparent 
public reporting, research, and improving the quality of care for patients 31, 55. 
The absence of standardised definitions for surgical outcomes has led to the 
development of scores such as the Clavien-Dindo classification of surgical 
complications, which grades adverse events by clinical severity and the 
treatment required 56. Such scores are widely used though there is no universal 
consensus, and outcomes continue to be reported with huge variation. 
In addition, whilst the clinical measures of morbidity and mortality are 
undoubtedly important, there is growing recognition of the need to also consider 
the perception of patients when choosing trial outcomes.  The NIHR promotes 
and requires Patient and Public Involvement (PPI) in all stages of trials research 
in the UK, and funds the INVOLVE programme to actively support public 
involvement in NHS, public health and social care research 57 . Specific to 
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selecting research outcomes, PPI involvement in the early stages of study design 
is vital to ensure that important clinical questions are answered and that 
outcomes are patient-focussed. With relevance to surgery, what patients consider 
to be important in terms of outcome, might be different to outcomes of interest to 
surgeons. For example, long-term function following hand surgery may be of 
more interest to patients, than whether or not they develop a short-term wound 
infection or how straight their fingers are. 
In terms of trial outcomes, the real issue of importance is to assess the longer-
term clinical effectiveness of surgery, and thus consider the true value of these 
procedures. Clinical, patient reported and economic outcomes that are relevant 
to patients, health care professionals and other key stakeholders such as funders 
and health policy makers all need to be reported to achieve this. The selection of 
appropriate outcomes is therefore pivotal to the process of improving the 
relevance of surgical trials so that they can influence health care decision making.   
The COMET (Core Outcome Measures in Effectiveness Trials) Initiative aims to 
develop agreed, standardised sets of outcomes, known as core outcome sets 
(COS), which represent the minimum number of outcomes that should be 
measured and reported in any trial of a specific condition 58. These sets are not 
restrictive but allow the results of trials and studies to be compared and 
combined in terms of the core set of outcomes relevant to the clinical area.  
There are now 52 (of a total of 1249) references to planned, ongoing and 
completed work to develop COS with surgery in title within the COMET 
database 58. Whilst COS standardise outcome reporting, thereby improving the 
ability for comparison between studies and institutions, they are often specific to 
a disease or condition.  This means that strategies must be employed to ensure 
outcome selection for each individual study is appropriate. An example of such a 
strategy, is the development of a new standardised measure to evaluate surgical 
site infection, which has built on the COS methodology and been completed 
within the context of pilot work 59. 
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1.3.4 Challenges & solutions relating to surgical 
culture 
Historically, there have also been cultural challenges surrounding surgical 
research, such as a lack of collaborative working and a lack of equipoise amongst 
surgeons 19. Similar to the examples of methodological work to improve surgical 
trials highlighted in the above sections, there has also been considerable 
movement to more broadly address these cultural issues and promote research 
around and participation in surgical trials. 
One method initiated by the Medical Research Council (MRC), was the 
investment and development of a Network of Regional Hubs for Trials 
Methodology Research 60. One of the five hubs, called the ConDuCT-II Hub 61 
(Collaboration and innovation in Difficult and Complex randomised controlled 
Trials In Invasive procedures), was specifically tasked with researching the 
methodology of trials of complex interventions, and in particular, trials in 
surgery. This initiative brought together the expertise of surgeons and 
methodologists to work collaboratively on optimising trials in surgery, thereby 
improving both the methodology and the culture surrounding the design and 
conduct of surgical trials.   
Such schemes are a stride forward, but perhaps remain the domain of the few 
rather than the many. A shift in understanding is also needed amongst the 
surgical community more generally, so that participation in trials becomes 
embedded within routine surgical practice. The Royal College of Surgeons of 
England (RCSEng) has lead a Surgical Trials Initiative 62 including the 
investment in Surgical Trials Centres throughout the UK and the appointment of 
Surgical Specialty Leads; individual surgeons to champion surgical research in 
their clinical specialty. The 2017-2018 Surgical Research Report published by 
RCSEng 63 lists the initiative’s achievements as: 85 current or completed clinical 
trials (42 open and recruiting, 34 in follow-up and 9 completed) with a further 35 
trials in the setting up phase, and over 25,000 patients recruited to this joint 
portfolio of trials in the ten different specialties. 
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This development has coincided with the now widespread surgical trainee 
collaboratives, which have an unprecedented record in recruiting patients to 
RCTs 64. For example, the West Midlands Research Collaborative completed the 
ROSSINI trial, recruiting ahead of schedule, which showed there was no 
difference in rates of surgical site infection following laparotomy when using a 
wound edge protection device compared with standard care 65. Challenges exist 
as to how the trainee collaborative model will develop in terms of trial delivery 
in the future, including the establishment of new collaboratives and the 
development of infrastructure such as access to online databases and statistical 
advice 64. However, trainee collaboratives have and continue to assist with the 
changing culture surrounding surgical trials. Through successive generations of 
trainees with understanding, interest and experience in being part of surgical 
trials and working collaboratively, taking up consultant posts, the network of 
experienced surgeon trialists will continue to grow thus building greater capacity 
for collaborative surgical research. 
Complementary to the growing collaborative research structure in the UK 66, is a 
demonstration of the importance of teamwork in the performance of RCTs. One 
study 67 showed that increased length of time working together as a research 
team combined with the experience of the team members, and a healthy 
competitive instinct towards recruitment, contributed to a successfully 
functioning trial research team.  
A significant challenge facing surgical trials, is the difficulty of integrating trials 
and research into busy clinical practice. Many surgeons, as well as not having 
formalised academic sessions as part of their NHS contract, find it difficult to 
engage in the complexities and nuances of trial processes alongside their clinical 
work. Treating as many patients as efficiently and effectively as possible is the 
main pressure faced by surgeons, and time to engage with clinical trials, for 
example to recruit patients, is very limited 68. More work is needed, to improve 
research infrastructure and supporting busy surgeons in engaging with clinical 
trials. 
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Whilst the culture around surgical trials is evolving and growing into a more 
established network of surgeon trialists, the challenge now is to build on 
momentum and established networks, so that participation in surgical research 
becomes routine for all surgical patients and clinicians. 
1.4 Summary 
The unique challenges of surgical trials have been identified and discussed in 
this chapter. Addressing the challenges described requires development of: (i). 
Methods to optimise recruitment; (ii). Methods to define and standardise 
interventions, monitor them, and select appropriate comparator interventions 
and; (iii). Methods to develop, select, measure and report relevant outcomes. 
Optimising surgical trials, therefore, requires both changes to methodological 
processes, and a shift in the culture surrounding the performance of surgical 
trials. Chapter two will review the role of pilot and feasibility work, as one 
solution to optimise trials more generally, and provide discussion of the 
importance of understanding why and how to optimally design and conduct 
pilot and feasibility work for surgical trials. 
 16 
CHAPTER 2 
Review of the role of pilot and 
feasibility work in optimising trials 
2.1 Introduction 
Chapter one described the many unique methodological and cultural challenges 
of surgical trials. This chapter will begin by discussing the applicability of pilot 
and feasibility work to optimising trials more generally, in the context of the 
methodological and theoretical literature surrounding pilot and feasibility work. 
In view of this knowledge, the rationale for understanding why and how pilot 
and feasibility work may be a potentially valuable method for improving 
surgical trial design and conduct will be presented at the end of this chapter, 
followed by a list of aims and objectives for this work. 
But what is pilot work?  The Oxford English Dictionary defines the word ‘pilot’ 
as “…an experimental undertaking designed to assess the viability of a full-scale project 
or activity…That serves as a prototype or trial prior to a full-scale operation or activity” 
69.  Pilot work could, therefore, be simply described as work undertaken a priori, 
to inform future work. 
However, defining what pilot and feasibility work is in the context of trials 
generally, has been inconsistent and fraught with resulting difficulties. This 
chapter will explore the published literature including the development in 
understanding of what pilot and feasibility work is; how it might be used and 
optimised to improve trial design and conduct and; why it might have been 
undervalued in the past. Throughout, the relevance of these questions to a 
surgical trials context will be considered.  
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This is a narrative literature review, exploring the most important aspects of 
current knowledge and research practice around pilot and feasibility work. 
Theoretical and methodological work is examined, discussed and considered in 
terms of surgery, as well as looking at the historical development of research 
practice around designing and conducting pilot and feasibility work. The aim 
was not to answer a clearly formulated question, by systematically examining all 
of the published literature, but to provide context for this thesis and consider 
inconsistencies or gaps in the body of current knowledge. This process allowed a 
rationale for this thesis to be described in terms of how exploring the issues 
surrounding pilot and feasibility work, may be integral to improving the design 
and conduct of surgical trials specifically.  The chapter will conclude with the 
overall aims and objectives of this thesis. 
2.2 Definitions of pilot & feasibility work 
There are several definitions of pilot work in the literature and, currently, terms 
are often used interchangeably and without universally accepted definitions 70-72. 
Pilot work could simply be defined as any preliminary work undertaken in 
preparation for conducting a main study 73-76. The National Institute of Health 
Research (NIHR) defines pilot studies as “…a smaller version of the main study used 
to test whether the components of the main study can all work together. It is focused on 
the processes of the main study, for example to ensure that recruitment, randomization, 
treatment, and follow-up assessments all run smoothly. It resembles the main study in 
many respects, including an assessment of the primary outcome” 77. In addition, the 
NIHR distinguishes feasibility studies from pilot studies, describing them as: 
“…pieces of research done before a main study in order to answer the question ‘Can this 
study be done?’ They are used to estimate important parameters that are needed to design 
the main study” 78. 
In contrast, the Medical Research Council (MRC) guidance on developing and 
evaluating complex interventions 13 makes no distinction between pilot and 
feasibility studies, describing how “the pilot and feasibility stage (of evaluating a 
complex intervention) includes testing procedures for their acceptability, estimating 
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the likely rates of recruitment and retention of subjects, and the calculation of appropriate 
sample sizes…A pilot study need not be a ‘scale model’ of the planned mainstage 
evaluation, but should address the main uncertainties that have been identified in the 
development work.” A key message in this MRC definition is that pilot and 
feasibility work should focus on identifying and addressing areas of uncertainty 
or ambiguity in the study protocol, to resolve any issues before the main trial 
begins.   
More recently, Eldridge et al. have developed a conceptual framework to define 
pilot and feasibility studies in preparation for RCTs 71 (see Figure 2a).  This work 
was integral to the primary research project of developing guidelines for 
reporting pilot and feasibility studies 79. The core components of the primary 
research were a large Delphi study and an international expert consensus 
meeting 80. During this research, the authors felt the lack of clarity, differences of 
opinion and interest in defining pilot and feasibility studies, warranted re-
evaluation and prompted the development of the definitions framework. 
Figure 2a Conceptual framework to describe the classification of pilot and feasibility studies 
(Figure reproduced from 71 – see acknowledgements)  
 
Within the framework, feasibility studies are defined as an umbrella term to  
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include all types of studies that ask: can this trial be done, should it be done and 
how? 71, 81. Feasibility studies are then further sub classified into three groups (see 
Table 2.1). A pilot study, whether randomised or non-randomised, may therefore 
be categorised as a subset of feasibility work that is intended to ask such 
questions about the viability and conduct of a proposed main trial but that has 
specific design features 81.   
Table 2.1 Sub classification of feasibility studies by Eldridge et al. 71 
 
These design features include determining the sample size of the main trial; 
addressing recruitment and randomisation, testing the implementation of 
interventions; assessing data collection and outcomes and considering harms, 
benefits and potential effectiveness of the intervention 82. These definitions by 
Eldridge et al, illustrate that pilot and feasibility work may not be seen as 
mutually exclusive but rather as part of the same paradigm that includes any 
work done in preparation for a main trial.   
Study type Definition 
Randomised pilot studies “… studies in which the future RCT, or parts of it, including the 
randomization of participants, is conducted on a smaller scale (piloted) to 
see if it can be done. Thus randomized pilot studies can include studies that 
for the most part reflect the design of a future definitive trial but, if 
necessary due to remaining uncertainty, may involve trying out alternative 
strategies, for example, collecting an outcome variable via telephone for 
some participants and online for others. Within the framework randomized 
pilot studies could also legitimately be called randomized feasibility studies.” 
 
Non-randomised pilot studies “… studies in which all or part of the intervention to be evaluated and other 
processes to be undertaken in a future trial is/are carried out (piloted) but 
without randomization of participants. These could also legitimately be 
called by the umbrella term, feasibility study. These studies cover a wide 
range from those that are very similar to randomized pilot studies except 
that the intervention and control groups have not been randomized, to 
those in which only the intervention, and no other trial processes, are 
piloted.” 
 
Feasibility studies that are not pilot 
studies 
“…(studies) in which investigators attempt to answer a question about 
whether some element of the future trial can be done but do not implement 
the intervention to be evaluated or other processes to be undertaken in a 




Importantly, the definitions defined by Eldridge et al, refer only to so-called 
external pilot studies; standalone studies that are completed before the start of an 
RCT and in which, according to the NIHR definition ‘….the data may be analysed 
and set aside’77. The definitions do not address so called internal pilot studies, 
which are described by the NIHR as ‘…the first phase of the substantive study and 
data from the pilot phase may contribute to the final analysis’ 77.  The design of and 
data from internal pilot studies are, therefore, integral to the main study. Internal 
pilot studies may consequently be considered more appropriate when there are 
fewer uncertainties about the trial and study protocol.  Internal pilot studies 
provide an opportunity for improved efficiency in terms of time, participants 
and funding, as the study may continue to the main phase if it meets the pre-
defined progression criteria 83, 84.   
These distinctions are important as, whilst different types of pilot work do exist 
and examples of such studies are diverse, there is no established guidance to aid 
selection of the most appropriate type of pilot or feasibility study to perform 
prior to undertaking a definitive main trial. 
Most recently, Cook et al. argue that the terms internal and external pilot are 
unhelpful and outdated 85. The authors emphasise the importance of researchers 
reporting and publishing in detail, the refinement of trial processes so that others 
can learn from the findings. An alternative taxonomy is proposed by Cook et al. 
to illustrate when each study type should be used (see Table 2.2).  Here, all pilot 
and feasibility studies are described as distinct studies in their own right. The 
authors suggest that as all trials have some form of internal assessment process 
allowing refinement to the study design, it is particularly important to improve 
clarity and transparency around what is actually done, including formal 
reporting. The overlapping terms of ‘stop go assessment’ and ‘routine 
monitoring’ are defined as terms to illustrate these internal processes, rather than 
the term ‘internal pilot’. 
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Table 2.2 Approaches to developing and modifying the trial design with particular reference to 
the recruitment strategy (Table reproduced from 85 – see acknowledgements) 
 
The examples provided above represent some of the more widely cited 
definitions of pilot and feasibility work in the context of healthcare research. A 
shared characteristic of all these published definitions is that they describe pilot 
and feasibility studies as preliminary work, performed in preparation for a main 
trial.  The debate over what pilot and feasibility studies are and how they should 
be defined continues.  Defining the different types of pilot and feasibility studies 
is relevant when designing trials, but also when creating guidance for the 
conduct, reporting, evaluation and publication of research. This is because to 
avoid further confusion in the literature, which provides the resource for further 
work, it is important to be clear about to which type of study the guidance refers.  
In the absence of a consensus on terminology currently, it is perhaps most 




Separate study Substantial uncertainty about 
whether it is possible or how 
to implement aspects of the 
trial design and conduct (e.g. 
delivery of the interventions 
and recruitment process) 
Exploration of the 
feasibility of a trial 
Assessment of the 
feasibility of a trial 
Pilot trial Separate study Limited refinement of the trial 
design, processes and 
recruitment strategy 
anticipated 
Refinement of trial 
design and 
processes prior to 
commencement of 
the main trial 
Minor 
modifications to 





Early in the 
recruitment 
period of the 
main trial 
Substantial adjustment of 
recruitment strategy and 
study processes is considered 
likely 
One-off within 
study assessment of 
recruitment and 
study processes to 
allow adjustment of 
the strategy 
(including the 












period of the 
main trial 
Minor modifications to study 
processes and recruitment 
strategy anticipated 
Regular monitoring 




of the recruitment 
strategy and study 
processes 
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important that researchers fully describe the study methodology used when 
describing the design and/or findings of pilot and feasibility work, so that it can 
be transparently understood, replicated or refined.   
It is noted, however, that none of these definitions are defined within the context 
of surgical trials specifically. Some surgical examples are used in the conceptual 
framework describing the different types of pilot and feasibility studies 71. Whilst 
the list of participants for the Delphi survey did include ‘clinicians’, it is unclear 
if surgeons were amongst those invited to take part. The later parts of the 
consensus process occurred at methodological conferences, so significant 
surgeon involvement is less likely. 
In the absence of a universally accepted definition of pilot and feasibility work 
for clinical trials, for the purposes of this thesis, if was necessary to define a clear 
and inclusive working definition. This definition is explained in more detail in 
Chapter 3 (Methods, Section 3.3.3) but for clarity whilst directly discussing 
definitions here, the term pilot/feasibility study (PFS) was coined for the 
purposes of this thesis and defined as:  
Any research that is undertaken before a main study and is explicitly intended 
to inform the design and/or conduct of a future main study where:  
Main study is defined as a definitive study (e.g. RCT) of an intervention(s).   
2.3 Broadening the potential scope of pilot and 
feasibility work 
Whilst the definitions of pilot and feasibility work have emphasised the intention 
to address areas of uncertainty or ambiguity, historically the scope of pilot work 
has often been narrow, focusing typically on issues related to safety and efficacy 
86, 87 or recruitment 88. It has been acknowledged, for example, that pilot work has 
not comprehensively evaluated methodological issues and has rarely detailed the 
intention or process of proceeding to a main trial 74, 89. For example, in 2011 
Shanyinde et al. performed a literature review of 50 pilot RCTs and illustrated 
that only 56% of the studies reviewed addressed methodological issues in any 
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depth 89. There is, however, increasing awareness of the greater potential for pilot 
work to inform the design and conduct of main trials more generally. In 
particular, there is awareness of the potential for pilot and feasibility studies to 
address the many methodological issues, uncertainties and ambiguities in the 
study process which have not been formally addressed previously 89. The 
investigation of these uncertainties may, therefore, further enhance the likelihood 
of success of the main trial 73, 75, 90. As such, perhaps the full potential of pilot 
work has arguably not yet been realised. 
The knowledge that there are many other areas that could be addressed to 
increase the benefits of pilot work has lead several authors to identify and 
categorise specific reasons for undertaking pilot work, in an effort to guide 
researchers into systematically considering these areas for their own studies (see 
Table 2.3).   
In 2001, van Teijlingen et al. 91 created a long list of 19 reasons for conducting 
pilot and feasibility work compiled from several sources (see Table 2.3). The 
main purpose of this article was to report learning from the conduct of a series of 
small pilot studies performed to determine the most effective way of surveying 
maternity care in Scotland and, therefore, did not consider surgical studies 
specifically. The need to assess the logistics of the study protocol is clear from 
this list of objectives. In particular, the authors emphasised at this early stage, the 
importance and value of pilot work both to the study team and to a much wider 
audience, therefore advocating mandatory reporting and publication of pilot 
studies. 
In 2004, Lancaster et al. 72 performed a literature review of six pilot and feasibility 
studies published in 1998 to 2002, from which they described seven possible key 
objectives for performing external pilot studies (see Table 2.3). Of these six 
studies, none considered surgical interventions specifically, with four 
considering pharmacological interventions, and the other two considering blood 
pressure monitoring and skin-to-skin contact postpartum as the intervention. 
This list was extended to add a further three key objectives to the list in 2010, in a 
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review article published by Lancaster et al. regarding statistical issues in the 
design and evaluation of complex interventions in primary care 92. These ten key 
objectives are perhaps more specific than those published by van Teijlingen 91, 
explicitly mentioning randomisation, recruitment, consent and the selection of a 
primary outcome measure. 
Also in 2004, Thabane et al. 75 condensed the list produced by van Teijlingen et al. 
91 and categorised the focus of pilot work as concentrating on the four main areas 
of processes, resources, management and scientific issues (see Table 2.3).  The 
fourth of these categories, ‘scientific’, is described as an assessment of treatment 
safety, dose and effect.  However, the authors themselves conclude in the 
discussion that pilot studies should be used with caution for estimating 
treatment effects. They make recommendations for reporting the results of pilot 
studies, by creating a checklist adapted from the CONSORT  (2001) statement 42, 
which emphasises appropriate labelling of the study as ‘pilot’ and defining and 
reporting feasibility objectives and outcomes. Whilst the focus of this work is 
again complex interventions, surgical studies are not specifically considered or 
mentioned. 
Shanyinde et al. 89 in 2011 expanded on this work by reviewing a random sample 
of 50 studies, which include 28 ‘drug’ and 22 ‘non drug’ pilot or feasibility 
studies, of which just two studies were of surgical interventions. From this, the 
authors produced a checklist of seven methodological issues that may/should be 
addressed in randomised pilot work specifically, prior to conducting an RCT. 
The authors contrasted this list with seven further issues that could be evaluated 
in other types of feasibility study (see Table 2.3).  Specific additions in this list 
include an assessment of blinding procedures and considering the logistics of a 
multicentre trial. This is important as the work was published ten years after that 
of van Teijlingen et al. 91, and gives insight into the developing understanding of 
trials methodology. 
In 2011 also, Leon et al. 93 discussed the different aspects of feasibility that can be 
examined in pilot work which are similar to those already listed (see Table 2.3). 
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The paper emphasises again that pilot studies are not powered to undertake 
hypothesis testing, and should not be used to evaluate, safety, efficacy, or 
effectiveness. 
Bugge et al. in 2013 94 used the list of 14 methodological issues published by 
Shanyinde et al. 89 (see Table 2.3) to develop the ADePT tool (A process for 
Decision-making after Pilot and feasibility Trials).  The authors justify the list 
published by Shanyinde et al. as ‘the best available’, though acknowledge it is not 
clear exactly how it was developed. The work is centred on the conduct of a pilot 
study for an RCT of pelvic floor muscle training for pelvic organ prolapse. The 14 
methodological issues were used as a checklist to assess how their own pilot 
study had addressed each area.  Based on the areas of difficulty and uncertainty 
identified, they then developed the ADePT tool to consider: i) the type of 
problem (only for the trial, only for the real world, or both); ii) potential solutions 
to the problem; and iii) an assessment of which would be the best solution to the 
problem. The authors stated that they plan to evaluate the tool in terms of its 
usefulness for developing an intervention and designing a trial to test it.  This 
work represents a growing understanding of how pilot work might be used to 
improve trial design, though not specifically considering the context of surgical 
trials. 
Most recently, Kistin et al. 95 in 2015 discussed  five main reasons for performing 
pilot work. The key addition here, is the third point of using pilot work to 
understand ‘…barriers and facilitators to eventual dissemination and implementation of 
the results’, thus exemplifying the importance of trial results being implementable 
in clinical practice. 
In summary, the literature has documented over the last 18 years, the multiple 
methodological issues that pilot and feasibility work may address prior to 
conducting a main trial. This work has been undertaken partly to address a 
growing understanding that pilot and feasibility studies are often narrow in 
scope. This work also reflects a gradual acknowledgement of the importance of 
having a clear rationale and objectives for pilot and feasibility studies to examine 
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specific issues prior to conducting a main trial. There is increasing understanding 
that because RCTs of complex interventions such as surgery face unique 
challenges (chapter one), pilot and feasibility studies may have greater benefit in 
such situations. However, whilst it is likely that many or all of the 
methodological issues described and discussed here are relevant to pilot and 
feasibility studies in surgery, none of the work reviews or explores surgery 
specifically. Next, the published guidance on optimal design and conduct of pilot 
and feasibility studies generally, with consideration of any guidance specific to 
surgery, will be discussed.
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Table 2.3 Reasons for conducting pilot work as reported in the literature.  
Author / publication Reasons for conducting pilot/feasibility work identified  
Van Teijlingen et al 200191 1) Developing and testing adequacy of research instruments; 
2) Assessing the feasibility of a (full-scale) study/survey; 
3) Assessing people's willingness to participate/potential or likely response rates; 
4) Designing a research protocol; 
5) Assessing whether the research protocol is realistic and workable; 
6) Assessing whether data collectors understand the protocol; 
7) Establishing whether sampling frame and technique are adequate and effective; 
8) Identifying logistical problems which might occur using proposed methods; 
9) Estimating variability in outcomes to help determining sample size; 
10) Collecting preliminary data; 
11) Determining what resources (finance/staff) are needed for main study; 
12) Assessing the proposed data analysis techniques to uncover potential problems; 
13) Developing a research question and/or research plan; 
14) Assessing whether or not each data collector obtains similarly valid information; 
15) Training researchers in as many elements of the research process as possible; 
16) Educating students about research methods and the research process;  
17) Convincing funding bodies that research team is competent and knowledgeable; 
18) Convincing funding bodies that the main study is feasible and worth funding; 
19) Convincing other stakeholders (service providers, ethics committees, managers, politicians, etc.) that the proposed main study is worth supporting. 
Lancaster et al 200472 1) To perform a sample size calculation;  
2) To test the integrity of the study protocol; 
3) To test data collection forms and/or questionnaires; 
4) To test the randomisation procedure; 
5) To assess rates of recruitment and consent; 
6) To determine the acceptability of the intervention and; 
7) To select the most appropriate primary outcome measure; 
Lancaster et al 201092 8) To develop and test the implementation and delivery of the intervention; 
9) To train staff in delivery and assessment procedures and; 
10) To prepare and plan data collection and monitoring procedures.  
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Thabane et al 201075 1) Process: analysing the feasibility of different steps in the trial such as assessment of numbers of eligible patients and the acceptability of 
randomisation;  
2) Resources: assessing the use of study resources such as, the usability of proposed software or the time it takes to fill in data forms; 
3) Management: considering human and data management problems for example, data entry, missing values, study personnel difficulties and; 
4) Scientific: an assessment of the treatment safety, dose and effect. 
Shanyinde et al 201189 1) Recruitment; 
2) Consent; 
3) Randomization procedures; 
4) Blinding procedures; 
5) Retention; 
6) Logistics of a multi-centre trial and; 
7) Testing that all components of the protocol work together. 
8) Sample size calculation; 
9) Eligibility; 
10) Compliance and/or adherence to the intervention; 
11) Acceptability of the intervention; 
12) Cost and duration of the intervention; 
13) Outcome assessment and; 
14) Selection of the most appropriate outcomes. 




5) Treatment adherence; 
6) Treatment fidelity and; 
7) The assessment process. 
Kirsten et al 201595 1) To field test logistical aspects of the future study and to incorporate these aspects into the study design; 
2) To optimize intervention delivery with specific attention to adherence and fidelity; 
3) To increase understanding of the barriers and facilitators to eventual dissemination and implementation of the results; 
4) To obtain empirical estimates of statistical parameters to inform power calculations and other design effects of a subsequent trial and; 
5) To estimate other critical study parameters such as the proportion of study participants who experience a key outcome event spontaneously without 
intervention, or the level of correlation over time for a repeated outcome measure, or the extent of a clustering effect. 
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2.4 Optimal design and conduct of pilot and 
feasibility work 
There are some guidelines for the design of pilot work published in medical 
disciplines, including occupational therapy 96 and nursing 97. The main 
characteristics of these guidelines are, however, based on the key works of others 
already discussed such as Thabane et al. 75 in 2010 and Arain et al. 74 in 2010, so are 
not consensus-based or surgery specific. Furthermore, these guidelines are not 
widely cited as useful for guiding the design of surgical pilot and feasibility 
studies. 
Some published recommendations, however, have provided more practical 
guidance regarding the use of pilot and feasibility work in complex interventions 
that might have specific relevance to surgery. The Medical Research Council 
(MRC) guidance on developing and evaluating all complex interventions, offers a 
framework to guide researchers through the development-evaluation-
implementation process 13. Conducting pilot or feasibility work of complex  
interventions prior to full-scale evaluation in a definitive main trial is considered 
‘vital preparatory work’ as part of this framework and is, therefore, recommended 
for the full evaluation of all complex interventions 13. Current developments in 
this area include work also funded by the MRC, to develop guidance specifically 
for pilot and feasibility studies in complex public health interventions 98, 99. 
Targeted specifically at surgery, the IDEAL framework 100 describes a pathway for 
new surgical interventions from first in man (Stage 1) to long-term study (Stage 4). 
Within this framework, pilot and feasibility studies are considered at Stage 2a 
(development) and 2b (exploration) focusing on addressing uncertainties prior to 
Stage 3 assessment in a definitive RCT. The initial publication however, was 
largely theoretical with little practical guidance as to how pilot and feasibility 
studies should be operationalised 101. Recently published updated IDEAL 
recommendations 102 now provide some clarification regarding the role of pilot 
and feasibility studies in surgery, as a result of recognition that the original IDEAL 
guidance published in 2009 101 had little impact on the design and conduct of 
surgical pilot and feasibility studies 103. The authors of the updated IDEAL 
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recommendations 102 also state that the development of a reporting checklist for 
IDEAL studies is underway, to improve appropriate reporting of all studies using 
the IDEAL framework in the literature. 
Whilst these strategic publications discuss pilot and feasibility work as part of a 
larger framework for developing, evaluating and implementing new complex 
interventions, such as surgery, it is still not clear exactly when and how pilot and 
feasibility work should be conducted. Specific to surgery, there is currently no 
formal guidance on how to design and conduct pilot or feasibility studies in 
surgery, in what situations this work should be done, and how or if pilot and 
feasibility work should be modified to differing circumstances, for example for 
different types of surgical intervention. It is identified, therefore, that further 
research is needed to understand the potential for pilot and feasibility studies to 
optimise future surgical trials.  
2.5 Rationale for this thesis 
Evidence of feasibility is increasingly required by funders, before agreement to 
fund a main trial is reached. This is based on the knowledge that poor research 
design, conduct and analysis are known to contribute to significant research waste 
104-108. This effect is further compounded by the poor reporting and dissemination 
of research findings 107, particularly those from clinical trials 109, 110. Interest in the 
design and conduct of pilot and feasibility work is, therefore, intensifying with the 
increasing recognition that such preliminary work may contribute extensively to 
the success of subsequent definitive main trials. Through avoiding common 
problems such as the inability to recruit and a corresponding reduction in 
statistical power, or excessive attrition due to intolerable procedures, it has been 
suggested that pilot studies may also reduce the proportion of failed trials 93. 
Practicality dictates that pilot studies should be a pre-requisite to trials of novel 
treatments or interventions or novel applications of treatments or interventions 93 
or in areas where trials have been historically difficult to do, because of the 
inevitable uncertainty surrounding these types of trial. As described in Chapter 1, 
surgical trials face unique complexities, and often interacting uncertainties 
 
 31 
surrounding the design, conduct and completion of trials, meaning there is an 
even greater need to consider if and how surgical trials can be improved.  
Pilot and feasibility work may be well placed to explore the complex uncertainty 
surrounding surgical trials. Whilst there may be growing recognition that pilot 
and feasibility work is beneficial to main trial success and should precede all main 
trials of complex interventions, there has been little research to explore how to 
design and conduct pilot and feasibility studies in different situations. 
Published guidance from the MRC and the IDEAL collaboration, describes the 
importance of pilot and feasibility work in overcoming the challenges of complex 
interventions, which includes surgical trials. However, the conduct, reporting and 
publication of pilot and feasibility work in surgery remains rare 111, 112. 
Furthermore, guidance tailored specifically to optimally design and undertake 
pilot and feasibility studies for surgical trials is lacking. For example, there is no 
surgery-specific guidance endorsed by funding bodies or professional 
membership organisations such as the Royal College of Surgeons (RCS), aimed at 
surgeons participating in or contemplating designing pilot and feasibility studies. 
Research is needed, therefore, to understand the potential for pilot and feasibility 
studies to optimise main trials, and develop guidance for surgeons regarding best 
practice in this area. 
2.6 Aim of thesis 
The overall aim of this thesis is to develop a detailed understanding of the 
potential for pilot and feasibility work to optimise surgical trials and provide clear 
recommendations for surgeons and study teams for how to improve research 
practice. 
2.7 Objectives of thesis 
Specific objectives of this thesis are: 
Objective 1 To undertake a targeted review and systematic analysis of 
protocols of pilot and feasibility studies funded by the National Institute for 
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Health Research (NIHR) to understand current practice in using pilot and 
feasibility studies to inform main trials in surgery; 
Objective 2 To use in-depth qualitative interviews to explore the experiences, 
perceptions and views of key stakeholders towards the role, value and 
challenges of designing and performing pilot and feasibility studies in surgery; 
Objective 3 To synthesise and interpret the findings of the targeted review 
and systematic analysis of protocols of pilot and feasibility studies funded by 
the NIHR and the in-depth qualitative interview findings, in light of the 
methodological and theoretical literature around pilot and feasibility studies 
(as reviewed in chapter one and two) and;  
Objective 4 To develop recommendations from this work for all key 
stakeholders and, specifically, accessible and practical top tips for surgeons to 
optimise the design and conduct of pilot and feasibility studies to inform main 
trials in surgery.  
 
Chapter three will describe in detail, the methods used for this work, and 







This chapter will describe the methods used in this thesis. The aims and objectives 
of this work are outlined on the previous page at the end of Chapter two. Phase 
one of this work was a targeted review and systematic analysis of NIHR funded 
pilot and feasibility studies to establish current practice in this area (objective 1). 
Phase two was a qualitative interview study with key stakeholders, to explore 
opinions, perceptions and views on the role, value and challenges of performing 
pilot and feasibility studies in surgery (objective 2). Phase three of this work 
synthesises and interprets the findings of the first two phases, in light of the 
evolving methodological and theoretical literature (objective 3), to produce 
recommendations for improving practice in this area (objective 4). This chapter 
will describe the methods and rationale for the use of these methods in each phase 
of the work. 
Phase I: A targeted review and systematic analysis 
of NIHR funded pilot and feasibility studies 
3.2 Rationale for Phase I of this thesis 
Chapter two described how major research funders are increasingly recognising 
the role of well-designed pilot and feasibility studies in informing the design and 
conduct of future surgical trials, but clear and accessible guidance on how and 
when to perform surgical pilot and feasibility studies is currently lacking. It was, 
therefore, hypothesised that reviewing and appraising completed examples of 
pilot and feasibility studies would be valuable to consider and evaluate exactly 
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what the issues regarding design and conduct are. It was also hypothesised that 
through defining and highlighting examples of well-designed pilot and feasibility 
studies, this would inform others and assist in designing future preparatory 
studies. It was considered, that examples of pilot and feasibility studies could 
have been searched for in the published literature. However, it is known that pilot 
and feasibility studies have been both inconsistently and under reported 
historically, meaning a review of the published literature would be unlikely to 
include examples of the full range of current research practice. The difficulties 
surrounding using the general literature as a resource to determine current 
practice in this area are explained below.  
3.2.1 Issues with reporting of pilot and feasibility 
work 
There are examples of good reporting in the scientific literature of how pilot work 
has explored specific uncertainties and methodological issues to usefully inform 
the viability and conduct of a main trial. The PROTECT thromboprophylaxis trial, 
for example, aimed to examine, the effect of low molecular weight heparin versus 
heparin on the primary outcome of proximal leg deep vein thrombosis (DVT) 
among medical and surgical critically ill patients. The published main trial 
protocol and analysis plan 113, clearly demonstrated how the main trial protocol 
had been improved as a result of the internal pilot study 114. Analysis of data from 
the internal pilot, allowed, for example, the participant exclusion criteria to be 
broadened, making a main trial feasible and improving the ultimate applicability 
of the results.  
In public health, the ‘Walk to Work’ RCT sought to examine the effectiveness and 
cost effectiveness of an employer-led scheme to increase walking during the 
commute 115, and was funded as a result of a successful feasibility study 116.  The 
first phase of the feasibility study was development of the intervention including a 
resource review and focus group work. The second phase was a pilot exploratory 
cluster RCT to test the intervention and evaluate the processes and costs involved.  
The results demonstrated the feasibility of both the proposed intervention and its 
evaluation and secured further NIHR funding for a full-scale cluster RCT.  
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Surgical examples also exist. The ROCSS external feasibility study randomising 
patients to standard vs biological mesh closure of stoma site reinforcement, aimed 
to evaluate recruitment, randomisation and deliverability of the new surgical 
technique 117. This study successfully completed to inform a main trial funded by 
the NIHR 118. 
There are, therefore, some detailed examples in the published literature 
demonstrating how pilot work has informed main trial design. More commonly, 
however, pilot and feasibility studies have been vastly both inconsistently and 
under reported in the scientific literature. The reasons for this appear to be 
multifactorial and are discussed below. 
Inconsistent reporting of pilot and feasibility work 
It is possible that the lack of globally accepted definitions of pilot and feasibility 
studies (as discussed in chapter two) and the lack of understanding of their 
potential uses, may contribute to inconsistencies in the reporting literature. There 
are many examples of published surgical studies cited as ‘pilot studies’, that on 
closer inspection, are actually single centre, small RCTs 119-123 masquerading as 
pilot or feasibility studies. Interrogation of the work shows that the studies are not 
addressing areas of uncertainty preceding a main trial and are lacking 
investigation of possible uncertainties about the design or conduct of a main trial.  
Instead, the authors have undertaken formal hypothesis-testing and reported 
estimation of effect sizes 119-123. Studies may interpret the data to support or refute 
a hypothesis, even though many are not powered to test a hypothesis or 
adequately refute one. These studies therefore do not report on feasibility issues in 
order to inform definitive trials, and are also insufficient to inform evidence. Such 
studies can therefore be misleading and prevent main trials being undertaking by 
reporting definitive results.   
Certainly, in the past, the focus of much pilot work has been on hypothesis testing 
and estimating intervention effectiveness, but it is now generally accepted that 
pilot studies are not an appropriate setting in which to evaluate such issues 13, 72, 74, 
75, 92, 93, 95, 96. There has been acknowledgement amongst field experts that data on 
intervention safety or efficacy may be collected during a pilot or feasibility study 
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but should only be reported in descriptive terms. Such data should be clearly 
reported with the caveat of no firm conclusions being drawn because of a lack of 
statistical power 72, 75, 92, 124, 125, and changes in practice should therefore, not be 
based on the results of pilot work alone. Whilst misunderstanding may be the 
main reason why hypothesis testing has been performed within a pilot or 
feasibility study, another reason identified in the literature is judging such work 
may be more likely to be published, or more likely to be awarded funding or 
ethical approval if ‘results’ are given 74.   
The terms pilot and feasibility have also been used very loosely in the literature to 
mean for example, a study conducted by a junior or student 75, or a study looking 
at the technical feasibility of performing a new surgical procedure 126, 127. In 
addition, there is evidence in the literature of studies being redefined as pilot 
studies, a posteriori at the request of editorial boards. This practice has been 
undertaken seemingly to highlight the uncertainty of the results 128, which may 
include, for example, main trials that encountered difficulties with recruitment or 
intervention delivery. This is reiterated by Shanyinde et al 89 who suspected that 
many of the so called pilot RCTs in their review (n=50 of which 2 were surgical, 
also discussed in chapter 2), were named ‘pilot’ a posteriori when hypothesised 
effects were not seen or inadequate sample sizes were collated.   
Other reasons for mislabelling studies include the perceived lack of resources to 
perform a large adequately-powered study and replicating other small published 
‘pilot’ studies, thereby perpetuating the problems of misunderstanding and 
resource waste 75.  There has also been no requirement for formal registration of 
pilot and feasibility studies in the past, though improved regulation and guidance 
on research transparency and the requirement for formal registration of all clinical 
trials in order to gain ethical approval should improve this 129. 
Under reporting of pilot and feasibility work 
Previously, pilot work may frequently have been published as only a fleeting 
mention in the main trial report. There is now growing agreement that pilot and 
feasibility work, if conducted well, should always be published regardless of 
whether the results are ‘positive’ or ‘negative’ for conducting a main trial 74, to 
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allow others to learn about the best research processes and avoid future 
repetitions of ‘failed’ methods. A pilot study that shows a trial is not possible, may 
be considered to have had a negative outcome, but should still be published if the 
methodology is thorough and insightful 74, 130. Such studies may be important and 
useful to other researchers by, for example, avoiding repetition of the same 
mistakes and allowing development of methodological processes for future pilot 
and feasibility studies.  In addition, some have suggested that authors have an 
ethical obligation to report all issues arising from a study, including those from 
the pilot phase 91. All trials involve some risk to participants, which also increases 
the ethical obligation to publish the results 130.   
Although guidelines exist for the reporting of definitive main clinical trials 42, 131, 
until recently there have been no equivalent guidelines for reporting pilot and 
feasibility studies. Extensive methodological work amongst experts has now led to 
the development of an extension to the 2010 CONSORT statement 131, to 
standardise the reporting of external randomised pilot and feasibility studies done 
to inform a future RCT 79, 132. The statement does not, however, extend to internal 
pilot studies that are built into the design of a main trial or to non-randomised 
pilot and feasibility work, though the authors state that many of the principles will 
also apply to these types of study 79, 132.  The work involved establishing a working 
group and conducting a literature review, engaging stakeholders (including the 
CONSORT group, journal editors and publishers, the clinical trials community 
and funders), a Delphi process and a consensus meeting over the course of 5 years 
80.  The work also resulted in a new open access journal ‘Pilot and Feasibility 
Studies’ coming into print in January 2015, specifically to encourage the 
publication of pilot and feasibility study reports and protocols in all areas of 
research 133, 134. It is hoped that adhering to the CONSORT extension for the 
reporting of pilot and feasibility studies will significantly improve the 
dissemination of such work, and consequently improve the consistent and 
transparent sharing of ideas, methods, findings and lessons learned. 
In summary, the combination of a lack of established and widely used definitions, 
the narrow scope of issues explored, and both inconsistent and under reporting, 
may have previously hindered the perceived value of pilot and feasibility work.  
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Whilst the importance of pilot and feasibility work is acknowledged amongst 
experts in the field, and extensive methodological work has been done to try and 
improve the reporting of pilot and feasibility work, this view is as yet, not 
understood or accepted in the wider trials community.  Trials, therefore, may 
continue to be designed and conducted without the optimisation that learning 
from pilot and feasibility work would afford. With reference to surgery 
specifically, previous literature searches of the top 10 medical journals and the 
journal ‘Trials’ (01/01/11 to 31/08/13) identified 300 pilot studies of which, just 
five (6%) were in surgery. This work suggests the performance, accurate reporting 
and comprehensive publication of pilot and feasibility work in surgery is rare 111, 
112.  
In light of the knowledge accumulated from the published scientific literature both 
in general and specific to surgery, it was hypothesised that a traditional systematic 
review, sourcing published surgical pilot and feasibility studies from the scientific 
literature, would have added little to current knowledge and understanding of 
practice in this area. 
3.2.2 Rationale for a targeted review and systematic 
analysis of protocols of funded pilot/feasibility 
studies 
As established above, a narrative or systematic review of the literature regarding 
reported surgical pilot and feasibility studies would not have been helpful due to 
the ingrained challenges of inconsistent and under reporting of pilot and 
feasibility work in the literature. It was hypothesised, therefore, that a targeted 
review and systematic analysis of protocols of pilot and feasibility studies 
submitted for peer-review and successfully funded by established national bodies, 
might be more abundant and have more thorough methodological designs and 
describe those methods in more detail, than reports of pilot and feasibility studies 
published in the general scientific literature. The protocols of funded pilot and 
feasibility studies may, therefore, be more likely to contain relevant detail to aid 
understanding of how pre-surgical trial work may optimally inform future 
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definitive studies, and therefore, be of greater relevance to the overall aim of this 
thesis. 
A narrative review of published reports of funded pilot and feasibility projects 
would also have had significant limitations. Narrative literature reviews do not 
systematically select articles for inclusion, and are therefore subject to bias 135, as 
all the available data sources are not necessarily identified, included and 
objectively analysed. Narrative reviews may also be criticised for lack of 
transparency as the unsystematic approach means that the methods are not easily 
reproducible. A narrative review of funded surgical pilot and feasibility studies 
would also not have yielded the detailed information desired, to explicitly identify 
the issues around the design and conduct of such studies.  
Focusing on reviewing research funded by the National Institute for Health 
Research (NIHR) was hypothesised to be the most efficient use of time and 
resources within the limitations of this doctoral research. Other potential funders 
of surgical pilot and feasibility studies include, for example, the British Heart 
Foundation (BHF) and the Medical Research Council (MRC). However, whilst 
pilot and feasibility studies are funded by other groups, the NIHR is the major 
funder of studies of surgical interventions in the UK. The limitations of 
considering only NIHR funded pilot and feasibility work for this thesis, are 
further discussed in Chapter 7, section 7.4.1. The methods used for a targeted 
review and systematic analysis of protocols of surgical pilot and feasibility studies 
funded by the NIHR from are described in detail below.  
3.3 Definitions used in this thesis 
To begin this analysis of pilot and feasibility study protocols, it was necessary to 
first consider what a surgical trial is, and consequently therefore, what a surgical 
intervention is, to enable formation of inclusion and exclusion criteria for the 
review. It was also necessary to define pilot and feasibility work for the purposes 
of this thesis, in the absence of a universally accepted definition. The working 
definitions of a surgical trial, surgical intervention and a pilot/feasibility study are 
described in detail below. These definitions were developed by the author of this 
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thesis in light of consideration of definitions already available, the limitations of 
these definitions and the author’s personal experience of surgical practice and 
what this entails. Iterative discussion with other researchers (Avery/Blazeby) 
involved in this work also took place, informed by early scoping searches of the 
NIHR databases, to ensure that the definitions of both a surgical intervention and 
a pilot or feasibility study, were inclusive and relevant to modern surgical 
practice. 
3.3.1 What is a surgical trial? 
There is currently no consensus on what a surgical trial constitutes, because there 
is no consensus on the definition of what a surgical intervention is. The noun 
‘surgery’ is conventionally defined by the Oxford English Dictionary as “The art or 
practice of treating injuries, deformities, and other disorders by manual operation or 
instrumental appliances” 136.  Simplistically, a surgical trial could therefore be 
defined as one involving surgery as an intervention 137. However, surgical trials 
could also include those where surgery is performed, for example, as a co-
intervention to oncological treatment 138 or other medical therapies 139. Such trials 
are traditionally considered as oncological or pharmaceutical trials of medical 
therapies. However, surgery is often performed as a co-intervention to chemo- or 
radiotherapy or other pharmacological treatments in a pragmatic way, with no 
assessment or control. Additionally, surgical trials could include those where the 
intervention is not surgery in the traditional sense, but the intervention is 
performed by a surgeon. This would include trials of therapeutic endoscopy 
procedures and the medical management of surgical conditions such as acute 
pancreatitis or diverticulitis 140. Trials of the management of surgical conditions 
through the intervention of other healthcare professionals, may also be considered 
as surgical trials. This would include interventional radiological procedures, for 
example, to place a drain for an infected intra-abdominal collection, angioplasty 
for an ischaemic limb, or a stent for an obstructed colon.  Patients with these 
conditions would be admitted under the care of surgeons and have their treatment 
decisions and management co-ordinated by surgeons, but the management plan 
 
 41 
may include the intervention of other professionals, for example, physiotherapists 
or radiologists.   
In summary, surgical trials could be considered to more broadly encompass: i) 
trials where surgery is the main intervention; ii) trials where surgery is a co-
intervention; iii) trials where no surgery is performed but surgeons are 
administering or managing other treatments or; iv) trials where other health 
professionals are administering treatments to patients under the care and 
responsibility of surgeons. When we consider trials, it is the complexity of the 
intervention, which defines the challenges of trial design and the methodology 
used to design, implement and conduct them. It may be more helpful, therefore, to 
consider and define what a surgical intervention is. 
3.3.2 What is a surgical intervention? 
Surgical interventions have been described in many ways and there is currently no 
universally agreed definition. Cook described surgical interventions as: “…those 
which involve physically changing body tissues and organs through manual operation 
such as cutting, abrading, suturing or the use of lasers” 12. Blencowe et al. expanded on 
this definition and described a surgical intervention as one: “…that cuts or 
physically alters a patient’s tissues (whether using a scalpel, stapler, laser or another 
instrument or device) and involves the use of a sterile environment, anaesthesia, antiseptic 
conditions and suturing or stapling” 14.  In a subsequent systematic review published 
by some of the same authors, surgical interventions were defined as “…procedures 
involving an incision with instruments usually performed in an operating theatre and 
normally involving anaesthesia and/or respiratory assistance” 15.  
The key points in these definitions include cutting or incising a patient’s tissues in 
a sterile environment, involving anaesthesia. They seem to define a more 
traditional operation in an operating theatre. As surgical techniques continue to 
evolve, especially in the areas of endoscopy and interventional radiology, these 
definitions may no longer be broad reaching enough. They lack wider 
consideration of who can perform a surgical intervention, where it can be 
performed; using what if any form of anaesthesia, and for what reasons. 
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For the purposes of this thesis, a surgical intervention was defined as (see also 
Figure 3a):  
A diagnostic, therapeutic or adjunctive invasive intervention performed by a 
trained clinician, using hands, instruments and/or devices where: 
Diagnostic is defined as – Performed to aid in reaching a diagnosis and; 
Therapeutic is defined as - Performed to attempt to treat and/or cure pathology 
and; 
Adjunctive is defined as – Performed to allow another intervention to proceed 
and; 
Invasive is defined as - Penetrating the body of a patient either via the patient 
being cut or via a natural external orifice and; 
Trained clinician is defined as – A registered healthcare professional qualified 
and trained to perform surgical interventions. This will include surgeons, 
interventional radiologists, endoscopists, dentists and surgical care practitioners. 
Importantly, a surgical intervention is not necessarily always performed by a 
surgeon, but must be performed by a registered doctor, dentist or nurse and; 
Hands, instruments and/or devices encompasses all surgical equipment and 
techniques.  
A surgical intervention may be performed using anaesthesia (local or general), 
sedation or with the patient awake and fully co-operative. To clarify further, 
surgical interventions may also be considered in terms of their method of 
performance and be sub classified as operative and/or endoscopic and/or 




Figure 3a Classification of surgical interventions 
KEY: CT = Computerised Tomography 
 
This definition does not include diagnostic imaging performed with the 
administration of intravenous contrast through a simple single-use needle or 
cannula which is not inserted under image guidance, for example, computerised 
tomography (CT), angiography or fluoroscopy. Similarly, the administration of 
drugs via a simple needle or cannula being percutaneously inserted into a blood 
vessel without image guidance (for example, chemotherapy, intravenous fluids or 
haemodialysis) are not considered to be surgical interventions.  Acupuncture is an 
alternative therapy administered though the placement of needles at certain 
points, but this is not done under image guidance, so would not be considered a 
form of surgical intervention. 
Finally, this definition excludes manipulations done by hand, for example external 
cephalic version (ECV) of a breech or transverse lying foetus, or manipulation of a 
fractured bone. These procedures do not require penetration of the patient’s body 
and are therefore non-invasive. ECV may be performed by any trained person 
Surgical Intervention
A diagnostic, therapeutic or adjunctive invasive intervention 
performed by a trained clinician, using hands, instruments 
and/or devices.
Operative 
A procedure that 
involves the clinician 
gaining access via the 
patient being cut.
Endoscopic
A procedure that 
involves the clinician 
gaining a view and access 
within a body cavity via a 
natural external orifice 
using any form of 
endoscope.
Radiological
A procedure that involves 
the clinician gaining 
percutaneous access to 
the body and takes place 
under the guidance of an 
imaging technique such 




















with appropriate ultrasound skills and in an environment with access to theatre 
facilities should complications arise. Many manipulations of fractures are simply 
performed in the accident and emergency department by trained physicians or 
nurses, with only children needing to undergo general anaesthesia routinely.  
Some procedures cross multiple categories. The adaption of endoscopic or 
radiological techniques to gain access through the skin or via the gastrointestinal 
tract lumen to a normally closed body cavity, for example.  Such procedures 
include percutaneous necrosectomy (the insertion of the drain is an adjunctive 
radiological surgical intervention and the necrosectomy is a therapeutic operative 
surgical intervention), transgastric necrosectomy (the insertion of the 
cystgastrostomy is an adjunctive endoscopic surgical intervention and the 
necrosectomy a therapeutic endoscopic and operative surgical intervention) and 
percutaneous nephrolithotomy (again the insertion of the stent is an adjunctive  
radiological surgical intervention and the nephrolithotomy is a therapeutic 
operative surgical intervention. 
The definition described above and used for the work in phase one of this thesis, 
was used as the preliminary definition for the work published by Cousins et al in 
2019 141, to describe and define what an invasive procedure is. The final definition 
of an invasive procedure described by Cousins et al 141, which includes reference to 
the method of access to the body, instrumentation and requirement for operator 
skill, was created by applying it iteratively to 3946 included articles published 
over ten years, therefore verifying that the final definition was applicable to all 
invasive procedures.  
3.3.3 What is a pilot and/or feasibility study? 
As already discussed in Chapter two, there are many definitions of pilot and 
feasibility studies. Those relevant to clinical trials and the nuances and difficulties 
with universal acceptance, have been discussed in detail.  
For clarity and inclusivity, the term pilot/feasibility study (PFS) was coined for 
the purposes of this thesis and defined as: 
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Any research that is undertaken before a main study and is explicitly intended 
to inform the design and/or conduct of a future main study where:  
Main study is defined as a definitive study (e.g. RCT) of an intervention(s).   
Traditionally, so called internal pilot studies, have been included within the wider 
definitions of pilot and feasibility studies (see also Chapter two). However, expert 
opinion has grown over the course of this thesis amongst trial methodologists that 
internal pilots do not meet the ‘true’ definition of pilot studies 85. Internal pilots 
are very distinct from external pilots in their methodology, being designed and 
funded as the first phase of a main trial with all data generated from this first 
phase contributing to the final analysis 84. Internal pilots are, therefore, most often 
utilised when no substantive changes to key components of the trial, such as the 
intervention or outcomes, are anticipated. In addition, study protocols of RCTs 
with an internal pilot phase usually include only limited detail regarding the 
internal pilot phase itself, such as a list of proposed progression criteria. It was 
considered, therefore, that a review of trial protocols with an integrated internal 
pilot phase, would be of limited value for the purposes of this work. Internal pilots 
were, therefore, not considered to meet the definition of pilot studies in this thesis.  
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Table 3.1 Sub classification of surgical interventions in terms of method of performance
Sub-classification Definition Examples 
Operative A procedure that involves 
the clinician gaining access 
via the patient being cut. 
 
• Laparoscopic procedures (as cuts to the skin are made to gain access).   
• Laparotomy for bowel resection 
• Excision of a breast lump 
• High tie and strip of varicose veins.   
• Insertion of peritoneal dialysis catheters (adjunctive operative surgical intervention as the intervention to insert the PD catheter 
is surgical but the Continual Abdominal Peritoneal Dialysis (CAPD) intervention given via the catheter is not).   
• Some types of dental surgery where cuts in the mouth are made. 
Endoscopic A procedure that involves 
the clinician gaining a view 
and access within a body 
cavity via a natural external 
orifice using any form of 
endoscope.   
• Simple endoscopy procedures with or without biopsy (diagnostic endoscopic surgical interventions).   
All therapeutic endoscopic procedures:  
• Oesophagogastroduodenoscopy and Botox injection/stent insertion/PEG placement 
• Endoscopic retrograde cholangiopancreatography (ERCP) and stone extraction 
• Colonoscopy and polyp removal 
• Sigmoidoscopy and transanal endoscopic microsurgery (TEMS) 
• Proctoscopy and haemorrhoid treatments 
• Ureteroscopy and stone extraction 
• Cystoscopy and resection of a bladder tumour 
• Urethroscopy and urethrotomy 
• Hysteroscopy and removal of fibroids 
• Colposcopy and large loop excision of the transformation zone (LLETZ) 
• Bronchoscopy and removal of foreign body 
• Rhinoscopy and removal of polyps.   
Radiological A procedure that involves 
the clinician gaining 
percutaneous access to the 
body and takes place under 
the guidance of an imaging 
technique such as 
ultrasound, x-ray or 
computerised tomography 
(CT).   
• Angiogram and angioplasty 
• Insertion of a drain to treat a collection 
• Percutaneous transhepatic cholangiography (PTC) and stent insertion 
• Insertion of a pacemaker 
• Simple biopsy procedures under image guidance e.g. liver biopsy (diagnostic radiological surgical intervention) 
• Insertion of tunnelled lines e.g. Hickman or Pick lines under ultrasound guidance, via a percutaneous needle puncture to the skin 
and tunnelled within the subcutaneous tissues.  The lines themselves are neither diagnostic nor therapeutic but are used for the 
purpose of administering drugs, nutrition or for monitoring.  Such lines would therefore be considered as adjunctive radiological 
surgical interventions.   
• Aspiration and steroid injection of joints under image guidance would be classified as therapeutic radiological surgical 
interventions (percutaneous access is gained under image guidance and treatment given). 
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3.4 Methods for the targeted review and 
systematic analysis of NIHR funded surgical pilot 
and feasibility studies 
3.4.1 Characteristics of information sources 
The UK NIHR Health Technology Assessment (HTA) and Research for Patient 
Benefit (RfPB) programmes were selected to identify PFS of surgical interventions. 
These programmes are established major national funders of high-quality patient-
centred research. The HTA have funded trials for 26 years (since 1993) and up to 
£10m and RfPB for 13 years (since 2006) and up £350K. Both programmes fund 
definitive evaluations of the clinical and cost-effectiveness of interventions as well 
as feasibility studies to inform future definitive trials. They have publicly available 
and searchable databases of funded studies 142, 143. Given the scope and longevity 
of both programmes, it was hypothesised that each would have funded surgical 
PFS, providing a sample of potentially well-designed work from which to explore 
the role of PFS in surgery. Other NIHR funding streams were considered but 
excluded early on, as they fund surgical research far less commonly. The 
limitations of this approach are discussed in detail in Chapter seven, section 7.4.1. 
3.4.2 Search strategy and screening 
The HTA and RfPB databases 142, 143 were searched for surgical PFS studies, which 
met the definitions as described above. Titles and abstracts were screened in 
duplicate by two researchers (Fairhurst/Rowlands – see acknowledgements), with 
any issues resolved by discussion (Fairhurst/Rowlands) and/or senior input 
where necessary (Avery/Blazeby – see acknowledgments). Protocols for all 
included HTA studies were downloaded from the HTA website and those for all 
included RfPB studies (apart from one available online) were obtained by 
contacting the chief investigator of each study directly by email. Additional 
publications relating to included studies were identified by searching for links to 
published outputs on the NIHR website (HTA only), and using the study title, 
acronym and chief investigator name to search on two electronic bibliographic 
databases, PubMed and Google Scholar, and the International Standard 
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Randomised Controlled Trials Number (ISRCTN) trials registry online. It was 
important to search for published outputs, to attempt to consider the outcomes of 
the PFS, in terms of publication of the PFS and main trial feasibility, development 
and funding.  
In addition to searching electronically, chief investigators of the PFS were also 
contacted by email once the study end date had passed beyond six months, to 
request PFS outcome information. Finally, at the end of the PhD studentship 
period, the NIHR were contacted (see acknowledgements) to corroborate 
published data sources and confirm any main trial funding granted for the 
included PFS. This was necessary, particularly for the RfPB funded studies, for 
which there is currently no requirement for public reporting. In addition, main 
trials do not always retain the same PFS title, study acronym, or chief investigator, 
making it difficult to search for subsequent main trials electronically. 
3.4.3 Inclusion and exclusion criteria 
Protocols of all surgical PFS funded by the NIHR HTA and RfPB programmes 
between 01.01.2005 and 31.12.2015 were included. The most recent ten-year period 
was chosen for inclusion, as it was known that the methodological developments 
surrounding the design and conduct of PFS for complex interventions had 
happened over the last ten to fifteen years. In addition, the RfPB only started 
funding studies in 2006. To reiterate, in the absence of universally adopted 
definitions of ‘surgical interventions’ and ‘pilot/feasibility studies’, for the 
purposes of this work, pilot/feasibility work was defined as (see section 3.3.4): 
Any research that is undertaken before a main study and is explicitly intended 
to inform the design and/or conduct of a future main study where:  
Main study is defined as a definitive study (e.g. RCT) of an intervention(s).   
A surgical intervention was defined as (see section 3.3.2): 
A diagnostic, therapeutic or adjunctive invasive intervention performed by a 
trained clinician, using hands, instruments and/or devices and includes 
operative, radiological and endoscopic procedures.  
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As described in section 3.3.3 above, internal pilot studies were excluded as they 
did not meet the definition of a PFS used in this thesis. Funded systematic reviews 
that did not state any intention to inform a future definitive study (and therefore 
did not meet the definition of a PFS) were also excluded. In addition, studies that 
focused on the evaluation of co-interventions to surgery as the main intervention 
under examination, for example the administration of anaesthetic drugs, and post-
operative rehabilitation or enhanced recovery programmes were also excluded. 
This was because the primary focus of this work was to explore the specific 
difficulties surrounding studies of surgical interventions (as defined above and 
section 3.3.2), rather than interventions that have relevance to surgical practice, 
but are not actually surgical interventions themselves. Table 3.2 below 
summarises the inclusion and exclusion criteria for the systematic analysis and 
targeted review. 
Table 3.2 Inclusion/exclusion criteria for screening NIHR HTA and RfPB funded studies 
 
3.4.4 Data extraction 
Data were extracted using a standardised database developed in Microsoft Excel 
(See Appendix I for details of data extraction), including general study 
characteristics, available data sources in addition to the study protocol (published 
papers) and the surgical specialty of the study. Details of the PFS design 
(randomised or non-randomised; quantitative or qualitative) and conduct, 
including characteristics of the patient population, were extracted. A framework 
was developed for capturing the uncertainties and challenges regarding the 
viability of a future main trial, informed by expert knowledge and previous 
methodological work regarding the design, definitions and reporting of PFS 71, 72, 
74, 75, 79, 89, 91-93, 95, 96, the published MRC guidelines 13 and the IDEAL framework 101, 
144.  
Inclusion Criteria Exclusion Criteria 
1 Pilot/feasibility work of a surgical intervention 1 Not a surgical intervention 
2 Funded by the HTA/RfPB between 2005-2015 2 Surgical intervention, not pilot/feasibility work 
  3 
3a 
Surgical intervention is a co-intervention 
And not pilot/feasibility work 
  4 Protocol/publication not in English 
  5 Study not in humans 
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All possible reasons identified for undertaking PFS were grouped into five key 
domains: 1) main trial design; 2) logistics; 3) recruitment; 4) intervention, and; 5) 
outcomes. When developing the domains, the timeline of trial design and conduct 
was considered and the domains broadly follow this from logistics (domain 2) in 
terms of trial processes and set-up, to outcomes (domain 5) as the end point of 
trials. The first domain of ‘main trial design’ consisted of predominantly 
overarching uncertainty questions, such as the feasibility or necessity of a main 
trial, the trial costs, and sample size calculations.  
The domains were constructed and ordered as data extraction progressed with 
cross checking between researchers (Fairhurst/Avery). The framework was 
modified in an iterative manner as data collection and extraction progressed to be 
responsive to the emerging data, as further reasons for undertaking PFS were 
identified. Special consideration was given to uncertainties and challenges 
considered more specific and/or relevant to surgical trials. 
3.4.5 Data analyses 
Results were analysed within Microsoft Excel, using simple descriptive statistical 
methods (means, medians, percentages). Data were tabulated and descriptive 
statistics are reported in Chapter four, with comparison between the HTA and 
RfPB and randomised and non-randomised cohorts where relevant. Analysing the 
HTA and RfPB cohorts separately was deemed important to consider any 




Phase II: Exploring Perceptions and Experiences 
of Pilot Work for Surgical Trials: A Qualitative 
Research Study (PEPSTAR) 
3.5 Rationale for Phase II of this thesis 
The rationale and methods for the qualitative interview study to explore key 
stakeholder’s views, perceptions and experiences of surgical PFS will now be 
described. In phase I of this thesis, the quantitative targeted review and systematic 
analysis of NIHR funded surgical PFS protocols, the methods of which are 
described in sections 3.2-3.4 of this chapter, aimed to identify the type and 
frequency of surgical PFS being funded and performed in the UK. In addition, the 
type and frequency of misunderstandings and potential challenges in this area, 
that may be preventing the optimal design and conduct of PFS and thereby 
hampering definitive surgical trials were sought.  
To improve understanding of why challenges and barriers may exist to optimally 
designing and conducting PFS in surgery, an in-depth exploration of the views of 
key stakeholders was considered necessary. The aim of this ‘PEPSTAR’ study was, 
therefore, to use qualitative methods to explore in detail the experience, 
perceptions, attitudes and opinions of surgeons, trialists, methodologists and 
funders of the role of PFS in surgical trials and identify any barriers and potential 
solutions. A detailed rationale for using qualitative methods, followed by a 
description of the specific methods used in the PEPSTAR qualitative interview 
study are reported below. 
3.5.1 Rationale for using qualitative methods in 
Health Services Research 
Qualitative research is very simply defined as study of the social world, and has 
been described as a “very broad church” 145 crossing a range of techniques, 
approaches and research disciplines. Over the last century, the field has been 
influenced by many disciplines such as sociology and anthropology, and 
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numerous different schools of thought have emerged resulting in extensive 
variation regarding the purpose and practice of qualitative research methods 146. 
The wider applications of qualitative research are increasingly recognised with the 
realisation that such techniques may complement and enhance more traditional 
quantitative methods in answering questions more effectively and efficiently 147.   
Qualitative research is rooted within the social sciences and very simply, seeks to 
understand ‘why’ and ‘how’ social phenomena occur, by interpreting data on the 
perspectives of people involved 148. It may be performed as standalone research, 
or in combination with, and complimentary to, quantitative research (such that the 
combination of these different methods is termed ‘mixed-methods’ research) 149. It 
is now widely recognised that in the context of Health Services Research, the 
importance of understanding people from the perspective of being both providers 
and/or recipients of services and treatments, is essential 146. The widespread 
inclusion of qualitative research in areas such as Health Services Research and 
health technology assessment is, therefore, now fairly common practice in the UK 
149-151. However, the robustness of all research depends on the quality of the 
methods used. As qualitative research is such a broad field it is, therefore, vital 
that the specific methods used in any project, are described and justified in the 
context of the research question being asked. 
3.5.2 Previous qualitative work exploring 
stakeholders’ views towards pilot and feasibility 
work for surgical trials 
No previous qualitative work has specifically explored the experiences and 
perceptions of surgeons, trialists, methodologists and funders regarding the role 
of and challenges to completing pilot work for surgical trials. However, 
qualitative work has been widely utilised in surgical trials more broadly to, for 
example, explore barriers to recruitment to surgical trials 17, 24, 152-155, explore 
different surgical trial designs 156, and train surgeons in conveying equipoise and 
optimising recruitment techniques to surgical trials 157-159. With the knowledge 
that qualitative work has been proven to optimise the success of surgical trials 157 
such work is therefore, often deemed essential for the design, conduct and 
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optimisation of surgical trials, though it is often not well reported in the scientific 
literature 160. 
Qualitative work is therefore justified as important to explore why PFS in surgery 
are not currently optimised, through better understanding key stakeholders’ 
perspectives, experiences and views, and to formulate solutions for how PFS for 
surgical trials might be pragmatically optimised in the future. 
A description and overview of various qualitative research methods that are 
considered relevant to achieve the aims and objectives of this work now follows. A 
justification and detailed description of the qualitative methods used for the 
PEPSTAR qualitative interview study will then be described in detail. 
3.6 Philosophical approaches to qualitative 
research  
Qualitative and quantitative research methodologies are rooted in philosophy, 
being influenced by different ontological and epistemological assumptions, often 
via embedding of such assumptions within a particular research paradigm. 
Ontology is defined by the Oxford English Dictionary as: “The science or study of 
being”, and epistemology as: “The theory of knowledge and understanding, especially 
with regard to its methods, validity and scope, and the distinction between justified belief 
and opinion” 136. Both methodologies focus on defining a research paradigm as a 
theoretical framework, by which to describe a belief system about knowledge and 
understanding relating to a given topic. The research paradigm (or theoretical 
framework) includes the ontological and epistemological assumptions made as 
part of this belief system 148. Different research paradigms, such as the posited 
opposites of positivism and interpretivism, therefore assume different ontological 
and epistemological approaches to each other (see Table 3.3).
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 Table 3.3 Qualitative research paradigms 148, 161, 162 
The paradigms of positivism and interpretivism can be considered as opposing 
with respect to the view that the former focuses on hypothesis testing using 
quantitative methods, and the latter hypothesis generating using qualitative 
methods. The so termed “paradigm debate” encompasses consideration as to 
whether qualitative and quantitative methodology can be combined 163. 
Qualitative research has mostly emerged from the concept of interpretivism, as an 
alternative to positivism, meaning that there may be many realities and all of these 
need to be interpreted in the context of social, historical and individual influences 
(or alternatively reality is ‘constructed’ by the influence of these contexts; so 
termed constructivism) 148. However, positivism and interpretivism should 
probably not be considered simply as polar opposites 162. For any research, the 
approach, or combination of approaches will be determined by what one is trying 
to achieve 162, and therefore, any single research paradigm may not sit entirely 
separately from another.  
It is suggested that our ontological beliefs, and epistemological understandings 
are interconnected with the methodology and methods and none can therefore, be 
viewed in isolation 164.  Many argue that subscribing to a single research paradigm 
Paradigm Ontology Epistemology Methodology 
Positivism 
 
Objective reality or 
truth 
People know, accept and 






No single reality or 
truth 
Reality needs to be 
interpreted (or is variable 





Postmodernism A fragmented ever-
changing reality 
Many ways of 
understanding reality 
(epistemological pluralism) 
which may include e.g. 
premodernism (revelation), 
modernism (science & 
reason), intuition etc. 
Wide range of 
methods 
Realism Critical  Ability to know an 
objective reality is 
imperfect 
Objective reality is an ideal 
to strive for through 
research, but we cannot 
separate ourselves from 










is unhelpful and restrictive, and that doing so is neither “necessary or desirable” for 
qualitative research 165. As a result of recognition that different research questions 
require different approaches, other recognised research paradigms have emerged 
which blend and build on positivism and interpretivism.  
Modern qualitative research, for example, also considers the characteristics and 
experiences of the researcher(s) and how these may influence the methodology, 
data collection and analysis (a concept known as reflexivity – see sections 3.7.4 
and 3.12) 166. This is based on the understanding that, at the core of all qualitative 
research, is the concept that individuals may interpret the world around them 
differently, depending on the social contexts to which they are subjected 148. 
Paradigms such as critical realism 167 (see table 3.3), for example, acknowledge 
both the way individuals may interpret the world around them, and how the 
broader social constructs may impact on those interpretations, whilst also 
retaining a focus on the data itself.  
The philosophical basis for research, may also be described as the ‘theoretical lens’ 
that underlies the researcher’s choices and assumptions, and through which the 
data collection, analysis and interpretation of the findings is viewed 168. Primarily, 
it is key that the researcher identifies if a philosophical paradigm is subscribed to, 
and clearly describes and justifies the choice (or not) of philosophical paradigm, 
and how it may affect the interpretation of the results. 
3.7 Ensuring rigour of qualitative research 
There has been much discussion about how to ensure the scientific rigour of 
qualitative research 162, 164. Much of this discussion has been around whether it is 
possible to judge qualitative research by the same quality criteria as quantitative 
research 150, 169. This discussion opens a wider epistemological debate about the 
nature of knowledge produced by qualitative research and if and how the quality 
of this knowledge and research can feasibly be critiqued. A realist approach, as 
described in section 3.6 above, assumes that an objective reality or ‘truth’ is a goal 
to aim for through research, but might never be fully attained. In the absence of an 
absolute ‘truth’, it therefore allows the assessment of the perspectives and values 
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of different research methods in relation to each other 150. The various ways of 
improving and justifying the quality of qualitative research are outlined below. 
3.7.1 Clear description of qualitative research methods 
All research is a product of good (or bad) methodology. A clear account of the 
process of data collection and analysis is, therefore, essential to determine if and 
how the research was thoroughly conducted. Unfortunately, it has been observed 
that many qualitative researchers have neglected to give an adequate description 
of the assumptions and methods used, which has probably contributed to 
criticisms of bias and lack of rigour from quantitative researchers 169. A detailed 
description of the various qualitative methods available, and how these may be 
optimally used, is documented below. 
3.7.2 Qualitative sampling  
Qualitative sampling techniques 
The purpose of qualitative research is to consider a more holistic view of the 
phenomena being investigated 170. Achieving a statistically representative sample 
of the population of interest is, therefore, not the aim of qualitative research. 
Instead, purposive or theoretical sampling strategies, also termed non-probability 
sampling, are employed to select participants, settings or events with particular 
characteristics that relate to the research question 169. 
Generalisability is defined as the extent to which the findings can be applied 
more widely to other settings or populations 171. It is a method used in 
quantitative research to determine the importance or relevance of the research 
more widely. A criticism of qualitative research has been the difficulty of 
demonstrating generalisability because of a lack of systematic probability 
sampling 169, 171.  
However, there are many types of purposive sampling, that range from the 
heterogeneous (sampling to capture a wide range of perspectives relating to the 
phenomena being studied), to the homogenous (aiming to achieve a sample 
sharing very similar characteristics). Sampling techniques also have variant 
terminology, so it is most important to describe what technique was used and 
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why. Though qualitative samples do not seek to be statistically representative, if a 
thoughtful, well informed and described sampling strategy is used, it minimises 
bias from convenience sampling and produces a sample most relevant to the 
research question. Different purposive sampling techniques include: 
Maximum variation sampling: Also termed heterogeneous sampling, is used to 
capture a wide range of perspectives of the phenomena being studied. The 
populations being studied may, therefore, exhibit a wide range of characteristics 
in terms of attributes, behaviours, experiences, opinions, for example. A maximum 
variation derived sample should include typical, extreme/deviant and critical 
cases (see below); 
Typical case sampling: Refers to selecting the most usual, commonly occurring or 
ordinary cases of the phenomena being studied; 
Extreme/deviant case sampling: Aims to sample cases that may offer unusual or 
rare examples of the phenomena being studied; 
Critical case sampling: Samples cases with unique perspectives of the phenomena 
being studied that may provide particularly decisive or important data;  
Homogeneous sampling: Focuses on sampling cases with very similar attributes, 
behaviours, characteristics, experiences and so on. Homogenous sampling is the 
opposite of heterogeneous sampling (maximum variation sampling); 
Theoretical sampling: First described by Glaser and Strauss 172, this is a form of 
purposive sampling, where the sample is selected based on the potential 
contribution to the development of a hypothesis. It involves an iterative approach 
where an initial sample is selected, the data analysed, and a further sample then 
selected to refine the emerging theories.  
Snowball sampling: This sampling technique involves asking current participants 
to suggest other participants who may usefully contribute to the research through 
adding additional or different perspectives to the phenomena being studied. 




In practice, a combination of sampling approaches is often utilised. Pragmatic 
factors such as time and availability of resources may also legitimately contribute 
to decisions regarding the sampling method 173. 
In terms of sample size, for qualitative research this is usually small because 
phenomena only need to occur once 145.  This means that, as the data are analysed, 
there will be a point at which data saturation is reached and no new themes are 
emerging and established themes cease to evolve 148. Data saturation was first 
coined as a term, in Glaser and Strauss’ original publication on grounded theory 
172 to signify when data collection and analysis could cease. Since then, extensive 
methodological discussion in the literature has identified different models of data 
saturation, which should be operationalised dependent on the research question, 
theoretical position and data analysis approach taken 174. In particular, it is 
advocated that a ‘point’ of data saturation may not always be appropriate and that 
defining saturation should be considered as a process, where further data 
collection becomes “counterproductive” 175 or a matter of “diminishing returns” 176. 
Data saturation may therefore be considered as a “cumulative judgment” which 
considers whether “sufficient depth of understanding has been achieved in relation to 
emergent theoretical categories” 174. Additional reasons for a moderate sample size 
include that there is no requirement for statistical analysis and an appropriately 
powered sample size to determine statistical significance, and that the data are 
very rich in detail meaning analysis is resource intensive 145.  
3.7.3 Qualitative data collection 
Types of qualitative data collection 
The main types of data analysed in qualitative research include direct 
observations, interviews, and documents.  
Observations 
The systematic study of people and cultures, designed to explore the cultural 
phenomena from the perspectives of the study subjects, is called ethnography. 
Predominantly, ethnography involves observation of people and events within 
their natural or usual setting, either as an immersed participant or as a non-
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participant observer. In the former, the researcher immerses oneself within the 
group, which may allow a unique perspective for gaining deep understanding 
about the nuances of social interactions 166. 
Interviews 
Individual interviews with participants may be structured or semi-structured. 
Structured interviews use a questionnaire which delivers the same questions to all 
participants, whereas semi-structured interviews are usually based around a topic 
guide, providing a basic structure around which to ask open-ended questions, 
therefore allowing experiences to be explored and topics of importance to 
participants to emerge. Regardless of the degree of structure, in-depth interviews 
allow specific topics or experiences to be explored in more detail. 
Focus groups are a form of group interview in which a small group of participants 
are interviewed together, and their responses to each other, as well as to the 
interviewer are collected. This group interview technique is useful for exploring 
shared experiences and, for example, identifying contentious issues and achieving 
consensus 164. 
Documents 
Ethnographic data collection may also be performed by gathering documents 
important to the population being studied, such as minutes of meetings, diaries, or 
photographs 177.   
3.7.4 Qualitative data analysis 
One of the major ways in which qualitative research differs from quantitative 
research is in the plurality of data analyses and interpretations, whereas in 
quantitative research the only route from data to conclusions is via statistical or 
other numerical analysis 171. Qualitative data analysis begins during data 
collection and is almost inevitable as the researcher is ‘in the field’ and naturally 
beginning to process the data being collected during, for example, one-to-one 
interviews 178. The term ‘grounded theory’ describes an approach first described 
by Glaser and Strauss 172, which aims to develop theories around phenomena that 
are ‘grounded’ in systematic examination of the qualitative data. The key concepts 
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of grounded theory are that the data are analysed in an iterative and cyclical 
approach of data collection, using theoretical sampling, and simultaneous 
analysis. This type of qualitative data analysis may be described as inductive, 
where data are collected and analysed and theories emerge from the data itself. 
An inductive approach to data analysis is opposite to a deductive approach, 
where theories or hypotheses are developed a priori, and tested against the 
analysed data 148. In the inductive approach consistent with grounded theory, data 
are collected, analysed, and further participant sampling takes place based on 
emerging theories, to confirm or challenge these emerging theories 179. Therefore, 
a principle of constant comparison is central to grounded theory, where the data 
are compared and contrasted to emerging theories to allow those theories to 
develop and evolve into well-grounded theories, induced by the data 179. 
Thematic analysis, first named and explicitly described in the ‘how to’ guidance 
published in 2006 by Braun and Clarke 180, is a flexible form of qualitative data 
analysis which is independent of any specific theory or epistemology.  Braun and 
Clarke describe how thematic analysis includes many of the concepts of grounded 
theory, but without needing researchers to “subscribe to the implicit theoretical 
commitments of grounded theory”, though also emphasising that it is still essential to 
be clear on what philosophical assumptions have been made. Thematic analysis is, 
therefore, proposed by Braun and Clarke 180 as a more accessible form of analysis 
for those in the early stages of a qualitative research career. Consequently, 
thematic analysis is a commonly used approach to analysing qualitative data 177. 
The Braun and Clarke guidance 180 describes the six stages of thematic analysis as: 
1. Familiarising yourself with the data; 2. Generating initial codes; 3. Searching for 
themes; 4. Reviewing themes; 5. Defining and naming themes and; 6. Producing 
the report.  The authors describe how thematic analysis can be applied in an 
inductive or ‘bottom up’ way, where data are collected specifically for the research 
(for example, interviews) and analysed without trying to fit it into a pre-existing 
framework, or the researcher’s preconceptions of the subject area. Alternatively, 
Braun and Clarke describe how thematic analysis can be applied in a deductive or 
theoretical ‘top down’ way in which a framework is derived at the start of data 
analysis and the data coded against this framework. Braun and Clarke describe 
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how thematic analysis can, therefore, take many different approaches, but a key 
concept of their thematic approach is that the final account details what approach 
was taken and why 180. 
Ensuring validity and reliability of the data analysis 
Computer software packages have become increasingly popular to aid qualitative 
data analysis 169, 178. They can be used to assist data organisation, sorting and 
retrieval and also some forms of analysis, for example by using algorithms to 
identify repeatedly occurring codes 178. However, it has been widely noted that 
computer software such as NVivo 181 and ATLAS 182 are not complete methods of 
analysis in themselves and are, therefore, unable to make the sometimes complex 
conceptual links between data and emerging theories 178. It has been proposed that 
computer software packages may improve the transparency of qualitative data 
analysis (by producing a well-documented audit trail of the analysis process) and 
consequently improve reliability 146. 
Multiple coding has been advocated as another method to improve the reliability 
of qualitative data analysis. In this approach, independent assessment and coding 
of the data by more than one researcher occurs, in an attempt to improve inter-
rater reliability 169. However, the purpose of the multiple coding is mostly to 
identify potentially different explanations for the findings, and therefore refine the 
emerging themes 183. 
The process of respondent validation or member checking seeks to feed back the 
research findings to the participants, with the aim of establishing correlations and 
incorporating any feedback from participants into the final study findings. 
However, it is thought that this method has limited value in improving qualitative 
research validity 150. Researchers seek to summarise and theorise the data, but 
participants offer a personal and potentially unique view, which may be at odds 
with the overall study findings. Respondent validation may be more 
constructively considered as an additional research process to reduce error, which 
also generates additional data requiring further interpretation 184. 
Triangulation refers to a process by which data or evidence is sought from two or 
more independent sources. Whilst often proposed as a method of ensuring 
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validity it perhaps more accurately describes a method to ensure 
comprehensiveness and encouraging a reflexive approach to the data 150.  
Researchers should also thoroughly examine the data for deviant or negative 
cases which are defined as those data by which the researcher’s explanatory 
theory appears weak or contradicted. This allows emerging theories to be further 
evolved and refined, or at the very least demonstrate a range of viewpoints 150.  
Reflexivity refers to being mindful of how both the researcher and research 
methods have shaped the data collection and analysis. The effects of age, sex, 
social class, professional status and prior knowledge of the research area can all 
have an affected on the data collection and analysis (even if unintended). It is 
vitally important for the validity of the research findings, to explicitly report 
contextual details around personal or intellectual biases 171. 
3.8 Qualitative methods used for the PEPSTAR 
study 
3.8.1 Ethical approval 
Ethical approval was sought for the PEPSTAR study through the University of 
Bristol Faculty of Health Sciences Research ethics committee (FREC) and granted 
on 13th October 2016 (Application Number 41001 – See Appendix III to thesis: 
Favourable opinion letter). 
3.8.2 PEPSTAR philosophical approach  
A critical realist approach was taken to the project conduct and interpretation of 
the data. A critical realist approach (or theoretical lens), as described in section 3.6 
earlier in this chapter, acknowledges that our ability to know an objective reality 
or ‘truth’ is imperfect, and that our interpretation of this truth is influenced both 
by our own knowledge and by the broader social constructs around us. As already 
established in chapter two, there is no universally accepted truth regarding the 
definitions, design and conduct of surgical PFS. However, there are published 
available definitions of PFS and methodological frameworks for designing and 
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conducting PFS (for example, the IDEAL framework and the MRC complex 
interventions guidance) in existence, though these are considered imperfect.  
In terms of the PEPSTAR interview study, the objective reality, or ‘truth’, was 
considered as the available, though imperfectly and variably perceived, 
definitions and current methodological understanding of PFS as thoroughly 
described in Chapter 2. A critical realist philosophical approach, or theoretical 
lens, is therefore justified as appropriate for this work. Specifically, an objective 
reality currently exists around the design and conduct of PFS, and the perception 
of this reality may vary and be influenced by the professional roles and 
experiences of both the participants, and the researcher.   
3.8.3 PEPSTAR sampling strategy 
For PEPSTAR, a list of potential participants was created through considering: 
• Trial team members of the studies included in the targeted review and 
systematic analysis of NIHR funded PFS; 
• Team members of other PFS/RCTs of surgical interventions in the UK; 
• Senior members of Clinical Trials Units (CTUs) and Royal College of 
Surgeons Trials Centres in the UK; 
• Senior authors of published literature on PFS work methodology; 
• Senior editors of surgical journals and those publishing PFS specifically; 
• Senior funding panel members of major funding bodies in the UK 
including: 
o  National Institute for Health Research (NIHR) 
▪ Health Technology Assessment Commissioning Board (HTA 
CB) 
▪ Health Technology Assessment Clinical Evaluation and Trials 
Board (HTA CEAT) 
▪ Health Technology Assessment General Board (HTA GB)  
▪ Research for Patient Benefit (RfPB) 
▪ Efficacy and Mechanism Evaluation (EME) 
▪ Programme Grants for Applied Research (PGfAR) 
o Cancer Research UK (CRUK)  
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o Chief Scientist Office (CSO)  
o Arthritis Research UK (ARUK) 
• Senior surgeons with extensive experience of trials research and 
methodology. 
A matrix was developed, including the names, places of work, surgical speciality 
(for surgeons), areas of expertise, and research roles as a chief investigator, journal 
editor and/or funding panel member. Seniority was deemed important to ensure 
extensive experience and involvement with the design, conduct and/or funding of 
PFS and surgical trials. The matrix of potential interview participants was 
compiled with the aim of including a broad range of key professional stakeholders 
involved in designing, funding, conducting and publishing PFS for surgical trials, 
including surgeons, trial methodologists, funders and journal editors. Potential 
participants were purposively sampled from the matrix, by considering all the 
relevant characteristics listed and through discussion with the other researchers 
involved (Blazeby/Avery/Potter) in order to achieve maximum sample variation 
across both the clinical and non-clinical participant groups.  
Only participants from and/or working in the UK were sampled. International 
participants were not considered both due to the time and resource limitations of 
this doctoral thesis, and the relatively different research funding strategies and 
systems in other countries (see Chapter seven, section 7.4.2 for further discussion 
of limitations of the sampling strategy). Clinical participants included those 
working in a range of surgical specialties throughout the UK and those with 
experience of research as a chief investigator or trial team member and/or a 
journal editor, and/or a funding panel member.  Similarly, non-clinical 
participants included those working throughout the UK with extensive 
methodological experience (e.g. as a CTU director or senior statistician) and/or 
holding a senior position on a funding panel (e.g. NIHR HTA/EME/RfPB, CRUK) 
and/or a senior editorial position for a surgical journal, and/or experience of 
designing and conducting surgical trials.   
Potential participants were approached by email or face to face at conferences, 
meetings and other networking opportunities.  A copy of the letter sent and/or 
given to participants can be seen in Appendix IV to this thesis. All participants 
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received information about the study before the interview (Appendix V: 
Participant information sheet). In addition, snowballing sampling was employed, 
by asking participants during the interview, if they had suggestions for other 
participants who may have relevant or important perspectives for this work. In 
this way, a variety of sampling strategies were used to ensure that the final sample 
was heterogeneous and inclusive of a wide range of perspectives and experiences.  
3.8.4 PEPSTAR data collection 
In-depth, semi structured interviews were performed with all consenting 
participants. The interviews were conducted either face to face or by telephone, at 
times and locations convenient to the participants. A topic guide was used to 
inform the interview questions (Appendix VI). 
The topic guide was developed by initially mind-mapping a list of questions 
relevant to the research question. Key concepts and details from the 
methodological literature and background data and the findings from the 
quantitative work (Phase I) were considered, to frame questions which explored 
why PFS are not being optimally designed and conducted. The guide was then 
ordered to consider how a conversation about these topics would flow 
sequentially and with natural fluency.  
Some introductory questions and gathering of general information were posed at 
the start of the topic guide (sections one and two). The third section dealt with the 
different topic areas to be explored.  The purpose and importance of PFS more 
generally and then specific to surgery were considered first, to gauge broad 
understanding of PFS. For example, participants were asked how they defined 
PFS and whether they thought their view was the general view. Another question 
posed was what role participants perceived PFS to have, and what role they 
thought it should have. This led sequentially into asking participants about their 
experiences of PFS, in terms of design, conduct and funding. With personal 
experiences then in mind, questions were posed around the challenges of 
difficulties of PFS and components considered essential to the design, conduct and 
funding of PFS.  
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The topic guide was updated, but not substantially changed after the first eight 
interviews. The changes mainly related to the order of questions, for example, the 
impact of PFS was considered with the questions on importance earlier on. In 
addition, further prompts on topics that had emerged from the first phase of 
interviews were added (see Appendix VIa). 
Whilst the topic guide was used as a tool to frame the interview and provide 
prompts for the interviewer, the semi-structured approach to the interviews was 
the chosen method for this research project. This allowed guidance of the 
conversation to relevant topics of interest around the design, conduct and funding 
of PFS, whilst also allowing topics of importance to the participants to emerge 
naturally and be explored further as appropriate. A focus group methodology 
may also have offered insightful findings but could have hindered exploration of 
specific experiences and opinions. For example, because a focus of the data 
collection was exploration of the challenges and difficulties of doing PFS in 
surgery, a focus group may have led participants to hide contentious or critical 
issues around funding and funding bodies, for fear of causing offence or 
jeopardising future research funding. In addition, participants may have hidden 
their misunderstanding from others for fear of losing face in a room full of experts. 
It would have been possible to split the sample into clinicians/non clinicians, but 
with a lot of cross categorisation, this would not have been a simple task. In 
addition, all participants sampled, were extremely busy professional people 
working all over the UK. Finding a convenient time to bring groups together at a 
single location would have, therefore, been logistically challenging.   
Written consent was taken either before (if done by telephone) or at the time of the 
interview in person (Appendix VII: Consent form). The interviews were audio 
recorded using an encrypted tape recorder, transcribed verbatim in full by a third 
party (see acknowledgements), and anonymised for the purposes of data storage 
and anonymity of participants. 
3.8.5 PEPSTAR data analysis 
The analysis was undertaken using a thematic inductive approach, underpinned 
by the principles of grounded theory, as described above and in the Braun and 
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Clarke publication 180. This method was chosen as it is considered suitable for 
early career researchers allowing flexibility in its approach for those new to the 
field 177, 185. As described in section 3.7.4 in this chapter above, the thematic 
inductive method offers a step-by-step approach to thoroughly and completely 
analysing qualitative data, with a reasoned assessment of validity and reliability. 
As also detailed above, reflexivity is considered a vitally important method to 
increase the validity and reliability of qualitative research, so reporting these 
details is, therefore, an essential part of any qualitative data analysis. Reflexive 
considerations were made throughout the design and conduct of the PEPSTAR 
study, and also in phase 3 of the work, to synthesise the findings from phases one 
and two. These considerations are discussed towards the end of the chapter in 
section 3.12. 
The timeline in Figure 3b demonstrates when data were collected and analysed. It 
should be noted that the author of this thesis took a period of maternity leave 
from January 2018 to October 2018. At the point the maternity leave was 
commenced, the interviews had been completed, transcription and coding had 
occurred, and the process of searching for themes had begun. Following the 
period of maternity leave, it was necessary to re-familiarise with the full data set, 
before beginning the process of reviewing, refining themes and subthemes and 
completing the full narrative account. 
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Figure 3b Timeline of qualitative data collection and analysis during the PhD studentship, with reference to the six stages of thematic analysis described by Braun 
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Thematic inductive data analysis  
The thematic inductive data analysis method used in phase two of this work is 
now described. 
Firstly, familiarisation of the data was done through listening to the interview files 
and making field notes immediately after the interviews, then reading and re-
reading the transcripts and field notes alongside listening to the interview files 
and checking for accuracy. Generation of an initial ‘mind map’ of numerous codes 
and groups of codes was produced as familiarisation with the data progressed. 
The data from the first eight interviews were then collated into the codes 
identified using NVivo 10 software. The use of NVivo software allowed 
organisation and coding of the data, to improve visibility and transparency of the 
data analysis, though only the basic functions of this software were used. 
The first eight interviews and field notes were read, listened to, and double coded 
by a senior (non-surgeon/clinician) researcher (Avery – see acknowledgements), 
to check understanding of the methodological process, consider reflexive 
influences, and discuss emerging codes and groups of codes (early potential 
themes). An early descriptive account was written after the first eight interviews, 
to further understanding of the methodological process of qualitative research (see 
Figure 3b above). As further interviews were conducted, the process of coding 
continued, and codes were checked, amalgamated, renamed as appropriate, with 
new codes being added as necessary. The process of double coding and discussion 
with a senior, non-surgical, qualitative researcher, contributed to improving the 
reliability of the findings, and also assisted with beginning to consider the 
emerging themes and allowing minor updates to the topic guide used in 
interviews (See Appendix V and Va)  
As the interviews and coding process continued, the data were continually 
assessed for saturation. The interviews and data analysis continued in three main 
phases, with the precise order of interviews, mainly determined by participant 
availability. The coding and thematic diagrams (see Chapter five) evolved over the 
course of the data collection and analysis, and it was clear that no new codes were 
emerging towards the end of the third phase of interviews. A few of the 
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interviews in the final phase were conducted via snowball sampling, but these did 
not add significantly to the cumulative findings. Satisfaction was therefore 
reached that participants had been widely sampled for a range of characteristics, 
and that established codes were no longer evolving, and no new codes were 
emerging from the data. A judgment was made, both from the final interviews 
taking place, and the ongoing data collection and analysis, that further interviews 
were unlikely to add significantly to the data set. Data saturation was therefore 
judged to be complete, as described above in section 3.8.3. 
Once the interviews were complete and transcribed, with the familiarisation and 
data coding process concluded, the process of searching for, reviewing and 
refining themes began. This process involved analysing the many codes already 
applied to the data, considering how different data-containing codes related to 
each other and how they could be amalgamated to create themes or sub themes. It 
was possible that further interviews may have become necessary at this point, and 
time was allowed for this but, reassuringly, this was not deemed necessary as no 
new or disconnected themes emerged.  
At this point, a full narrative account was begun, through organising the data for 
each theme into a coherent and logical written account. Deviant or negative cases 
within the data, were particularly sought, to make sure that all perspectives, 
experiences and opinions were illustrated and considered. The story that each 
theme told individually was analysed in detail, alongside consideration of how 
the themes interlinked. Sub themes allowed the larger main themes to be 
simplified and illustrated more clearly.  At the end of this process, the data-
containing codes had been fully defined as themes and subthemes with working 
titles. The final narrative account was then produced (Chapter five) in which the 
themes and subthemes were organised in a logical, non-repetitive report, with the 
findings fully supported by embedded participant quotes encapsulating the 
essence of each point made. 
3.8.6 Format of the narrative account 
The narrative account (Chapter five) was divided into sub-sections relating to the 
main themes and subthemes that developed and emerged throughout the analysis 
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of the interviews as described above. Verbatim quotations from the range of 
participants were provided to illustrate key findings, preceded by a participant 
identification number. Each quote presented was also preceded by a note of the 
primary occupation of the participant (e.g. Surgeon or Methodologist) and 
whether the participant had a role on a funding panel, to clarify the context of 
each viewpoint.  
Ellipses in square brackets ([...]) were used to indicate any omitted words or 
phrases (for example where two relevant quotes about a topic from the same 
participant were said at different time points during the interview, or to keep the 
data anonymised). Words written within square brackets e.g. [xxx] are not direct 
quotes but used to clarify the context of the quote. Indication of omission was not 
deemed necessary for: ‘Umms’ and ‘errs’; frequent use of terms such as ‘you 
know’, ‘sort of’, ‘kind of’; ‘ok’; ‘I guess’ or ‘I mean’; and immediate repetitions of 
words. These words were always omitted unless their inclusion adds to the 
meaning of the quote. A sequence of dots (…) not within brackets, was used to 
indicate a minor pause in conversation. 
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Phase III: A synthesis and interpretation of 
quantitative and qualitative research findings  
3.9 Rationale for Phase III of this thesis 
Mixed methods research describes the use of both quantitative and qualitative 
methods and the synthesis and interpretation of data from these different sources 
to answer a research question 179. Justification for using a mixed methods 
approach in this thesis and a detailed description of the precise methods used to 
synthesise the data sources from phases one and two of this work, are described 
and discussed below. 
3.9.1 Rationale for using mixed methods research 
generally 
As a now accepted, stand-alone research method, much has been written about 
the application of various mixed methods research designs 186-188. In terms of 
Health Services Research, a mixed methods approach has gained popularity as 
an appreciation of the impact of the psychosocial elements of health and human 
nature on medical care has grown 148.  A mixed methods approach should not, 
however, be applied indiscriminately or without explicitly justifying the 
rationale for doing so 186.  
Conceptual frameworks for using mixed methods 
Various conceptual frameworks have been developed 186, 189, 190 justifying the use 
of mixed methods research and these overlap considerably. In addition, several 
mixed methods texts are published which comprehensively discuss the issues 
around the rationale for mixed-methods research 186, 187, 191 and these are 
summarised by Hanson et al in their 2005 paper 168. All these works 168, 186, 189, 190 




Reason 1 To generate hypotheses or allow the evolution of hypotheses using 
one method to generate theories, and another method to test them; 
Reason 2 To identify measurable variables or constructs which may 
subsequently be measured through the use of existing tools or instigate the 
development of new measuring instruments; 
Reason 3 To increase the validity of results by using the data and results from 
one method (quantitative or qualitative) to identify populations to study by 
the other, therefore expanding on, verifying and/or adding credibility to the 
results and; 
Reason 4 To overall enhance the breadth and comprehensive understanding 
of research problems and results by converging quantitative and qualitative 
data and in particular, allowing the needs or voice of marginalised or under-
represented groups to be better considered and understood. 
3.9.2 Rationale for the mixed methods approach used 
in this thesis 
Three of the four reasons justifying the use of mixed methods research, described 
above, apply to the approach taken for this thesis and these three reasons are 
identified and then described below. For clarity, each of the three reasons for 
using a mixed methods approach is first repeated in italics, with confirmation in 
brackets ([Xxx]) of which part of the work in this thesis relates to that reason. 
Reason 2: To identify measurable constructs [Surgical PFS design and 
misunderstanding and/or challenges faced identified in Phase I] which may 
be subsequently measured through the use of existing tools’ [Phase II PEPSTAR 
qualitative interview study to understand why problems exist].   
Phase one of this research was a quantitative targeted review and systematic 
analysis of NIHR funded PFS protocols to identify the scope and detail of what 
PFS were being designed and funded in surgery, and to begin to differentiate 
some of the areas in which PFS in surgery are not currently optimised.  The 
issues identified in phase one, were explored and expanded on in phase two to 
optimally understand why challenges and barriers exist to completing PFS in 
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surgery. Using two different methods, therefore allowed further exploration in 
phase two, of the problems identified in phase one. 
Reason 3: To increase the validity of the results by using data and results from one 
method [Phase I findings] to identify populations to study by the other [Phase II 
participants and topic guide for the PEPSTAR qualitative interviews]. 
The findings from the quantitative part of this thesis (Phase one) informed the 
qualitative component (Phase two), by identifying some of the people involved 
in surgical PFS in the UK whom would be usefully included as research 
participants, and also by contributing to and evolving the semi-structured 
interview topic guide. Again, the use of two different methods in this thesis 
increased the validity of the findings overall, as the quantitative findings in 
phase one informed the qualitative data collection in phase two. 
Reason 4: To overall enhance the breadth and comprehensive understanding of 
research problems and results by converging [Phase III] quantitative [Phase I] and 
qualitative data [Phase II] and in particular, allowing the needs or voice of 
marginalised or under-represented groups to be better considered and understood 
[Surgeons and PFS in surgery]. 
This is the key reason justifying the use of a mixed methods approach in this 
thesis. Phase three of this thesis is the synthesis and interpretation of the 
quantitative (Phase one) and qualitative (Phase two) components of this work to 
overall enhance understanding of the potential for PFS to optimise trials in 
surgery.  
The next section will describe the key methodological approaches underpinning 
mixed methods research generally. This will be followed by description and 
justification for the methods used in this thesis, to synthesise and interpret the 
quantitative and qualitative data to produce recommendations for research 
practice from this work.  
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3.10 Methodological approaches for using mixed 
methods  
Three basic steps have been defined when designing a mixed methods study by 
Hanson et al. 168 as: 1) Whether and which philosophical paradigm will be used to 
underpin the methodological basis of the study; 2) Deciding how the data 
collection will be sequenced (concurrent or sequential) and prioritised (equal, or 
either method prioritised) and; 3) How and when data analysis and integration 
will occur. Each of these three steps will now be discussed. 
Step one: Philosophical paradigm 
Because the philosophical approaches of quantitative and qualitative research are 
traditionally opposed (see section 3.6 earlier), there has been much debate about 
the philosophical assumptions that are required for mixed methods research. 
Some argue that using competing research paradigms results in contradictory 
and challenged ideas and theories, which can positively impact on the research 
168. Others argue that pragmatism is the best research paradigm for mixed 
methods research, meaning both methods can be used in a single study, and that 
the research question is of primary importance, rather than the method, or 
philosophical research paradigm that underlies it 187. As described earlier (see 
sections 3.6), the philosophical basis for research, may also be described as the 
‘theoretical lens’ that underlies the researcher’s choices and assumptions, and 
through which the data collection, analysis and interpretation is viewed 168. Most 
importantly it is key that the researcher identifies if a philosophical paradigm is 
subscribed to, and clearly describes and justifies the choice (or not) of 
philosophical paradigm, and how it may affect the interpretation of the results. 
Step two: Data collection 
Data collection in a mixed methods project can occur in different ways. The 
implementation of data collection of different parts of the research may be 
concurrent (collected at the same time) or sequential (collected at different times). 
Priority may be given to one form of data over another (unequal) or the data sets 
may have equal emphasis on the findings. Again, the important part of this step 
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is that the process used is described, though several authors have produced 
typologies to formally classify mixed methods research designs 186, 188 
Step three: Data analysis and integration 
Data analysis and integration may be completed separately, or using 
transformation (where for example, qualitative data is transformed into a 
quantitative format such as counts or ratings), or they may be connected, where 
the analysis of one type of data, informs the analysis of the other. When data 
analysis and interpretation will be performed must also be defined and may 
occur during the data collection, analysis or interpretation stages.  
Three techniques for integrating data from mixed methods studies have been 
identified and described, with particular reference to Health Services Research, 
by O’Cathain et al. 192. These are termed: 1) Following a thread; 2) Developing a 
mixed methods matrix; and 3) Triangulation. The latter two methods occur at the 
analysis stage, whereas the triangulation method would be followed at the 
interpretation stage. Each of these techniques are described in turn. 
The technique of following a thread involves, first performing initial analysis of 
each data set, then identifying key themes that need further exploration and 
‘following’ these themes from one data set to the other. O’Cathain offers an 
example of using this technique in Health Services Research (primary care) 193, 
but describes following a thread as a technique that is infrequently described in 
the published literature 192. 
Developing a mixed methods matrix, is a data integration method which can be 
used when there is data from two or more sources available for the same 
populations (e.g. individuals or settings). A physical matrix can then be created 
that displays, for example, quantitative and qualitative data available for each 
population in rows, and columns illustrating the different data categories 
collected. The mixed methods matrix then allows direct comparison of the 
different data sets collected across the same populations, and themes and/or 
inconsistencies identified, which allows for further exploration 192, 194. 
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The term triangulation can have different meanings in research methodology. It 
can be used to describe degrees of corroboration between two sets of findings, 
therefore reflecting the validity of the findings 150. However, it can also mean the 
process of studying a problem using different methods to gain a more 
comprehensive answer, and this is the meaning most often used in mixed 
methods studies 192. Several techniques for triangulating findings have been 
described, but in summary they involve assessing to see where findings from 
each method might converge fully or partially (convergence), offer 
complementary information (complementarity) or contradict (discrepancy or 
dissonance) 192. A fourth outcome of ‘silence’ has also been described by some 195, 
albeit in relation to two types of qualitative data, which fits within the 
‘contradictory’ category, and describes a situation where findings are seen in one 
set of results but not another. Farmer et al., describe silences as potentially 
expected due to differences in the purpose and nature of the data sets 195. This 
can be extrapolated to mixed methods studies, as one purpose of these studies is 
to strengthen the findings by using different methods to explore different 
elements of the same problem. However, O’Cathain et al. emphasize that finding 
unexpected silences in one data set might help to increase understanding of the 
problem and lead to further avenues of research 192. 
3.11 Methodological approach for a synthesis and 
interpretation of quantitative and qualitative 
data in this thesis 
The methods used to synthesise the data from phases one and two of the 
research conducted in this thesis will now be described in light of the theory 
underpinning different mixed methods approaches just described. Each of the 
three steps necessary when designing a mixed methods study will now be 
described in relation to the mixed methods approach used in this thesis. 
Step one: Philosophical paradigm 
Earlier in this chapter (see section 3.8.2), the rationale for using a critical realist 
approach for analysing the qualitative data in phase two, was presented and 
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justified. A critical realist theoretical lens was also applied during phase three of 
the research to synthesise the findings from phases one and two. This critical 
realist theoretical lens was considered appropriate because as with analysing the 
qualitative data from the PEPSTAR study, the available definitions and 
methodological work in the area of PFS, were perceived as the imperfect truth (or 
objective reality), against which all data (both quantitative and qualitative) were 
compared.  
Step two: Data collection 
The published literature, current guidance documents relevant to designing and 
conducting PFS 9, 13, 102, 144, and the methodological conceptual work on PFS 
design and conduct described by others 71, 72, 74, 75, 79, 89, 91-93, 95, 96, was extensively 
described, discussed and illustrated in Chapter two.  Some of the evolution of 
thinking and publications in the area of PFS design and conduct, occurred during 
the process of this thesis (October 2015 – October 2019). The staggered 
availability of these information sources was, therefore, taken into consideration 
during the synthesis and interpretation of findings. All three phases of the 
research in this thesis were, therefore, conducted in light of the background 
literature and methodological knowledge around PFS, using a critical realist 
approach, as described in step one above (See Figure 3c).  
The quantitative targeted review and systematic analysis of the NIHR funded 
PFS protocols, was performed and analysed before the PEPSTAR qualitative 
interviews (as described in section 3.4 of this chapter). The quantitative data 
analysis, therefore, informed the qualitative data collection and analysis. This is a 
sequential data collection model, with equal priority of components. Data 
analyses were, therefore, connected, as the quantitative findings, impacted on 
what data were collected in the qualitative work, and how these qualitative data 

























Figure 3c Process of data collection and analysis in this thesis 
 
Step three: Data analysis and integration 
Whilst the quantitative and qualitative data were analysed separately initially 
(see Results; Chapters four and five), the process of interpretation was one of 
data triangulation to synthesise the findings from phases one and two 
subsequently (see Results; Chapter six), in light of the background literature 
review and methodological work in this area (described in detail in Chapter 
two). This process is illustrated in Figure 3c above.  
The overall aim of the work in this thesis, was to develop a detailed 
understanding of the potential for pilot and feasibility work to optimise surgical 
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Phase 3: Recommendations  
For improving research practice more 








to improve research practice. As described at the end of chapter two, what is 
currently lacking is guidance tailored specifically to optimally design and 
undertake PFS. The fourth objective of this thesis (see section 3.1) was, therefore: 
Objective 4  To develop recommendations from this work for all key 
stakeholders and, specifically, accessible and practical top tips for surgeons to 
optimise the design and conduct of pilot and feasibility studies to inform 
main trials in surgery.  
Phase three of this work, therefore, results in recommendations for improving 
research practice more widely amongst all key stakeholder groups. In addition, a 
brief practical ‘Top Tips’ tool to operationalise these recommendations for use by 
surgeons designing and conducting PFS in surgery was produced (as illustrated 
in Figure 3c above). 
The methodological approach employed in phase three of this work, utilised a 
process of identifying the key findings from each of the data sources, and 
representing these diagrammatically. Through the triangulation approach, it was 
sought to define current guidance and theoretical understanding of PFS, define 
what the potential issues for surgical PFS are, and explore why these barriers 
exist and what solutions may be needed for optimisation of future PFS in 
surgery, the learnings from which would inform the development of the 
recommendations and ‘Top Tips’ tool for surgeons. A process of seeking 
evidence of any convergence, complementarity and dissonance between the data 
sets was undertaken to produce a detailed written narrative account of 
recommendations from this work in Chapter six. 
3.12 Reflexive considerations for this thesis 
In practice, the process of data interpretation for phase three of this work began, 
once the qualitative data collection started in phase two, as it is impossible to 
separate oneself from one’s own knowledge 180. Reflexive considerations, which 





The author of this thesis (KF) is a female general surgical trainee, with a 
subspecialty interest in oncoplastic breast surgery. KF completed a BSC in 
physiology in 2000, then qualified from medical school with an MBChB in 2004 
and worked as an NHS doctor for 11 years before starting this PhD. Whilst KF 
had been involved in a variety of small research projects prior to starting this 
PhD, including a systematic review of the resection of breast cancer liver 
metastases and publishing work on surgical simulation, she had no previous 
involvement in or experience of qualitative research. To address this, KF 
attended several structured qualitative research courses at the University of 
Bristol in the early stages of her PhD Studentship (Introduction to Qualitative 
Research Methods, School of Social and Community Medicine, May 2016; NVivo 
Training, February 2017), and was supervised by two (of four) researchers with 
extensive experience of using mixed methods and qualitative methods in Health 
Services Research. 
As a surgical trainee, KF may have been perceived differently by clinical and 
non-clinical participants. Her preconceptions of the knowledge and 
understanding of the surgical community may have been influenced by her 
previous NHS work and experiences. In addition, the thesis was supervised 
within the Centre of Surgical Research at the University of Bristol, which has a 
longstanding role in using qualitative methods to understand the role of 
surgeons in surgical trial recruitment, and in the education of surgeons in trials 
methodology. Her supervisors may, therefore, also have had preconceptions 
about the relative depths of knowledge and understanding of PFS amongst 
surgeons and methodologists. 
As the author of this thesis is a surgical trainee, when reflective influences are 
considered, this work was perhaps inevitably done with surgeons and research 
practice amongst surgeons in mind. It would be fair to surmise that as a surgical 
trainee, KF had witnessed first-hand, many of the difficulties of performing 
surgical research without formal methodological training, and the consequences 
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of not working with a robust evidence base underpinning surgical practice. 
These experiences certainly influenced the reasons for undertaking of this PhD. 
Reflexivity was therefore employed throughout this work, where KF recognised: 
a) The impact of both her knowledge and experiences of working as an NHS 
surgical trainee; b) How the quantitative results of the systematic analysis of 
NIHR funded PFS protocols exploring the use of PFS in surgery impacted on and 
related to the PEPSTAR interviews, c) The impact of working within the Centre 
for Surgical Research at the University of Bristol, which has strong 
methodological expertise in surgical trials methodology and the training of 
surgeons in trial design and recruitment, and developing surgical trials for 
research questions that have previously been considered impossible and; d) The 
evolving methodological literature and guidance documents relevant to surgical 
PFS, such as the IDEAL guidance. These considerations were kept in mind 
throughout the process of data collection, analysis and interpretation. 
 
The next chapter (Chapter four) will describe the results of the targeted review 
and systematic analysis of NIHR funded PFS protocols. This will be followed by 
the results of the PEPSTAR qualitative interview study (Chapter five), and finally 
the synthesis and interpretation of the findings from the first two phases to 






A targeted review and systematic 
analysis of surgical pilot and 
feasibility work funded by the 
National Institute for Health 
Research  
4.1 Introduction 
In order to consider how to optimise future PFS for surgical trials, it is important 
to understand, what and how PFS have been designed and conducted in recent 
years. This chapter describes the results from phase one of this work, which was 
a comprehensive quantitative targeted review and systematic analysis of NIHR 
funded PFS performed over a recent 10-year period. The results of this work 
illustrate and describe the quantity, type and quality of PFS being funded and 
performed nationally, within a surgical context. 
4.2 Results of a targeted review and systematic 
analysis of surgical pilot and feasibility 
studies funded by the National Institute for 
Health Research  
Screening 
Over the 10-year period (2005 to 2015), 1341 funded studies were identified from 
the RfPB (n= 638, 48%) and HTA (n=703, 52%) databases (see Figure 4a). Of 
these, 1265 (93.7%) studies (RfPB n=610/638, 95.6%; HTA n=655/703, 93.2%) 
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were excluded primarily because the study interventions were not surgical 
(n=1115, 88.1%).  Other reasons for exclusion included: Surgical intervention but 
not a PFS (n=65, 5.1%), surgical intervention being studied was a co-intervention 
(n=28, 2.2%), surgical intervention being studies is a co-intervention and also not 
a PFS (n=57, 4.5%).  
Of all clinical research funded by the NIHR HTA and RfPB programmes in the 
last 10 years, 16.7% (225/1341) had some association with surgery (n=75 surgical 
studies assessed for eligibility [76 studies – 1 study with no surgical intervention] 
+ n= 150 surgical studies excluded for reasons 2/3/3a: 225/1341]. Of these 
studies, surgery was a co-intervention in more than a third (studies excluded for 
reasons 3 + 3a = 85/225, 37.8%), with only 10.4% of the funded research in this 
cohort examining surgery as the main intervention in one or more of the study 
groups (n=75 surgical studies assessed for eligibility + n=65 surgical studies 
excluded for reason 2: 140/1341) (data all from Figure 4a). Just a quarter of this 
work was pilot/feasibility work for surgical interventions (35/140, 25%). 
Eligibility 
The remaining 76 studies (RfPB 28, 36.8%; HTA 48, 63.2%) were assessed for 
eligibility. Of these, 30 (RfPB n=1; HTA n=29) were internal pilot studies; 8 (RfPB 
n=0, HTA n=8) were systematic reviews, 2 (RfPB n=1; HTA n=1) had no available 
study protocol and one did not include a surgical intervention.  These studies 
were excluded. In total, 35 study protocols (RfPB n=25, HTA n=10) were 
included in the analysis. Details of these studies are available in Appendix II. 
Agreement on included studies 
Of the 1341 studies screened in duplicate, agreement was reached on inclusion or 
exclusion for 1283 (95.7%) studies at the first attempt.  The remaining n=58 (4.3%) 
studies where there was disagreement were discussed (Fairhurst/Rowlands) and 
agreement reached in all cases.  For example, in 25/58 (43.1%), the studies were 
excluded by the second screener (Rowlands) as being an internal pilot or 
systematic review and not meeting the definition of pilot/feasibility work; these 
studies were later excluded anyway, as per the PRISMA diagram in Figure 4a. 
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Difficulties determining the type of surgical intervention and whether the study 
was pilot/feasibility work were the main reasons for discordance in the 




Figure 4a PRISMA flow diagram of studies identified and selected for a systematic analysis of 
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4.3 Data sources available for included studies 
All 35 included study protocols were available either through contact with the 
chief investigator or via the HTA website as detailed in the methods (section 
3.4.2). Additional data sources were available for 26/35 (71.4%) studies; this 
included a published protocol paper for 13/35 (37%) studies and a paper (or 
abstract n=1 only) reporting the study findings for 21/35 (60%) studies (Figure 
4b). Studies funded by the HTA were more likely to publish the results (HTA 
10/10, 100% vs RfPB 11/25, 44%), than those funded by the RfPB, but the study 
protocols had a similar publication rate between funding streams (published 
protocol: HTA 4/10, 40% vs RfPB 9/25, 36%)  
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Published protocol   
n= 9   
( 36 % )   
  
Published results     
n=11   
( 44 % )   
  
RfPB   
n =25   
HTA   
n =10   
Published protocol   
n = 4   
( 40 % )   
  
Study  protocols   
n=35   
SOURCED :   
RfPB: via contact with CI   
HTA: via NIHR website   
  
Published results     
n=  10   





Published protocol   
n=1 3   
( 37 %)   
Published results   
n=21    
( 60 %)   
KEY:   
  
CI:   Chief Investigator   
HTA:   Health Technology Assessment    
NIHR:   National Institute of Health Research   
RfPB:   Research for Patient Benefit   
Published results: 
    
HTA = HTA report +/- other paper(s) in peer reviewed journal -     
RfPB = published in peer reviewed journal (NB n=1 abstract only)   
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4.4 Characteristics of included studies 
Randomised pilot/feasibility studies 
Most (29/35, 83%) of the 35 included studies used a randomised design (Figure 
4a), the design characteristics of which are detailed in Table 4.1. These 29 
randomised PFS covered a breadth of surgical specialties, with the majority 
(22/29, 75.9%) planned as multi-centre and a quarter (7/29, 24.1%) as single 
centre studies. The proposed median sample size of these studies was 60 (range 
30-200), with most planned in adult populations (24/29, 82.8%) of both sexes 
(24/29, 82.8%) and predominantly in the UK only (27/29, 93.1%).  A minority of 
studies also had collaborative centres in Europe (2/29, 6.9%, both RfPB). The 
median number of personnel proposed in the trial team was nine, with a range of 
0-24 (some studies did not state the proposed study personnel).   
Operative therapeutic interventions (19/29, 65.5%) were investigated most 
commonly, followed by endoscopic therapeutic interventions (6/29, 20.7%). The 
most common comparator was an operative therapeutic intervention (9/32, 
28.1%), followed by a pharmacological comparator (5/32, 15.6%). Most studies 
had two study groups (25/29, 86.2%) and a single comparator (26/29, 89.7%). 
While primarily randomised in design, over half (15/29, 52%) of studies also 
included other types of pre-trial work, such as qualitative interviews (with staff 
and participants), surveys/questionnaires (with surgeons and/or participating 
centres), and economic modelling. 
Non-randomised pilot/feasibility studies 
Like the randomised PFS, the 6/35 (17%) non-randomised studies were 
conducted in a variety of surgical specialties (Table 4.2). Their design varied 
considerably, including a national audit (n=1), a non-randomised cohort study 
(n=1), a systematic review (n=1) and questionnaire surveys and/or qualitative 
work (for example, interviews/focus groups) to explore stakeholders’ opinions 
(n=9). Unlike the randomised studies, most were planned as single centre 
(n=4/6, 67%), with fewer multi-centre studies (n=2/6, 33%). Most were planned 
in the UK only (n=5/6, 83%) and in adults (n=4/6, 67%) of both sexes (n=4/6, 
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67%). The study teams of the non-randomised studies comprised fewer 
personnel than the randomised studies, with a median of six (range of 0-25).  
Because all six studies were, in comparison to the randomised studies, earlier on 
in the research process, only two focused on a specific intervention and none 
specified any comparator intervention(s).
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Table 4.1 Summary of the design characteristics of the 29 randomised pilot/feasibility studies included in the analysis. 







































Number of centres, n (%) 









Median (range) 3 (1-23) 4 (2-10) 3 (1-23) 
Proposed number of participants in study 
Median (range) 50 (30-200) 70 (60-144) 60 (30-200) 




19 (86.4)/2 (9.1)/1 (4.5) 
1 (4.5)/3 (13.6)/18 (81.9) 
20 (90.9)/2 (9.1)/0 (0) 
5 (71.4)/1 (14.3)/1 (14.3) 
1 (14.3)/0 (0)/6 (85.7) 
7 (100)/0 (0)/0 (0) 
24 (82.8)/3 (10.3)/2 (6.9) 
2 (6.9)/3 (10.3)/24 (82.8) 
27 (93.1)/2 (6.9)/0 (0) 
Number of personnel in trial team 
Median (range) 6.5 (4-19) 9.5 (0-24) 9 (0-24) 









































NB HTA cohort adds up to n=9 as one intervention is both endoscopic & radiological adjunctive and another is both endoscopic & radiological therapeutic. 


















Type of comparator intervention, n (%)  
 NB for n=23 comparators NB for n=8 comparators NB for n=32 comparators 
Pharmacological 
Usual/standard care 
Other invasive procedure 
Expectant management 
























































Types of non-randomised pre-trials work for n=15 studies, n 
 NB for n= 9 studies NB for n= 6 studies* NB for n=15 studies* 












* Some studies planned more than one type of non-randomised work 
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Table 4.2: Summary of the design characteristics of the six non-randomised pilot/feasibility 
studies included in the analysis. 
 
4.5 Rationale for conducting surgical pilot and 
feasibility studies 
The rationale described in the protocols, for conducting the 35 PFS included in 
the systematic analysis are summarised in Table 4.3. The work identified 43 
reasons for conducting PFS, and these reasons were grouped into five key 
domains (or themes) of: 1) main trial design; 2) logistics; 3) recruitment; 4) 
intervention, and 5) outcomes, as described in chapter 3, section 3.4.4. 
Uncertainty surrounding main trial design  
The overarching aim to determine whether a main trial was possible or necessary 
(Total: 27/35, 77.1%; RfPB: 17/25, 68%; HTA: 10/10, 100%) was the second most 
commonly cited as a reason for performing PFS, which is perhaps unsurprising 
given that this is generally the overall purpose of PFS. Around half of all studies 
also considered issues regarding the sample size for the main trial (Total: 19/35, 



























Number of centres, n 









Median (range) 1 (1) 2 (1-65) 1 (1-65) 
Number of personnel in trial team 
Median (range) 1 (0-12) 7 (2-25) 5.5 (0-25) 





















Types of non-randomised pre-trial 






















* Most studies planned more than one type of non-randomised work. 
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54.3%; RfPB: 17/25, 68 %; HTA: 2/10, 20%) and costs/funding for the main trial 
(Total: 16/35, 47.7%; RfPB: 14/25, 56%; HTA: 2/10, 20%). Despite being termed 
pilot/feasibility work, one third of studies (n=11, 31.4%, all RfPB funded) aimed 
to collect data regarding the safety or effectiveness of an intervention to inform 
the main trial (Table 4.3). Of these, almost three quarters (8/11, 72.7%) specified 
plans for formal hypothesis testing by statistically comparing the intervention(s) 
and/or control groups to test effectiveness and/or safety.  
Uncertainty surrounding logistics  
Uncertainties surrounding logistics were considered in two thirds of studies 
(Total: 23/35, 65.7%; RfPB: 16/25, 64%; HTA: 7/10, 70%) (Table 4.3). The most 
common logistical uncertainty given was to develop/test data collection 
forms/methods (Total: 19/35, 54.3%; RfPB: 16/25, 64%; HTA: 6/10, 60%), 
followed by to test the logistics of multicentre studies (Total: 6/35, 17.1%; RfPB: 
5/25, 20%; HTA: 1/10, 10%), and to develop/test questionnaires/surveys (Total: 
6/35, 17.1%; RfPB: 5/25, 20%; HTA: 1/10, 10%). Less commonly explored 
logistical uncertainties were to test response rates to questionnaires/surveys, to 
develop a research network as a resource for a future main trial and to assess the 
logistics of delivering an intervention as part of a trial in the NHS. 
Uncertainty surrounding recruitment  
Addressing uncertainties around trial recruitment, was cited as the most 
common reason overall (Total: 32/35, 91.4%; RfPB: 23/25, 92%; HTA: 9/10, 90%) 
for undertaking PFS (Table 4.3). Specifically, two thirds of studies (Total: 22/35, 
62.9%; RfPB: 9/25, 36%; HTA: 5/10, 50%) considered assessing the 
numbers/rates of recruitment and consent. Other commonly explored 
recruitment uncertainties included testing the acceptability of 
randomisation/trial design (Total: 17/35; 48.6%; RfPB: 12/25, 48%; HTA: 5/10, 
50%), and determining the acceptability of the intervention to clinicians and 
patients (Total: 16/35; 45.7%; RfPB: 12/25, 48%; HTA: 4/10, 40%). More rarely 
explored issues around recruitment were to test/modify 
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inclusion/exclusion/eligibility criteria, and to estimate the expected prevalence 
or rate of incident cases in the population.  
Uncertainty surrounding the intervention 
Only a quarter (10, 28.6%) of PFS sought to explore uncertainties around the 
surgical intervention itself, such as intervention development, stability, delivery 
or the surgical learning curve (RfPB: 6/25, 24%; HTA: 4/10, 40%) (Table 4.3). The 
ten studies that did plan to explore uncertainties around the intervention, most 
commonly considered developing and testing the implementation and delivery 
of the intervention (Total: 4/35, 11.4%; RfPB: 1/25, 4%; HTA: 3/10, 30%), 
followed by assessing and monitoring the development of an intervention 
and/or it’s stability (Total: 3/35, 8.6%; RfPB: 2/25, 8%; HTA: 1/10, 10%). Less 
frequently explored uncertainties around the intervention included developing 
pathways and protocols for co-interventions, testing rates of crossover, training 
staff in delivery and assessment procedures. 
Further details of the ten studies specifically examining aspects of the 
intervention are summarised in Table 4.4.  Of these, six studies were comparing 
surgery with no surgery, three studies were comparing a novel/new surgical 
technique with a standard surgical procedure and one study was a non-
randomised study examining novel/new surgical techniques.   
Of the 25 studies not stating plans to explore uncertainties around the 
intervention, a third (n=9) were comparing surgery with no surgery, a quarter 
(n=6) were evaluating novel surgical interventions and one study aimed to 
compare surgery to a placebo and no surgery (three arm study) (Table 4.5).   
When comparing the study type used in those studies stating examination of the 
intervention versus those that did not, the commonest study type for both 
groups was surgery versus no surgery, followed by novel/new surgical 
technique versus standard surgery (see Table 4.5). However, the studies not 
stating examination of the intervention were more likely to be surgery versus no 
surgery studies where both interventions were an established technique (4/25, 
16% vs 0/10, 0%), or non randomised PFS (5/25, 20% vs 0/10, 0%) (See Table 4.5)
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Uncertainty surrounding outcomes 
Less than half of studies considered uncertainties around outcomes (Total: 15/35, 
42.9%; RfPB: 11/25, 44%; HTA: 4/10, 40%).  Specifically, those studies stating 
exploration of outcomes planned to use PFS to select the most appropriate 
primary outcome measure (Total: 9/35, 25.7%; RfPB: 9/25, 36%; HTA: 0/10, 0%) 
and/or determine appropriate/important/suitability of outcome measures for 




Table 4.3 Reasons cited in the study protocols for conducting PFS for the 35 included studies.
Area examined Rationale Number of studies stating each rationale in 
the study protocol, n 
Proportion of studies stating examination of each area 
























Main trial possible +/- 
necessary 









To assess whether main trial is needed and/or produce a protocol 3 [0] 0 [2] 3 [2] 
To test whether the protocol can be adhered to and modify it as necessary 2 [0] 2 [0] 4 [0] 





 To determine a sample size for the main trial 3 [0] 0 [0] 3 [0] 
Costs / funding To assess/gather information on costs of performing the trial (direct and indirect) 2 [0] 0 [0] 2 [0] 
56% (14) 20% (2) 45.7% (16) To perform/prepare for a cost effectiveness analysis of the intervention(s) 13 [1] 2 [0] 15 [1] 
To provide information/evidence to funders 1 [0] 0 [0] 1 [0] 
Safety and 
effectiveness data 
Preliminary data on safety to inform a main trial 2 [0] 0 [0] 2 [0] 
44% (11) 0% (0)  31.4% (11) 
Information on adverse events 4 [0] 0 [0] 4 [0] 
Planned formal hypothesis testing of safety outcomes * 3 [1]  0 [0] 3 [1] 
Preliminary data on effectiveness to inform a main trial 0 [0] 0 [0] 0 [0] 






 To test the logistics of multicentre studies 5 [0] 1 [0] 6 [0] 
64% (16) 70% (7) 65.7% (23) 
To develop a research network as a resource for a future main trial 1 [1] 0 [0] 1 [1] 
To develop/test patient information content/forms/methods of delivery 1 [0] 3 [0] 4 [0] 
To develop/test data collection forms/methods 13 [1] 6 [1] 19 [2] 
To develop/test questionnaires/surveys 5 [0] 1 [0] 6 [0] 
To test response rates to questionnaires/surveys 0 [0] 0 [0] 0 [0] 
To prepare/plan/assess monitoring procedures 0 [0] 1 [0] 1 [0] 
To determine what resources are needed for a main trial (funding/staff) 3 [0] 0 [0] 3 [0] 
To assess the logistics of delivering an intervention as part of a trial in the NHS 1 [0] 0 [0] 1 [0] 
To test (novel) methods of blinding 1 [0] 1 [0] 2 [0] 
To assess proposed data analysis techniques 1 [0] 1 [0] 2 [0] 








 To test/modify inclusion/exclusion/eligibility criteria 2 [0] 0 [1] 2 [1] 
92% (23) 90% (9) 91.4 % (32) 
To estimate the expected prevalence or rate of incident cases in the population 1 [1] 1 [0] 2 [1] 
To estimate the number to be screened and proportions of eligible patients 9 [0] 3 [0] 12 [0] 
To assess numbers/rates of recruitment and consent 17 [0] 5 [0] 22 [0] 
To test the randomisation procedure 5 [0] 3 [0] 8 [0] 
To test the acceptability of randomisation/trial design 12 [1] 5 [2] 17 [3] 
To determine the acceptability of the intervention to clinicians and patients 12 [1] 4 [2] 16 [3] 









 To assess and monitor the development of an intervention and/or it’s stability 2 [1] 1 [0] 3 [1] 
24% (6) 40% (4) 28.6% (10) 
To develop and test the implementation and delivery of the intervention 1 [0] 3 [0] 4 [0] 
To train staff in delivery and assessment procedures 1 [0] 0 [0] 1 [0] 
To monitor the surgical learning curve 2 [1] 0 [0] 2 [1] 
To test rates of crossover 0 [0] 1 [0] 1 [0]  
To examine reasons for non-adherence/cross-over for the main trial 2 [0] 0 [0] 2 [0] 







  To select the most appropriate primary outcome measure 9 [1] 0 [0] 9 [1] 
44% (11) 40% (4) 42.9% (15) 
To develop and test a new outcome measure 0 [0] 0 [0] 0 [0] 
To determine appropriate/important/suitability of outcome measures for patients/clinicians 3 [0] 4 [2] 7 [2] 
  * Formal hypothesis testing to demonstrate the safety and/or effectiveness of an intervention is generally not 
recommended for PFS because of the underpowered sample size 
NR = Non-randomised study    
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Table 4.4 Details of the ten studies that examined elements of the intervention 
 
 
Evaluation INTERVENTION Categorised type COMPARATOR Categorised type 





Eye muscle surgery Operative therapeutic Active monitoring of 










Re-suturing of dehisced 
perineal wounds 






bladder in children 
Single administration of an 
intravesical injection of 
Botox® into the bladder, in 
a dosage of 5 IU/Kg 
(maximum dose of 150 IU) 
under general anaesthesia 
Endoscopic therapeutic Tolterodine XL, 4 mg 
orally once daily, for the 












techniques & lifestyle 








head and neck cancer 
Pre-chemo/radiotherapy 
gastrostomy (may be either 





Oral feeding unless/until 






peripheral stage 1 
non-small cell lung 
cancer in patients 
considered higher risk 
of complication from 
surgical resection 
Surgery - Thoracotomy or 
VATS (Video Assisted 
Thoracoscopic Surgery) 









1. laparoscopic gastric 
mobilisation and right 
thoracotomy 2. totally 
minimally invasive surgery 
Operative therapeutic Open gastric mobilisation 
and right thoracotomy 
Operative therapeutic 
Techniques for portal 




Portal vein clamping 
(during liver resection for 
colorectal metastases). The 
portal vein will be isolated 
and occluded with a clamp. 
Operative adjunctive Pringle manoeuvre 
(during liver resection for 
colorectal liver 
metastases to prevent 
bleeding. The entire 
hepatico-duodenal 
ligament containing both 
hepatic artery and portal 
vein, will be occluded 








Acetic acid endoscopy of 
Barrett's oesophagus 
(targeted biopsy) 
Endoscopic diagnostic Mapping biopsy 











Operative therapeutic None N/A 
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Table 4.5 Type of trial for studies that examined details of the surgical intervention and those that 
did not 
Comparison between randomised and non-randomised pilot/feasibility 
studies 
Some differences between the rationale for undertaking randomised and non-
randomised PFS were observed, as detailed in Table 4.6, though recruitment 
issues and trial feasibility were the most common reasons for undertaking both 
randomised and non-randomised PFS. Non-randomised studies were more likely 
than randomised studies to be conducted to determine whether a main trial was 
possible or necessary (n=5, 83.3% vs n=22, 75.9%) and to inform outcome selection 
(n=3, 50% vs n=12, 41.4%).  However, randomised studies were more likely to 
explore logistical issues (n=21, 72.4% vs n=2, 33.3%), collect data to inform sample 
size calculations (n=18, 62.1% vs n=1, 16.7%) and address issues around costs and 
funding (n=15, 51.7% vs n=1, 16.7%) than non-randomised PFS.  When 
randomised studies are compared to non-randomised studies, uncertainties 
around the intervention were still the least explored area of all in both cohorts 
(non-randomised: n=1/6, 16.7% vs randomised: n=8/29, 27.6%) (See Table 4.6). 
Consideration of the number of uncertainties addressed 
When the number of reasons for conducting each study was considered (Table 
4.7), a minority of studies stated the intention to address more than ten areas of 
uncertainty (Total: 4/35, 11.4%; RfPB: 3/25, 12%; HTA 1/10, 10%). Almost a third 
planned to address fewer than five uncertainties (Total: 10/35, 28.6%, RfPB 5/25, 
20%; HTA 5/10, 50%) (Table 4.7). 
The number of uncertainties addressed in the PFS did not vary considerably 
between the HTA and RfPB cohorts (see Table 4.7). However, non-randomised 
studies tended to address far fewer uncertainties than randomised studies (n=5/6, 
Type of study Studies 
examining the 
intervention 




(n=25) n (%) 
Total  
(n=35) 
Surgery vs no surgery 6 (60) 9 (36) 15 (43) 
Novel/new surgical technique vs surgery 4 (40) 6 (24) 10 (29) 
Non-randomised pilot/feasibility work 0 (0) 5 (20) 5 (14) 
Surgery vs surgery (both established techniques) 0 (0) 4 (16) 4 (11) 
Surgery vs placebo & no surgery (2 arms) 0 (0) 1 (4) 1 (3) 
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83.3% non-randomised addressed 1-5 uncertainties vs 5/29, 17.2% randomised) 
(Table 4.7).   
Table 4.6 Comparison of proportions of randomised and non-randomised studies stating 
examination of each area in the study protocol. 
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4 (57.1%) 0 (0%) 9 (31.0%) 1 (16.7%) 
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10 (45.5%) 1 (33.3%) 2 (28.6%) 2 (66.7%) 12 (41.4%) 3 (50%) 
Number of uncertainties 


















1-5 10 (28.6%) 5 (20%) 5 (50%) 5 (17.2%) 5 (83.3%) 
 
6-10 21 (60.0%) 17 (68%) 4 (40%) 20 (69.0%) 1 (16.7%) 
 




Consideration of the PFS study outcomes 
In order to assess the true value of PFS, it would be helpful to evaluate the 
outcomes of if and/or how PFS informed the design and successful funding of a 
subsequent main trial. This was certainly considered as part of the study plan but 
was not entirely possible due to a lack of accessible and complete data. Whilst all 
HTA studies submit and publish a full report via the NIHR journals 
infrastructure, the same is not true of RfPB studies. For these studies, a report is 
submitted to the funder, but is not currently made publicly available. It was hoped 
that all studies could be followed up to categorise the outcomes of the PFS, as 
shown in table 4.8 below. 
Table 4.8 Outcomes of surgical PFS where data publicly available 
 
For 11/35 (31.4%) studies (all RfPB funded), there was no available data for the 
outcome of the PFS, despite searching online (see methods) and contacting the 
NIHR and the chief investigators and/or study team directly. The NIHR were 
very helpfully able to confirm (see acknowledgements) where studies had been 
published and where studies had been granted further funding for a main trial, as 
Outcome of PFS 
 
Proportion of studies  
HTA, n=10 RfPB, n=25 TOTAL, n=35  
R (n=7) NR (n=3) R (n=22) NR (n=3) 
R (n=29)  
 
NR (n=6) All Studies 


























2 (20%) 0 (0%) 1 (4%) 0 (0%) 3 (8.6%) 0 (0%) 
3  
8.6% 
Completed 0 (0%) 0 (0%) 0 (0%) 0 (0%) 0 (0%) 0 (0%) 
0  
0% 
Unable to get 
funding 
0 (0%) 0 (0%) 0 (0%) 0 (0%) 0 (0%) 0 (0%) 
0 
0% 
Main trial feasible but no 
further studies planned 
(e.g. RCT no longer 
needed/done by others) 
1 (10%) 0 (0%) 0 (0%) 0 (0%) 1 (2.9%) 0 (0%) 
1 
2.9% 
Main trial feasible but 
uncertain if further work is 
planned (lack of data) 
2 (20%) 2 (20%) 2 (8%) 1 (4%) 4 (11.4%) 3 (8.6%) 
7 
20% 





this data is in the public domain. For a further 7/35 (20%) of studies, whilst the 
report or published results stated that a main trial was feasible, it was unclear 
whether plans to design this trial and apply for funding were planned, started or 
in progress. There were 5/35 (14.3%) studies concluding a main trial was not 
feasible, 7/35 (20%) showing the feasibility of a main trial was still uncertain and 
either more work was needed before a definitive trial (6/35, 17.1%), or another 
separate trial was already in progress (1/35, 2.9%). A further 3/35 (8.6%) studies 
had progressed to securing main trial funding and/or beginning the trial. A single 
study (1/35, 2.6%), whilst demonstrating feasibility of the main trial, was not 
planning to proceed to a main trial, as the intervention in question was already 
falling out of use as a treatment option. 
4.6 Summary 
This review and analysis of NIHR funded PFS in surgery, has examined the type 
and scope of PFS conducted in surgery. Firstly, this work has demonstrated that 
surgical studies were rarely funded relative to all work funded by the NIHR in the 
ten-year period reviewed: only one in ten studies were examining surgery as the 
main intervention and only a quarter of these were PFS.  
A result of this work was to group and label domains of uncertainty that can be 
explored in PFS. The five identified domains were 1) main trial design; 2) logistics; 
3) recruitment; 4) intervention, and 5) outcomes. Within each of these, frequently 
explored specific uncertainties existed. For example, with regard to main trial 
design (domain 1), the overarching reason of examining and testing whether a 
main trial was possible was the predominant reason mentioned in many PFS 
protocols, which is unsurprising given that this is the principal rationale for 
performing PFS. The two other most prevalent reasons for performing PFS 
identified with regard to main trial design, were estimating the variability in 
outcomes to help determine main trial sample size, and performing or preparing 
for a cost effectiveness analysis of an intervention. With regard to logistics 
(domain 2) developing or testing questionnaires of surveys was by far the most 
commonly identified reason for performing PFS, and within recruitment (domain 
3), assessing the numbers/rates of recruitment and consent was easily the 
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favoured uncertainty to explore. The intervention (domain 4) as described above 
was the least commonly explored area of uncertainty overall. Exploring 
uncertainty around outcomes (domain 5), was also not frequently planned for in 
comparison to issues around recruitment or logistics, and this is surprising, 
particularly given the need for patient and public involvement in this area of trial 
design. Secondly, these results suggest that PFS design is centred around 
addressing a favoured few uncertainties and that the full potential of PFS in 
surgery is, therefore,  yet to be realised, despite the wider range of uncertainties 
identified, which could be specifically considered when designing surgical PFS.  
Thirdly, whilst the expectation is not that every study should examine every 
uncertainty, it is apparent that surgical pilot work could be further optimised, 
with particular emphasis on exploration of the intervention. More than two thirds 
of all studies (25/35, 71.4%) did not plan to explore uncertainties around the 
intervention. Undoubted uncertainty existed around the intervention in two thirds 
(15/25, 60%) of these studies, simply by way of the trial design being to either 
compare surgery with no surgery or to evaluate a novel surgical intervention. The 
expectation would be that all PFS studies of surgical interventions, would explore 
some element of the intervention. 
In addition, it is clear that the purpose of PFS in surgery is still misunderstood, 
with the continued inappropriate testing of the safety and effectiveness of 
interventions using PFS data. Poor dissemination of PFS results may also be 
contributing to widespread misunderstanding of the purpose, breadth and value 
of PFS in optimising surgical trials, with less than two thirds of studies (21/35, 
61%) having published their results to date. 
The next chapter (Chapter five) describes the results of the PEPSTAR qualitative 
interview study, which sought to explore in depth, key stakeholders’ opinions, 
perceptions and experiences regarding why there are challenges and barriers to 
designing and conducting PFS for surgical trials, and what solutions might be 





EXPLORING PERCEPTIONS AND 
EXPERIENCES OF PILOT WORK 




The targeted review and systematic analysis of NIHR funded PFS protocols 
(Chapter four) highlighted that surgical PFS are relatively rare, their design and 
conduct not optimised and that they continue to be poorly reported and 
disseminated. This chapter describes the findings from an in-depth qualitative 
interview study, which sought to explore the perspectives and experiences of key 
stakeholders around the challenges and barriers to undertaking PFS in surgery. In 
addition, the interview study considered what solutions might be needed to 
improve current research practice, in order to inform development of 
recommendations to improve research practice in this area. 
5.2 Demographics of the sample 
A total of 33 participants were invited to participate in an interview by the 
research team (see Chapter three, Methods, section 3.8.3 for details of how the 
participants were selected). Of these, 28 (85%) expressed an interest and 27 (81%) 
consented and were interviewed. These included 18 (67%) males and 9 (33%) 
females. The interviews were undertaken over a period of ten months, in three 
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phases relating to the iterative phases of the analyses (first phase: participants 1-8; 
second phase: participants 9-20; third phase: participants 21-27). Most interviews 
were conducted by telephone (17/27) with the remainder (10/27) face-to face, 
mostly in university office locations. The length of interviews varied from 27 to 
101 minutes (mean 58 minutes). Participants were working throughout the UK 
including Scotland (2/27), Northern England (6/27), the Midlands (5/27) and 
Southern England (14/27). Further demographic characteristics and research 
experience of the 27 participants interviewed are described in Table 5.1.  
Surgeons 
Ten participants held a current clinical role as a surgeon, and one further 
participant had previously held a clinical role as a surgeon but had recently 
retired from practice. Surgeon participants were predominantly male (10/11) and 
were qualified in a broad spectrum of surgical specialties including 
hepatopancreaticobiliary (HPB), oesophagogastric, cardiovascular, colorectal, 
breast, vascular and orthopaedic surgery. All the surgeon participants interviewed 
were currently directly involved in surgical research (for example, as a chief 
investigator or co-applicant on a surgical research study and/or currently 
recruiting patients into surgical research studies) but experience of involvement in 
pilot and feasibility research studies varied widely.  All had experience of being 
the chief investigator of trials: two thirds (8/11) had experience of clinical trials of 
surgical interventions, with a quarter (3/11) being experts in this area (primarily 
university-employed to do research, and holding an honorary NHS contract); one 
quarter (3/11) had experience of predominantly translational and pharmaceutical 
studies (within the context of surgery), and; one surgeon had extensive experience 
of studies of novel (innovative) devices and technology in surgery.  
Methodologists 
The 16/27 participants who did not identify as surgeons, identified primarily as 
trial methodologists. Half (8/16) of the methodologist participants were females 
and half males. All reported experience in designing and conducting trials of 
complex interventions and some had a specific experience in surgical trials (3/16). 
All had experience of designing and conducting both internal and external pilot 
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studies. Of the methodologist participants, 9/16 were Clinical Trials Unit (CTU) 
directors, 4/16 were trial statisticians and one was a trial methodologist. Of the 16 
methodologist participants, 4/16 held or had previously held a role as a doctor in 
a clinical specialty other than surgery.  
Funders and editors 
More than two thirds (20/27) of participants interviewed had current or recent 
experience of membership on a UK research funding body panel. Of these, 6 had a 
position as a panel chair, 3 as a deputy chair and 12 as a panel member, though 
the length of individual experience varied considerably. More than half (15/27) 
were part of journal editorial teams and most (24/27) also currently held a 
professorial position at a UK university.  
Groups of participants 
During data analysis, it became apparent there were three distinct groups 
amongst the participants, based on the level of trials methodology experience they 
had. These groups are defined and termed in the narrative account as: Surgeons 
(with little or no methodological experience), methodological experienced 
surgeons, and methodologists.  The methodologically experienced surgeons all 
held a formal academic position at a UK University (not an honorary position) and 
all had experience of major funding panel membership and/or chair/deputy chair 
positions. As described in the methods, participants were asked at the start of the 
interviews about their roles relating to PFS, which enabled identification of those 
with significant methodological experience. It was considered important to 
distinguish between these groups because it was hypothesised that the level of 
methodological experience held by participants would influence their perceptions 
and opinions.  In addition, providing further individual detail in Table 5.1 of 



































KEY: CI = Chief Investigator, CTU = Clinical Trials Unit, S = surgeon, O = other clinical specialty, (previous) = no longer practicing in a clinical role
Participant ID Gender Date of interview 
 
Length of interview 
(HH:MM) 
 




Roles held currently/recently relating to research and/or trials 
Trial involvement 
 
Funding panel member Editor University academic position 
held 
Current Position Previous Current  Previous 
001 Male 04/02/17 00:29 Face-to-face S CI    x  Professor 
002 Male 04/02/17 00:27 Face-to-face S CI      Professor 
003 Male 17/02/17 00:57 Face-to-face S CI     x Professor 
004 Female 23/03/17 00:30 Face-to-face S CI   Deputy chair x  Professor 
005 Male 10/04/17 01:01 Face-to-face S CI    x  Professor 
006 Male 10/04/17 01:41 Face-to-face 
S 
(previous) 
CI   Member  x Professor 
007 Male 11/04/17 01:16 Face-to-face S CI    x  Professor 
008 Male 18/05/17 01:22 Face-to-face S CI x Member  x  Professor 
009 Male 31/07/17 01:08 Telephone 
O 
(previous) 
CTU director   Member x  Professor 
010 Female 20/07/17 00:56 Telephone  Statistician x Member  x  Professor 
011 Male 01/08/17 00:42 Telephone O CI x Chair  x  Professor 
012 Female 02/08/17 00:57 Telephone 
O 
(previous) 
CTU director   Member   Professor 
013 Female 03/08/17 00:40 Telephone  Statistician x Member    Principal Research Associate 
014 Female 08/08/17 00:50 Telephone  Statistician    x  Professor 
015 Male 08/08/17 01:12 Telephone  Methodologist x Deputy chair  x  Professor 
016 Male 09/08/17 00:55 Telephone  Statistician x Member Chair x  Professor 
017 Female 10/08/17 00:57 Telephone  CTU Director x Chair    Professor 
018 Male 11/08/17 01:25 Telephone  CTU Director   Member x  Professor 
019 Male 14/08/17 01:28 Telephone  CTU Director x Member    Fellow 
020 Female 15/08/17 01:23 Face-to-face  CTU Director x Member    Professor 
021 Male 04/09/17 00:41 Telephone S CI    x  None 
022 Male 11/09/17 00:47 Face-to-face S CI x Chair    Professor 
023 Male 14/09/17 00:44 Telephone S CI   Member x  Professor 
024 Male 18/09/17 00:36 Telephone 
O 
(previous) 
CTU Director x Chair    Professor 
025 Female 09/10/17 00:58 Telephone  CTU Director x Member  x  Professor 
026 Female 11/10/17 01:01 Telephone  CTU Director x Deputy chair    Professor 
027 Male 05/12/17 00:52 Telephone 
O 
(previous) 
CI x Chair    Professor 
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5.3 Results from a thematic inductive analysis of 
the PEPSTAR qualitative interview data 
Derivation of themes 
As described in the methods (Chapter 3, section 3.8.5), analysis of the PEPSTAR 
interview data was undertaken using a thematic inductive approach as described 
by Braun and Clarke 180. This approach includes six stages named as: 1. 
Familiarising yourself with the data; 2. Generating initial codes; 3. Searching for 
themes; 4. Reviewing themes, 5. Defining and naming themes and; 6. Producing 
the report.  
Evolving themes 
An initial mind map of numerous codes and groups of codes was produced as 
familiarisation of the data progressed (Figure 5a). As further interviews were 
completed codes were checked, amalgamated, renamed as appropriate and new 
codes added as necessary, leading to an evolving coding map as illustrated in 
Figure 5b. Once all the interviews were complete, the process of searching for, 
reviewing and refining themes began leading to the thematic diagram illustrated 
in Figure 5c. This figure illustrates how the different data containing codes began 
to relate to each other and how they began being amalgamated to produce themes 
and subthemes. Once the narrative account was begun, it became possible to 
determine the story that each theme told individually and consider further how 
these themes interlinked (Figure 5d). Ultimately, this process led to the themes 
and subthemes being fully defined with working titles as illustrated in Figure 5e.  
Final thematic framework 
Figure 5e illustrated the final thematic framework, with three distinct but related 
key themes of: A) Differential understanding of PFS; B) Challenges of PFS for 
surgical trials and; C) Solutions to optimise the design and conduct of PFS for 
surgical trials. This diagram (Figure 5e), illustrates the format of the narrative 
account in this chapter to follow, where each of these themes and sub themes will 
be discussed in turn. 
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Figure 5d Reviewing and refining themes and subthemes from the final data set  
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Figure 5e Final thematic framework illustrating the key themes and sub themes that 
emerged from the in-depth interview study. 
 











KEY: PFS = Pilot and feasibility studies 







B. Challenges of PFS in 
surgery















5.4 A) Differential understanding of pilot and 
feasibility studies  
008 (Surgeon/Funder): “I think the truth is most, many surgeons even those involved in trials 
don’t actually understand what feasibility and pilot work is and confuse it with a… it’s just a 
smaller trial, well no it’s not, it has a completely different role, maybe it’s stepping stone role 
but a very different role […] so, it’s not universal, but I think actually if you ask me what the 
average surgeon understood by that, they wouldn’t have a clue really…” 
5.4.1 Differential understanding of purpose 
A key finding throughout the data was a differential understanding between 
methodologists and surgeons of the purpose of PFS. Methodologists demonstrated 
a more complete and accurate understanding of the principal purpose of PFS in 
optimising the design and conduct of a future main trial. 
014 (Methodologist): “Well you hope it’s going to improve it; stop the trial going ahead if it’s 
too problematic. I just think there’s so many things to think about, certainly in complex 
interventions, that I just can’t see that you can think about them all until you’ve had one dry 
run.” 
 
010 (Methodologist/Funder): “You’ve got questions and objectives that you need to answer that 
will inform your running of the main study. They’ll either let you move forward with 
confidence that the processes that you’ve got in place are gonna work, or it will demonstrate 
that you need to alter them in some way.” 
In contrast, surgeons generally had a much narrower appreciation of what PFS are 
and how they can be utilised. Throughout, surgeons tended to focus on reasons 
that were more pragmatic for performing PFS, for example as a pre-requisite or 
necessary step to getting a main trial funded.  
005 (Surgeon): ‘I think pilot work is very important but mainly to demonstrate value for money 
that you can actually recruit to time and target, because pilot work in my opinion it’s more to 
benefit the funders […] I think whether we do a pilot or not really depends on money; that’s 
what it boils down to. Every trial if possible, should be set up as a pilot to full […] in the real 
world that’s not always the case…it boils down to the funds; sums that you can actually raise.  
So, if you can only raise enough for a pilot or feasibility, standalone, no matter how you call it, 
then that has to be how it is.” 
 
003 (Surgeon): “I think it’s essential for big studies and also its essential cos you won’t get it 
funded otherwise.” 
Other surgeons seemed to recognise only the face value of PFS by considering the 
feasibility of the main trial in very broad terms only. 




Some surgeons also regarded PFS as playing an important role in evaluating the 
safety and effectiveness of new surgical interventions not widely used in current 
clinical practice. This illustrates misunderstanding amongst surgeons about what 
PFS are and how they should be used. 
003 (Surgeon): “I think it’s extremely valuable if you’re looking at a surgical technique or a 
new surgical bit of kit, because I do not think we should introduce things willy nilly, which 
we’re notorious for doing.” 
 
006 (Surgeon): “I suppose increasingly, people will be less and less able to start doing 
something different, so instead of: ‘We happen to have pilot data cos we’ve all been having a go 
at it’, we will have to translate this to: ‘If you start this, you’ve got to document’.” 
Furthermore, some surgeons incorrectly perceived that the main purpose of PFS 
was to act as a formal mechanism to discard unfeasible new technologies and to 
speed up the process of evaluating multiple new interventions and devices 
simultaneously. 
023 (Surgeon): “I think that [PFS are] absolutely fundamentally important, so I think it’s very 
very important, not just important. And the reason I say that is, we have to start designing 
processes that sort the wheat from the chaff […] We need to be evaluating 10 technologies at 
once and decide that we’re taking two forward very quickly […] I see [PFS] as a mechanism for 
discarding things that don’t work, and in a way, it’s an early phase trial in terms of the 
selection process.” 
It was not always appreciated by surgeons that the fundamental function of PFS in 
optimising main trials was, as an essential precursor to generating high quality 
randomised evidence. A perceived external pressure for PFS to provide findings 
related to intervention effectiveness compounded this. 
003 (Surgeon): “I wouldn’t be a fan of doing a pilot study to see whether the design of the study 
worked…otherwise people are gonna go ‘oh what’, if you’ve not given them an answer; 
surgeons are pretty binary.” 
Funders, by contrast, perceived the importance and purpose of PFS as a way of 
managing risk. PFS were regarded as particularly important in surgery, where 
there is often significant uncertainty relating to either the pertinence of the 
research question, and/or the ability of the surgical trial team to deliver a main 
study. 
011 (Funder): “…if it’s an important question, then we should be trying to answer it and we 
should be prepared to take a bit more risk and spend a bit more money trying to answer it. So 
that’s why pilot and feasibility work is so important, because it gives us a way of managing that 
risk.” 
 
017 (Methodologist/Funder): “I think surgery absolutely is up there with the kind of things you 
think, are they ready to launch into the main expensive study yet?” 
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Some funders, therefore, emphasised how PFS served as an opportunity for the 
surgical team to prove that they could deliver a project within a certain time, 
thereby reducing their uncertainty about funding a future main trial. 
008 (Surgeon/Funder): “They will take a chance on new investigators if they’ve got the right 
support, but they want to see that they’re not brand new. You can’t have somebody who’s got 
no experience so if you’ve done that standalone pilot funded by industry, RfPB, charity 
whatever, and you’ve taken that through to completion and then that informs a bigger study, 
then actually that is pilot work but not about the interventions, outcome measures, 
participation. It’s about the team, the team showing they can deliver this project on a limited 
scale.  Now they’ll take a chance, and we’ll deliver it on a big scale.” 
5.4.2 Differential understanding of scope 
A differential understanding between methodologists and surgeons of the scope 
of PFS was also identified. Methodologists, for example, understood the full scope 
of PFS to explore all areas of uncertainty about a potential main trial.   
025 (CTU Director/Funder): “I think if you’ve not got uncertainty then no you don’t need to do 
any [PFS], but I think in most cases you would have some kind of uncertainty, so some sort of 
pilot and feasibility work, however small, would be necessary.” 
All methodologists therefore perceived PFS as having a particularly important role 
in surgical trials where there is often significant uncertainty in multiple areas.   
018 (CTU Director): “The more uncertainty you’ve got, the more you need a pilot, and if you’re 
uncertain about surgeon equipoise, uncertain about patient equipoise, uncertain about the 
actual intervention then, compliance whatever, then that increases the probability you need a 
pilot.” 
The surgeons were generally less specific about the breadth of uncertainty that 
could be explored in PFS, tending to focus on recruitment as a primary area of 
uncertainty. 
002 (Surgeon): “Well it’s all about recruiting isn’t it, at the end of the day? And the trial’s got 
to be attractive to clinicians and the staff who are addressing the patients. So, anything that 
obstructs recruitment has to be addressed in a pilot study, I would have thought…” 
 
021 (Surgeon): “So it’s good for telling you about recruitment and it’s good for telling you 
about compliance because sometimes you can be as clever as you like, but if people won’t 
consent into a trial then they’re never gonna work so…there’s lots you can learn from them.” 
A smaller number of surgeons with more methodological experience, however, 
demonstrated a greater depth of understanding about the range of uncertainties 
that PFS could address before a main trial. 
004 (Surgeon): “I think it’s done for lots of reasons. One is to improve the design of the main 
trial in terms of, to work out how to recruit, best methods to recruit, how to find patients, how 
to establish eligibility criteria.  How to get the interventions standardised, how to work out 
which outcome, how to measure the outcome, how to learn how to teamwork, all those things.” 
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These more methodologically experienced surgeons also emphasised the 
importance of using PFS as a vehicle for teaching and training surgeons how to 
perform trials. 
004 (Surgeon): “Just to practice it cos that’s the problem surgeons haven’t done it before, so to 
cut their teeth and actually faffing around with all the organisation and paperwork that’s 
involved in running a trial. I think that’s a really good place to do it, in the pilot phase or the 
feasibility work. So, it’s all just about preparation for hopefully running a seamless main trial.” 
 
008 (Surgeon/Funder): “Sometimes we do pilot work as vehicles for training […] it becomes a 
training vehicle to run a standalone pilot for someone and then the trainee or whoever is leading 
that would then, or sometimes a new investigator […] so you’re trying to provide support to 
them in a much more contained environment without the [funder] level overview.” 
5.4.3 Differential understanding of pilot and 
feasibility studies for limiting research waste 
Exploring all areas of uncertainty to optimise the main trial, enabling better trials 
and better evidence with which to change practice, was identified as the main 
objective of PFS by methodologists. However, the methodologists also understood 
that in doing so, this avoids failed trials, thereby limiting research waste. 
027 (Methodologist/Funder): “I think the problem is, we’ve wasted a lot of money by not having 
adequate development and fidelity work before heading off into the deep blue yonder of the main 
trial.” 
Some surgeons were also aware of the value of PFS in reducing research waste by 
demonstrating when a main trial would not be possible.  
001 (Surgeon): “I’m sort of quite conscious of the amount of money in the pot to fund things, 
and I think there needs to be some evidence to support a major investment otherwise the money 
could be spent better somewhere else.” 
 
022 (Surgeon/Funder): “Many people think that a successful pilot or feasibility study is one 
that shows you can do the trial. I think some of the most successful ones show that you can’t do 
the trial that you were sure you could do. So, it saves years and years of work and sometimes 
millions of pounds worth of money. A lot of people are looking ‘so I’ve failed’, but actually 
they’ve succeeded.” 
However, despite recognition that PFS may help in limiting research waste, some 
felt that PFS had also contributed to it. Several methodologists noted that 
historically, PFS had often been funded wastefully, without any intention (of the 
investigators, the funders, or both) of progressing to a main trial. Whilst PFS may 
show that a main trial is viable, if it does not progress to a definitive study, then 
this could be considered as adding to research waste. 
009 (CTU Director): “Sometimes you see pilot feasibility work, is seen as an end in itself […] 
[Funders have] funded masses of feasibility studies, most of which have gone nowhere and 
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produced nothing of any interest […] I look at these things and say well, why would we go for 
these things? They’re three years of work, they’re usually very thin on resource, they’re a lot of 
hard work, and at the end of it we get nothing out of it that is of any use to us […] You can 
write up your feasibility work, it will go into the Ruritanian Journal of Unreproducible Results, 
nobody will ever read it again and it ticks a box for our masters that we’re generating income. 
but it doesn’t generate us any really top-class research output, so most of it goes nowhere.”  
In contrast, funders perceived that increasing attention was being paid through 
greater consideration in recent years of the plausibility and likelihood of a main 
trial. Scrutiny of the relative importance of the research question when applicants 
proposed a PFS was regarded as crucial to this.   
019 (CTU Director/Funder): “That’s the process at [Funder] these days, for an opinion on it 
from [Funder] about whether this is interesting and sometimes that comes back as: ‘We can see 
no way that the [Funder] would fund this study, even if the pilot was successful’,  and that’s 
often, it’s usually the kiss of death. Because the [Funder] sees, if there isn’t anyone prepared to 
fund the main trial, what’s the point of doing the pilot.” 
 
016 (Methodologist/Funder): “I think that a funding panel could agree that a study was well 
designed, it had sensible objectives and it had methodology to address those objectives. But if it 
was asking a clinical question that ultimately wasn’t going to be of enough priority to [Funder], 
then it probably shouldn’t go ahead, because, you know that’s then wasteful.” 
5.4.4 Reasons for differential understanding 
A number of reasons for differential understanding of the scope and purpose of 
PFS amongst surgeons and methodologists were identified, but central to these 
was the perceived inaccessibility of guidance regarding the design and conduct of 
PFS. 
Inaccessibility of theoretical/conceptual guidance 
Most methodologists acknowledged and described key theoretical and/or 
conceptual literature (for example, scientific publications) on the optimal design 
and conduct of PFS but many felt that these publications were inaccessible to the 
wider trials community being too technically complex. Rather than help, many 
methodologists perceived this literature might actually add to the confusion 
surrounding the scope and purpose of PFS.  
015 (Methodologist/Funder): “There are some nice papers actually on pilot and feasibility 
studies, particularly to do with sample size and I think they’re a bit… I mean they are very 
useful if you’re a methods person, I think they’re a bit tricky if you’re not […] so they’re good, 
but it’s obvious from the stuff we get from the [name of funder], that that message is not getting 
across through those articles in a way that is understandable.” 
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In contrast, the surgeons either did not reference the conceptual literature at all, or 
if they did, focused on the literature that related to definitions and differences 
between types of pilot and feasibility studies. Surgeons therefore perceived the 
conceptual work as irrelevant in practical terms and, again, only important for a 
successful funding application. 
008 (Surgeon/Funder): “I struggle with that division between feasibility and pilot despite 
having read and re-read all the crap describing the differences, actually I don’t think the 
differences are particularly meaningful […] that division is probably not important but only 
exists, yes in funding scheme applications.’ 
Some methodologists specifically referenced conceptual tools such as the MRC 
guidance for designing and evaluating complex interventions as being helpful in 
the design of PFS. However, none of the surgeons mentioned use or awareness of 
this guidance document. 
025 (Methodologist/Funder): “I think I would go much more on the MRC framework [for 
complex interventions] which I think is very helpful actually […] They talk about uncertainty, 
that everything should be based on uncertainty, and I do think that’s true in pilot/feasibility 
work as well as in the main clinical trials that we do. So, I think that what people ought to be 
doing is to think about where their uncertainty is and try and build the pilot/feasibility work 
around that uncertainty.” 
Despite its unique relevance to surgery, participants rarely referred specifically to 
the IDEAL framework when discussing PFS. One methodologist, who 
acknowledged the IDEAL framework as a positive step towards changing the way 
surgical research is done, felt that most surgeons did not really understand the 
value and importance of PFS, and were not commonly using the IDEAL 
framework to help design such studies. 
014 (Methodologist): “In my opinion most surgeons haven’t got as far as pilot and feasibility 
studies, there wasn’t very much awareness of them […] I got the impression that not many 
people were using the IDEAL framework and weren’t aware of it […] They seem to be getting 
away with doing mini randomised controlled trials and, as I’ve described, they shouldn’t really 
be doing that […] I felt that they hadn’t got as far as doing pilot and feasibility studies, or 
embracing them in their work.” 
Inaccessibility of funder endorsed guidance 
Like the conceptual and theoretical guidance, most participants perceived funder 
guidance as generic, and offering limited direction in how to operationalise the 
guidance in practice. Funder guidance was, therefore, perceived as another 
potential barrier to widespread and comprehensive understanding around the 
design and conduct of high quality PFS. Whilst most funders offer some guidance 
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on their websites, this is mainly limited to brief definitions of PFS, which vary 
between funders.  
Most methodologists, for example, perceived that the definitions of PFS endorsed 
by funders, such as the NIHR, encouraged applicants to mould their PFS study 
design to match a specific definition.  
009 (CTU Director): “I think people get too bogged down sometimes in exactly what the words 
and definitions mean.” 
Some methodologists expanded on this viewpoint, explaining that definitions 
incorporating specific reasons for undertaking PFS (for example, to explore 
recruitment) may restrict applicants from thinking more widely, and encourage 
them to ignore other important uncertainties around their specific research 
question. 
019 (CTU Director/Funder): “I think they [the definitions] push people into particular boxes, 
whereas different questions are better answered using different approaches. As for almost any 
research question you care to name there are pros and cons to different approaches but here, the 
question you’re answering is ‘what’s stopping me doing the main trial’.” 
 
025 (Methodologist/Funder): “I think the key list of things is also a bit of a stumbling block, and 
that’s in the NIHR feasibility definition, they have this list of things, and I think people think 
they’ve got to do that.” 
Similarly, surgeons generally perceived the defined methodological differences 
between ‘pilot’ and ‘feasibility’ studies as only relevant in terms of funding 
applications and felt that confusion existed even amongst the funding panel 
members. 
005 (Surgeon): “It’s an interesting question you’ve asked and the distinction between feasibility 
and pilot is not very clear in the funding body’s perspective.”  
Most methodologists agreed, in line with the NIHR definitions that the major 
difference between an internal and external pilot was that an internal pilot was 
integral to the main study, with the data contributing to the final analysis, and that 
an external pilot was a standalone piece of work. However, many methodologists 
expressed concern over the unhelpfulness of these terms, feeling they may be 
contributing to general confusion.  
019 (CTU Director/Funder): “But the internal pilot, in the last couple of years I’ve come to 
believe an internal pilot just shouldn’t exist. In [that] it’s not particularly a useful term, and 
it’s a bit artificial in terms of how you then handle it.” 
 
015 (Methodologist/Funder): “I wouldn’t call it an internal pilot. I think we’re treating [an 
internal pilot] more like monitoring. I know it’s still, of course, a possibility that in the three 
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sites you did it in, your external pilot things went fine and as soon as you go to some sites that 
were not involved, things do not go fine. But I wouldn’t call that a pilot, we’re just now 
running the trial, and we’re trying to make it work.” 
The terms internal and external pilot are used almost exclusively by the NIHR. 
Representatives from other funding bodies also found the distinction to be mostly 
irrelevant to what really happens in practice. 
024 (CTU Director/Funder): “I would think that if we were doing a pilot study, what we’re 
doing is, well it is proof of concept, is the concept warranting further study. So it’s pilot data to 
put into your grant application. So, that’s not the way the NIHR think about it, I don’t really 
know how they think about it quite honestly […] we never talk about pilot studies in that sense, 
we don’t talk about internal pilots, and I know NIHR does, but I don’t know what they mean 
about it. So, there is clearly a distinction between what funders, how funders use these terms.” 
Perhaps unsurprisingly, the surgeons demonstrated difficulty understanding the 
predominantly funder-coined nomenclature of ‘internal’ and ‘external’ pilot 
studies. 
005 (Surgeon): “No I’m not too familiar. What I understand from an internal pilot is that you 
get a set number of either one centre or set number of centres first and then followed by… or the 
external component is people who join in after the progression goals have been met.” 
 
001 (Surgeon): “I think that, when you say internal do you mean you do a pilot study and then 
it continues to become a larger trial?” 
Some methodologists also felt that a lack of universally accepted terms and 
explanations of types of PFS across funding bodies added to applicants’ confusion.  
026 (CTU Director/Funder): “I think although it is well defined, the terms are used 
interchangeably by researchers, and perhaps may even be used differently by other funding 
bodies […] From a funders point of view […] when we see the terms, we expect a certain set of 
questions to be, a range of questions to be answered, depending on the term that’s given, and 
also we’re expecting a certain kind of discussion around those terms. So, if the terms are not 
used appropriately it does cause confusion […] It would be better, yes it would be better if we all 
had a terminology that we understood more clearly.” 
Both surgeons and methodologists felt that funders’ definitions and descriptions 
of PFS drive what is written in funding applications. However, some 
methodologists also felt that reviewers and journal editors’ misunderstandings of 
the purpose and scope of PFS potentially caused further confusion. 
025 (CTU Director/Funder): “What the funders say drives a lot of what people write in their 
application, so obviously they’re going to try and match what they say in their funding 
applications with the definitions that the funders have produced, and they think that’s going to 
be more likely to get them funding. I think the second thing […] is that there’s a lot of confusion 
about what people should be doing in these studies, and I think a lot of that comes from 




5.5 B) Challenges of pilot and feasibility studies 
for surgical trials 
5.5.1 Challenges with designing and conducting pilot 
and feasibility studies in general 
Methodologists and surgeons with methodological experience identified several 
challenges with the design and conduct of PFS more generally, which were not 
necessarily related to surgical trials specifically. When considering a main trial, 
challenges were perceived as predominantly managerial and logistical relating to 
running the trial on a larger scale. In contrast, the challenges of PFS were 
perceived as more fundamental, relating to the many potential uncertainties about 
how the research question should best be answered. 
022 (Surgeon/Funder): “There are different challenges so… when you go into the main trial it’s 
upscaling it all so your feasibility and your pilot work […] actually the fundamentals of how 
you run your trial. You could have made some decisions around that that are basically wrong or 
you…there were things you didn’t know that you had to find out whilst you’re running a 
multi-centre thing, about logistics, understanding of a health care setting for each individual 
one […] You might have 6 or 7 different outcome measures, you wanna decide which one you 
wanna use but you’re not gonna be faced with that in the main trial […] So they’re different 
kinds of problems. It’s much more managerial [in the main trial] as to… you’ve got the basic 
machine that can run now, it’s now making that machine run in all these various settings and 
trying to make it run the same way in all the various settings, when every hospital is unique in 
the way it runs things.” 
Challenges with identifying uncertainties 
Some methodologists noted that PFS are inherently challenging specifically 
because their objective is to focus on addressing uncertainty or ‘unknowns’, some 
of which are anticipated (known unknowns) and some of which are not (unknown 
unknowns). 
020 (CTU Director/Funder): “I think what’s so difficult and challenging with feasibility studies 
is that it is a walk into the unknown. You might not know what you don’t know, and actually 
just even costing them, planning for them is really challenging because you feel like you’re 
going down a certain path with your sat nav and then suddenly, you’re kind of going off in a 
different direction” 
 
017 (CTU Director/Funder): “They’re inherently difficult because by definition you’re doing 
them because you’re not quite sure how best to do it, so they’re not off the shelf things but yea 
that’s also the fun of them.” 
One participant referred to a quote from Tolstoy in Anna Karenina: “All happy 
families are alike; each unhappy family is unhappy in its own way”. The participant, a 
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surgeon, associated this philosophy with the common identifiable challenges that 
might be applicable to most PFS, and other more specific challenges that are 
individual to the study and may, therefore, be more difficult to identify a priori. 
022 (Surgeon/Funder): “What does Tolstoy say?[…] All happy families are happy in the same 
way but not every unhappy family is unhappy in their own unique way (laugh)[…] there’ll be 
some commonalities but there are always some things that you never thought about.” 
Following on from this, methodologists and surgeons with more methodological 
experience perceived that identifying which uncertainties need exploring was 
more challenging than designing an appropriate PFS study to explore those 
uncertainties. 
008 (Surgeon/Funder): “More people fall down because they’ve not addressed the gaps where 
the uncertainty is, rather than they’ve not designed the study well enough to address the gaps 
they have identified.” 
Uncertainties to address in PFS 
All participants perceived recruitment as an important area of uncertainty to 
explore in PFS. Indeed, most surgeons, focused on recruitment as the key 
uncertainty to explore in PFS. 
004 (Surgeon): “I think for surgical trials, I think recruitment still remains to be… that’s the 
biggest reason why trials run into trouble. So, recruitment I think is really important.” 
However, methodologists and surgeons with more methodological experience 
identified several other additional uncertainties that were of key importance to 
address in PFS. In addition to recruitment, these included exploring the 
intervention and examining outcome measures.  
017 (CTU Director/Funder): “The thing we worry about as funders, and you’ll hear me keep 
saying it, recruitment, recruitment, recruitment. Another one on my list is implementation of 
the intervention would be a general thing, that and can you collect the outcome measures.” 
 
022 (Surgeon/Funder): “So, you know we can recruit the patients, we can do the intervention 
and we can follow them up and get an appropriate primary outcome measure.  I think those are 
the 3 most important things.” 
In contrast to surgeons though, most methodologists and funders, placed 
particular emphasis on using PFS to address uncertainties surrounding the 
surgical intervention itself. 
027 (Funder): ‘I guess the main, the first thing is, you want to know that your intervention is 
feasible, that it is acceptable, so the feasibility study will often involve exploring issues of the 
acceptability of the study intervention.’ 
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Whilst the surgeons also described some elements of the intervention that may be 
explored in PFS, they were generally less explicit in defining the intervention as a 
key parameter to explore for surgical studies.  
In addition to the three key areas of recruitment, the intervention and outcome 
measures, other logistical areas of uncertainty to explore in PFS were also 
mentioned, predominantly by the methodologists. These included administration 
(for example, paperwork), randomisation pathways, sample size calculations and 
formalising consent processes.  
012 (CTU Director): “Testing the feasibility of data collection, because some people sometimes, 
are being a bit ambitious, and actually it’s just not possible to collect certain data in certain 
ways.” 
 
020 (CTU Director/Funder): “Do you randomise at the start of the surgery […] How does that 
impact their behaviour in the surgery or do you randomise at the end of the operation […] Is it 
feasible to randomise at different time points, all those sorts of things. There were lots and lots of 
things. We did randomise at two different time points, each proved feasible to actually do it, but 
there were lots of unknowns so there was no way that study was ready to go to a trial, because it 
was just a string of question marks.” 
 
010 (Methodologist/Funder): “Obviously issues around sample size calculations, consent 
processes are a big one, and it allows you to get more information than you could do from say, a 
hypothetical study.” 
5.5.2 Challenges unique to trials of surgical 
interventions 
As demonstrated above, all groups of participants regarded PFS as an opportunity 
to address uncertainties around the intervention. However, several specific 
uncertainties related to the intervention that were unique to the context of surgical 
trials were identified.  
Methodological challenges related to delivery of a surgical intervention 
Most methodologists identified how exploring uncertainties around the 
intervention in PFS was critical for surgical trials. 
011 (Funder): “The area that’s probably more neglected, is the feasibility of the intervention and 
again there’s often a lack of appreciation of the complexity of interventions, lack of awareness of 
guidance in relation to evaluation of complex interventions, and often a naïve assumption that 
an intervention that’s been used by an expert in a specialist centre can simply be taken off the 
shelf and implemented throughout the NHS. And you really need to know about 
implementation before you start a full-scale pragmatic evaluation.” 
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Whilst surgeons did not necessarily name the intervention as a key parameter to 
explore in PFS, some were aware of why surgical interventions specifically may be 
challenging, giving examples from their own experience of how the intervention 
had been explored in PFS. 
023 (Surgeon): “So, in the feasibility study there, we had to actually look at stabilising the 
technique to see if we could actually reproduce it and train other people to do it. And after we 
ran a feasibility study on 20 patients, which we ran across five sites, after that we had a stable 
teaching rollout and a stable technique that we could then test.” 
However, whilst some surgeons could give reasons and examples why surgical 
interventions were specifically challenging, they did not always make the link as 
to how and why uncertainties could and should be explored in PFS, tending to 
focus instead on needing to obtain results about the effectiveness of surgical 
interventions quickly. 
003 (Surgeon): “Now, when we were asked whether we could do a randomised prospective 
study we said ‘no we can’t do a pilot study because we don’t have enough numbers, it’ll take 10 
years to get the results’ […] It will be unethical cos it was NICE approved in 2007 […] I don’t 
think for that sort of thing, that pilot studies are any good.” 
When elaborating on the issue of why surgical interventions were challenging, 
both methodologists and surgeons identified several unique challenges related to 
the development and delivery of surgical interventions. However, methodologists 
were seemingly much more aware than surgeons were, of the effect the unique 
nature of surgical interventions had on the design and conduct of trials and why 
PFS were particularly important to this context. 
The surgical learning curve  
The influence of the learning curve on trial results was identified by 
methodologists as one of the intervention-specific challenges unique to surgery 
that is necessary to address before beginning a randomised evaluation in a main 
trial. Sometimes, this was linked to needing to employ statistical methods to adjust 
for a possible learning curve effect. 
017 (CTU Director/Funder): “I think there’s things to do with clustering surgeon effect, they 
talk about learning effect. Now that can be individual surgeons, that can be teams, hospital 
systems and I think some of those are true […] But the RCT’s that have grown up from the 
pharmaceutical industry just don’t have to grapple with those kind of things, so I think 
although surgery isn’t unique, it’s got some really special things that if you’re not aware of, 




010 (Methodologist/Funder): “When you’re designing a surgical trial you’ve got issues around 
clustering and around the learning curve and in a lot of surgical trials there is very little 
mention of how they’re handling the learning curve or the clustering in the design. A limitation 
of pilot work would be that even if you were to do a pilot, and you were say looking at trying to 
get an estimate of clustering with the size of pilots, that would still be difficult to achieve.” 
Some surgeons were also keenly aware of the potential impact of the learning 
curve on trial results and the need to adjust or allow for this, particularly in trials 
of new or novel interventions. 
003 (Surgeon): “Learning curve is crucial isn’t it, especially for a new technique […] It is very 
difficult to analyse something where there’s a learning curve especially against an established 
procedure […] I think the learning curve issue is absolutely crucial and especially with the 
things you’re talking about introducing, new surgical techniques, new surgical instruments; 
it’s crucial.” 
Standardisation 
A second intervention-related challenge specific to surgical trials, was the lack of 
standardisation of many surgical procedures and practices. Methodologists 
perceived that the standardisation of certain elements of procedures between 
different surgeons and hospitals in order that they can be evaluated, as 
particularly important. 
011 (Funder): “Heterogeneity of surgical techniques. You may think that an operation is an 
operation and all surgeons do it the same way but when you actually look at what they’re doing 
they could be doing it in different ways, different degrees of competency. How similar do these 
surgical techniques need to be before you can say ‘well they’re all pretty much doing the same 
thing?’ How different do they have to be before you say; ‘well actually these two surgeons are 
doing something completely different so we can’t evaluate them together.’” 
Methodologists cited pragmatic trials as a method to overcome needing to 
standardise interventions explicitly, by allowing all variations of practice to be 
included. However, it was acknowledged that this might lead to subsequent 
problems with convincing the surgical community of the findings of such trials. 
012 (CTU Director): “I’d be really fascinated by that, to know whether we can standardise 
surgery because […] I don’t know whether you end up doing a trial and the sites are really 
selected because you get the people who yes, who are more team players, or wise with that sort of 
thing, but then it becomes difficult to translate that back into practice exactly. So, you’re almost 
better off doing a pragmatic trial, describing what the range of practices were, and then just… 
take the flak really, because there will be flak you know.” 
Some surgeons and methodologists perceived the need for quality assurance of 
surgical interventions in trials as important. These participants felt ensuring the 
delivery of sufficiently high-quality surgical interventions within a trial was to 
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enable acceptance of the trial results (whether positive or negative) by the wider 
surgical community. 
005 (Surgeon): “The main difficulty with surgical research is, that in my opinion when you… 
say an operation doesn’t work you need to demonstrate to the world that the operation was done 
by competent, experienced surgeons […] Is a trial explanatory or pragmatic, and so the question 
is does the operation work or does the operation work only in expert’s hands?” 
 
020 (CTU Director/Funder): “It’s got a surgery arm and a non-surgery arm, because a 
previous trial was criticised with the quality of the surgery. So they want, therefore, to prove, 
well hopefully to show, that the quality of the surgery for whatever; if they see an effect that it’s 
not attributable to poor surgical quality in some sense.” 
Surgical expertise 
Surgeons identified studies comparing more than one surgical technique as 
potentially problematic because surgeons may not want to take part if they don’t 
themselves use both the techniques in question, or because of issues with 
equipoise (discussed in further detail below). Several surgeons described 
difficulties with randomised PFS they had been involved with, where recruitment 
was affected and/or the pilot work had failed because surgeons would not or 
could not be randomised to performing one or other of the interventions. 
003 (Surgeon): “I agreed to take part in the study because I thought it was a valuable question, 
but I had trouble with the study because I didn’t think the [procedures] were equivalent so we 
didn’t enter very many so that’s… And we didn’t enter very many because we found reasons 
not to enter very many.” 
Again, surgeons focused on the more practical elements of trialling surgical 
interventions and appeared to be less aware of the importance of PFS to explore 
these issues. However, some more methodologically experienced surgeons 
described surgery versus no surgery trials as particularly challenging in terms of 
the acceptability of randomisation, and the sorts of trials for which PFS were, 
therefore, absolutely necessary. 
004 (Surgeon): “There’ll still be some surgical versus non-surgical trials where really to have a 
whole pilot on: ‘Is it possible to randomise someone to surgery or no surgery’, I think is worth 
it…It is incredibly difficult and a lot of training and investment is… I think external pilots are 
good for those difficult, surgery/no surgery trials.” 
 
008 (Surgeon/Funder): “I think a big element of any feasibility is can you get the surgeons to 
deliver the interventions in the context of a randomised trial, absolutely.” 
 
Cultural challenges related to the intervention 
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A fourth key challenge unique to trials of surgical interventions concerns the 
surgical culture itself. There was widespread acknowledgement among all groups 
of participants that the culture inherent to surgery presented difficulties to 
undertaking trials in this area. This was regarded as further justification for 
undertaking PFS.  
012 (CTU Director): “Surgeons are such, they’re really interesting people, and I think some are 
very obedient aren’t they… they’ll adapt their practice to fit in with the greater good, and others 
just don’t see it that way.” 
 
002 (Surgeon): “It’s a mindset, isn’t it? And surgeons aren’t historically that good at that. 
We’ve just heard a talk on how useless our RCTs are […] But that doesn’t mean to say that we 
shouldn’t be trying to do them. I suspect that was what you were trying to say to him.” 
All groups of participants frequently talked about challenges with community and 
individual equipoise. While these challenges are not unique to surgical trials, 
problems with equipoise appear to be compounded by issues relevant specifically 
to a surgical context. 
003 (Surgeon): “I think we missed the chance because the two [devices] developed at about the 
same time; we should have trialled them at the beginning…people, they weren’t in equipoise, 
they were really really wedded to one, because each one you had to fiddle around. It took years to 
get used to it, so that you could get it to work. As I say if the, if somebody said to me what 
operation do you think you spent most time fiddling around with, it would be those [devices] 
and I did spend years, and eventually I thought I’ve cracked it I really… And I’m sure other 
people with the other [device] found a whole load of ways to get theirs. So, we missed, we needed 
to do it at the beginning.’ 
Whilst the surgeons understood that a lack of equipoise often affected the success 
of trials, they were less able to articulate reasons why, and tended to accept the 
inevitable consequences of lacking equipoise, such as ‘impossible’ trials or failed 
trials. The methodologists, however, were much clearer on the reasons for 
equipoise complexities amongst surgeons. Some discussed that, whilst true 
equipoise may be difficult to achieve, there is capacity for all surgeons to have at 
least some uncertainty sufficient enough, to enable them to commit to answering 
the research question. 
019 (CTU Director/Funder): “If you get away from equipoise with the connotation of equals. If 
you’re talking uncertainty, even surgeons can often admit to uncertainty. Some are better at it 
than others. It doesn’t help that some of the old school surgeons have often been trained never to 
portray uncertainty but they… well you might not get equipoise, but I think in even surgeons, 
interventional cardiologists and people like that, you can get into the realm of uncertainty.’ 
In addition, methodologists understood that the interventions being studied in 
surgical trials can be vastly different, making equipoise more challenging. The 
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methodologists illustrated how surgery is perceived to be a much more personal 
treatment for both the delivering surgeon and the receiving patient. 
016 (Methodologist/Funder): “The really obvious one to me is trying to persuade both clinicians 
who are taking part in the study, or recruiting patients to the study and delivering the 
intervention in the study, so persuading them, and the patients to take part in the study when 
they could, by chance, they could receive one of two or more quite different treatments. So, I 
think that is a particular difficulty in surgery […] The difference between intervention and 
control can be more extreme, I think, than in other studies.”  
With surgery having the potential to cure or kill, confidence and self-belief that the 
treatments surgeons deliver are predominantly beneficial rather than harmful, is a 
natural expectation and requirement of a surgeon’s role. Methodologists 
understood that equipoise for surgeons can, therefore, be at direct odds with this 
well-developed confidence and belief such that being in equipoise, requires 
challenging not only personal beliefs, but also doing so very publicly to patients, 
peers and the wider trials community. 
020 (CTU Director/Funder): “I think possibly in all areas of medicine but particularly in 
surgery, surgeons have to make decisions, and they have to make decisions quickly. Very often, 
they’ve got people’s lives in their hand. They may be doing potentially life threatening surgery 
[…] They have to make decisions, and they have to make decisions quickly […] The whole idea 
of equipoise; equipoise is about uncertainty, equipoise is about not knowing and I think that is 
not what surgeons typically are about. They have to have faith in their… I mean I’m surmising 
I don’t know, but I think that they have to have faith and belief in their ability because of the 
nature of what they do.” 
 
013 (Methodologist/Funder): “It’s partly to do with the fact that surgeons are people who have 
to have a belief that the new intervention that they’re testing is better. I think there is less 
equipoise […] They wouldn’t be taking the knife to someone, unless you felt sure you were 
doing something good for them. It’s a different psychological phenotype of clinician, I think, and 
obviously they perform a very important task, but I think they’re slightly different from people 
who dispense drugs, which can be stopped quickly, and suddenly, if something goes wrong.” 
Methodologists described the centrality of the surgeon to delivering the 
intervention and the irreversibility of many surgical interventions as another 
reason why conveying uncertainty is more difficult in surgical trials. Many 
methodologists also perceived the unique nature of surgery as a craft specialty, 
with potentially incapacitating and often-irreversible invasive interventions being 
delivered by the hands of people who have undergone thousands of dedicated 
hours of training, all further explaining why surgery is a more personal 
intervention.  
015 (Methodologist/Funder): “One of the big differences with surgical trials, I think, is that the 
surgeon is such an important part in intervention delivery and it’s often irreversible. So, you 
can stop taking the pill but once you’ve removed something or changed something or whatever, 
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it’s difficult or impossible to go back. So, I think there’s something there about the irreversibility 
and the absolute centrality of the surgeon to the intervention, which is different for some other 
type of interventions.” 
Surgeons, whilst perhaps less clear on reasons for lacking equipoise, did discuss 
how elements of the ‘surgical personality’, such as being expected to demonstrate 
leadership and innovating, may negatively influence trials. For example, surgeons 
perceived that the desire to make progress quickly in a treatment area may mean 
the chance to develop or assess an intervention in the context of formal research is 
seen as a distraction.  
003 (Surgeon): “Not too late to do a trial probably, because I think it should be done, but 
probably too late to convince the zealots to do a trial. You’ve given them… it’s a bit like 
running after somebody if you’ve given too much of a head start. You’ll never catch you’ll never 
get them. You have to grab them at the beginning and go ‘whoa, whoa, whoa don’t run off’…” 
In addition, some surgeons perceived that driving progress forward too quickly 
without adequate thought and involvement of trials expertise, might result in 
trials running into difficulty because they have been designed around specific 
surgeon beliefs. 
006 (Surgeon): “The zealots amongst the surgeons have worked their way round by persuasion, 
muscle, conviction and all the usual things we do when we want to win our case into an 
explanatory mechanistic study and only if you do it the right way […] I think they may have 
evolved a trial to prove their own surgical machismo, and I would like to evolve a trial to see 
which benefits patients… They just regard me as a traitor […] You don’t want to lose too many 
friends, but who wants friends like that who can’t see the purpose of the trial is to get health 
gains for individual patients, patients in general, and for society.”  
An evolving surgical research culture  
Methodologists described how the historical lack of emphasis on surgical research 
has resulted in surgical trials not being embedded in routine practice. This was 
observed to contrast with other fields of research, such as oncology 
pharmaceutical trials, for example. A relative lack of regulation in the way that 
new surgical procedures can be introduced into clinical practice was regarded as a 
contributing factor. 
017 (CTU Director/Funder): “I think one of the issues is that there has been much less of a 
culture of research in surgery; there’s some good reasons for that. Trials in medicine are a 
highly regulated environment and so there’s a whole infrastructure of how you do a study that’s 
evolved because of that. Whereas in surgery, there is not. There is then intrinsic problems that 
genuinely, when do you study something. So, I think there are challenges in doing any kind of 
studies in surgery. I mean, there are some extremely good groups but there’s an awful lot where 
it’s a foreign language - they don’t have the culture, the training and so understanding about 
different sorts of studies like pilot and feasibility, might be hard to explain. But that also makes 
it an area where pilot and feasibility studies are probably needed for that kind of reason.” 
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Both surgeons and methodologists talked about observing a cultural shift in recent 
years in the standing of surgical trials within the surgical community. This was 
noted to be illustrated with the creation of certain surgical research initiatives, 
such as the RCSEng Surgical Trials Initiative 196 and the nationwide surgical 
trainee collaboratives, which have grown a network of surgeons interested in 
conducting trials. 
023 (Surgeon): “So I’m not saying that everything is roses, and everything is fine, but there has 
been a change in attitude in the last five years that I don’t think anyone would have believed 
would have occurred. And everyone knows what we do, and everyone knows what we’re trying 
to do and it’s almost, it’s on a par with LBG riots, in terms of, you can’t speak out against it. 
So, it’s a good place we’re in, and now it’s up to us to make sure that we maximise the patient 
benefits on it […] Your trainee collaboratives have been fantastic and inspirational to all of us.” 
 
015 (Methodologist/Funder): “I think there is a slow realisation that not only is it possible to do 
trials in surgery but that it ought to be done. It’s unacceptable to not rigorously evaluate 
something just because it’s surgical, so I think there’s a realisation from the surgeons I talk with 
[…] I think it’s more acceptable, more desirable to be involved with trials and doing trials in 
surgery, than it is perhaps in an older generation. The culture is different, so I think it… things 
are changing and I think again, the UK is a good place to be for those sorts of change. I think 
we’re ahead of the curve.” 
Some surgeons described how trainee collaboratives have helped to deliver PFS 
more quickly and efficiently, with less need for infrastructure investment in terms 
of trial personnel, recognising again the practical challenges of PFS. 
021 (Surgeon): “The trouble is, it becomes tricky as a researcher unless you, if you’re actually 
paying for a research team, if you’re buying a research team to put together and hiring people 
that’s tricky if they’re… you don’t know whether it’s going to go beyond one year […] The trial 
that [name of professor] was doing with the […] because it’s run by trainees, run by a trainee so 
it’s fantastic…it doesn’t matter whether it stops or starts or keeps going, because there’s nobody 
who needs to be laid off so, incredibly attractive of that sort of trial.” 
However, some methodologists were more sceptical about the current evidence 
for trainee collaboratives to deliver projects successfully, citing that not all projects 
initiated by these groups had succeeded.   
011 (Funder): “I know there have been some very successful trials delivered in surgery using 
trainee networks. But equally I think they’re having some unsuccessful ones, or some that have 
struggled. There’s been over reliance on the surgical network and that does make it quite 
difficult for funders to judge.” 
5.5.3 Research infrastructure barriers 
Whilst surgical interventions were felt to be specifically challenging, further 
necessitating exploration within PFS before a main trial, participants also 
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identified barriers within the current research infrastructure that further made 
surgical PFS challenging to instigate and complete. 
Inaccessible methodological expertise 
Methodology input to the design and conduct of PFS was perceived as important 
by most methodologists, funders and some more methodologically experienced 
surgeons. 
015 (Methodologist/Funder): “We’d like to see methods expertise in it. So a good way to get 
rejected is to be doing a pilot study, and in no way is there a statistician, mention of a 
statistician or a methods person, and often it’s very clear in the proposal that they haven’t, and 
they end up getting rejected. The one this morning, it was really obvious that what they need is 
methods input.” 
 
022 (Surgeon/Funder): “The surgeons were talking about just doing a little bit of statistical 
analysis themselves on the data, he said: ‘I’ll tell you what, you can do some statistical analysis 
and I’ll go do the operation’, and he said: ‘I think I know more about surgery and I can probably 
do a better fistula operation than you could do the stats.  What do you think?’  So, you could 
say if you are going to run a trial and you aren’t qualified to do it, should you really be doing 
it. We wouldn’t let the trialists come and run labour ward or… that sounds ridiculous to us, 
but we can have a go at it and it’s all right? Expertise is important.” 
The surgeons, however, recognised significant barriers in being able to access 
Clinical Trials Units (CTUs) and methodological expertise. Surgeons described 
these barriers firstly as inaccessibility if you were not employed within and/or 
collaboratively working directly with a CTU already, and secondly the expense of 
CTU input, which is not usually affordable within a PFS budget. 
008 (Surgeon/Funder): “I mean working within a trials unit to run these sorts of trials, you 
think is absolutely essential really, you can’t imagine working outside of it. I mean I can’t, but I 
know most, most clinicians do work outside and they have to. There’s a huge barrier between 
getting access to the trials units, getting CTUs to talk to you. Even well-established people are 
having trouble engaging with their CTU.” 
 
007 (Surgeon): “The major stumbling block is the fact that a lot of bodies require you to have a 
clinical trials unit, and the clinical trials units are often too expensive.” 
 
015 (Methodologist/Funder): “We can’t pay for a CTU to run it and nor will that ever be the 
case.” 
In addition, whilst methodologists and surgeons recognised that the funding 
package for PFS does not generally allow for full CTU involvement, some 
methodologists stated that it could be challenging to have only a peripheral role 
with PFS because they so heavily centre on potential uncertainties.  
020 (CTU Director/Funder): “I’ve done some advisory stuff that has been more peripheral to 
some studies, and to a CTU, it’s not a preferred model. I suppose because we more naturally like 
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to engage with the team throughout the study, and I think part of the issue with pilot and 
feasibility is that they do throw up, well every trial throws up things that you don’t expect 
every trial presents challenges, even the ones where you think you know what you’re doing.” 
A few methodologists were however aware that they, and the available guidance 
on PFS, may be relatively inaccessible to those working outside of CTUs, and that 
CTUs producing clearer guidance and becoming more approachable to potential 
surgeons needing advice, would be helpful. 
015 (Methodologist/Funder): “I think there’s a bit of a failure on our part, meaning methods 
people like me, to translate for want of a better word, our stuff into a format that people who 
really have got better things to do, to use. They’ve got better things to do, than read through half 
a dozen papers. What they really want is to distil the key things that they really, really need, so 
they can build it into their idea.” 
Inefficient research infrastructure 
Participants unanimously agreed that the overall length of time it took to seek 
funding and to complete PFS and main trials was a significant barrier to engaging 
with PFS at the start.  
023 (Surgeon): “So if you do it in the linear way, the way you’re supposed to, we’d all be dead 
before you finished the main trial, which again comes back to my point about the present 
structure, is just too inefficient.” 
 
010 (Methodologist/Funder): “I think one of the issues is how long it takes. So, somebody comes 
up with the question and then it can still take, you’re still looking at a good 18 months before; 
you’ve months to write, draft an application, send it in, go through a two stage process, get the 
funding, get the contract and get in a position to even recruit a patient. So, in some areas of 
need, you’re just not willing to wait for that kind of length of time.” 
The pressure to produce definitive results was perceived as particularly pertinent 
in surgical studies, where the clinical landscape can move relatively quickly, and 
where different or new techniques can be adopted before trials are completed.  
The research question can therefore, become obsolete during the time it takes to 
conduct the PFS and the subsequent main trial. In a sense PFS were perceived by 
all as potentially part of the problem, rather than the solution, because they 
prolong the time it takes to get definitive results. 
011 (Funder): “The concern with surgical trials is that you’re going to start evaluating 
something and it’s going to change while you’re evaluating it. So, the learning curve is 
obviously the surgeons learning the technique, and that’s an issue, but then there’s the 
technology itself that might move on while they’re doing the trial.” 
 
009 (CTU Director): “In your world of surgical trials, this is dreadful, because whatever you 
find in a surgical trial, by the time you’ve set up and run a full HTA trial over five years from 
inception to paper, the surgical technique has moved on five years. So, what you’re saying is 
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well what we did five years ago did or didn’t work, but what we do now may or not work, 
because we’re doing something different.” 
 
012 (CTU Director): “Things will move on, and it’s pointless to do a whole bunch of small pilot 
or feasibility studies, and then actually the question has moved on by the time we’ve worked out 
whether you can (laugh)…” 
External standalone PFS, were regarded as particularly problematic as they extend 
the time for answering the research question to an even greater extent because of 
the hiatus between completing the PFS and applying and getting funding for the 
main trial. 
015 (Methodologist/Funder): “You could get up to £300,000 for a feasibility study and after 
that you’re looking at NIHR money, so if you wanted £2 million, the only place you have to go 
is NIHR. HTA really, which means there’s a delay then of at least a year, and probably more 
than that. So, it really stretches out the development of that trial.” 
5.5.4 Funding barriers 
Both surgeons and methodologists perceived that difficulties with funding were a 
major barrier to completing PFS. Funders explained their rationale for careful 
funding decisions around PFS, perceiving that the importance of any surgical 
research question is determined through contextually considering its importance 
to patients, to surgeons, to the NHS and, through consideration of these groups, to 
funders. Funders felt that any pre-trial work must therefore contribute to 
ultimately answering a question (through a definitive trial) deemed to be 
important for all stakeholder groups.  
026 (Methodologist/Funder): “I mean as a funder, we want the main question to have been 
considered before the feasibility work is undertaken. So, unless it’s a question of real importance 
that, we want to answer, then the feasibility work shouldn’t be funded. So, I suppose we want 
people to engage with the main funder so, up front, look at the package, rather than individual 
feasibility.” 
 
011 (Funder): “Deciding whether a trial is worthwhile involves judging value for money and 
that value for money judgement has to be made from the point of view of the health service and 
the funder. There are one million-pound questions that are worth one million pounds, and there 
are five million-pound questions, or even ten million pound questions and we will look at the 
question, we will judge what it is. But we then need to know how much will a definitive trial 
cost. Because if a definitive trial is going to cost ten million pounds, and it’s only a one-million-
pound question, then there’s no point funding the standalone pilot and, again, I think this is 
often underappreciated.” 
Funders further emphasised the limited money available overall to fund clinical 
research, reinforcing why the judged importance of the research question was key 
in deciding which PFS are funded. 
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010 (Methodologist/Funder): “My experience on the board would probably say that cost is a 
significant issue… it doesn’t really matter whether it’s a pilot, or a main trial, whatever, it’s all 
about the research question.” 
 
015 (Methodologist/Funder): “It’s definitely the case that funding committees look at the 
headline figure of how much does this thing cost, and if you are doing a feasibility and it’s 
£300,000, you better have a really compelling case.” 
Funders perceived, therefore, that the main reason surgical PFS do not get funded 
is that the overall question is not considered valuable enough to warrant 
significant funding investment. 
011 (Funder): “I think if feasibility trials aren’t getting funded, it’s probably because they 
haven’t passed that value for money test […] We have to be very parsimonious in what we fund 
and there’s lots of good questions that we simply can’t fund because it’ll be too expensive to 
answer them.” 
In contrast, surgeons perceived a lack of surgical representation on funding 
panels, and competition with translational science and experienced research teams 
for funding, as significant barriers to fair funding opportunities. 
006 (Surgeon): “You’ll have one token surgeon with a grant giving body, who I should think, 
often, is not terribly diplomatic or very experienced in that sort of thing and it’s so competitive. 
Not just at the grant giving money for trials stage, but at the next level up where we’re going to 
spend our money, and translational studies and other types of sexy sounding personalised 
medicines and the humdrum randomised trial is hard to do. If they put their money into knock 
out mice, teams who know what they’re up to and have got to mould the work, crank that 
handle, they get the money and out comes a ‘Nature’ paper and we’re… it’s very hard for us to 
compete with that.” 
 
007 (Surgeon): “In terms of funding there are all sorts of funding streams that I’ve used in the 
past, including industry, and the major stumbling block is the disparity between what the 
funding bodies actually tell you, how they’re all interested in surgical research and how the 
minority of surgical research gets funded, and therefore, we’re all mobilising ourselves to make 
sure that that’s reversed. The fact that that’s not the case, and they’re completely disinterested 
in surgical research… I can say that safely across the board. I think it’s fair to say that a lot of 
charities are completely disinterested in anything that’s of clinical value, or that involves 
surgical research.” 
Surgeons also perceived other barriers to funding related to the lack of regulatory 
requirement for formal evaluation of new surgical procedures and surgical 
devices. This was observed to have led to a lack of research infrastructure within 
industry, resulting in fewer avenues for funding surgical research, when 
compared to for example, pharmaceutical research. 
008 (Surgeon/Funder): “Speaking candidly, the big companies have got no interest in… in fact 
it’s almost a disincentive to do head to head comparisons of their technology against whatever 
other interventions are out there, and because there was no requirement for them to do so and 




007 (Surgeon): “The difference is that the pharmaceutical industry, not only has more funding, 
but has the requirement to carry out the work, whereas the device industry has got less money, 
but has plenty of money, but has no requirement to carry out the work. There’s a lack of a 
regulatory requirement.” 
5.5.5 Challenges of reporting & interpreting pilot and 
feasibility studies 
Several issues with the interpretation and reporting of PFS were recognised, 
predominantly by methodologist participants.  
Underpowered RCTs masquerading as PFS 
Methodologists highlighted the ongoing problem of underpowered RCTs being 
published as PFS in the surgical literature. 
017 (Methodologist/Funder): “My pet hate is something described as a pilot study. When you 
read it, all of the objectives and everything else reads as if it’s a definitive study but with a 
massive, thumping great effect size and actually it’s nothing of the sort. It means, we wanted to 
do the full study but we couldn’t afford it, or couldn’t find enough patients so we’ve done 
something, we’ve called it pilot, and yes it’s neither fish nor fowl.” 
 
014 (Statistician): “They seem to be getting away with doing mini randomised controlled trials 
and, as I’ve described, they shouldn’t really be doing that.” 
Both surgeons and methodologists with editorial roles recognised the practice of 
publishing underpowered RCTs masquerading as PFS to be a phenomenon 
particularly common in surgery. This was understood to contribute to the 
widespread misunderstanding and devaluation of PFS. 
010 (Methodologist/Funder): “I think, that if you’re talking about an external pilot I think that 
there is, or at least there genuinely has been, the perception that these are small version clinical 
trials that you can do without a sample size calculation and can get passed onto a registrar, or 
somebody in need of a project.” 
 
021 (Surgeon): “I would say between 5 and 10% of the RCTs we see are badged as pilot trials or 
feasibility studies. We reject the vast majority of them […] The worst ones are what I said to 
you, they're underpowered RCTs and what I usually do is write back to them and say; ‘if you do 
the full RCT we’d like to see that […] but we don’t want a pilot trial thank you’ […] I’m sure 
they get it published somewhere else, yes, but to my knowledge, no one has ever come back with 
the full trial, after we’ve rejected their pilot.” 
In contrast, participants gave examples of the reverse situation, where pilot 
studies were performed, but then badged as RCTs in an attempt to achieve 
publication. 
008 (Surgeon/Funder): “With my journal editing hat on, I spend a lot of the time trying to 
persuade investigation groups so, they’ve actually done a pilot study and please report it as 
such. Even though they try and sell it to you as a definitive project with 20 patients in each 
group for a complex intervention.” 
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Some methodologists felt that this misunderstanding was cyclical, in that journal 
editors only want to publish definitive results, meaning study teams are tempted 
to offer these to achieve publication. 
025 (CTU Director/Funder): “There’s a lot of confusion about what people should be doing in 
these studies, and I think a lot of that comes from misunderstandings of journal editors and 
reviewers and trying to push people in a certain direction.” 
Some surgeons with editorial roles also felt that the publication of underpowered 
RCTs was acceptable practice, rationalising that such studies could be used in a 
meta-analysis. 
021 (Surgeon): “Sometimes we do get randomised trials that are underpowered cos a pilot 
randomised trial goes seamlessly into a grossly underpowered randomised trial, and I don’t feel 
so bad about publishing those because at least if they’re well done, and well written up, they can 
go into a meta-analysis… those sort of trials are never wasted, because they can then be used in 
meta-analyses. As long as they’re well described, I think that’s ok.” 
Views amongst funders towards the appropriateness of PFS objectives written in 
funding applications varied somewhat. Some funders explained that funding 
applications were commonly written with appropriate feasibility objectives but 
devoted the entire analysis section to planned hypothesis testing of effectiveness. 
015 (Methodologist/Funder): “When it comes to the analysis what they’re saying is: ‘We want 
to test out our procedures, testing recruitment, willingness to be randomised, willingness to fill 
in the data blahblahblah’, and all of the analysis section is about some multi-level logistic 
modelling that they’re doing on the outcome data.  I actually saw one this morning…It’s in a 
grant application. So, we see a lot of that and then we bang our heads together and think ‘oh it’s 
a shame’, but they’re not telling us anything about what they’re going to do on the things that 
the whole pilot is really being done for.  They can do some outcome analysis if you’re looking for 
promise too, but to have that entire focus; very, very common.” 
Other funders, however, emphasised that such applications were now in the 
minority, with underpowered RCTs more commonly observed only in the 
published literature. 
017 (Methodologist/Funder): “At least within [name of funder] I’m not saying every last 
nuance is worked out but there is now a good understanding of what they do, what they’re for 
and so on.  I think the one’s, my pet hates, are the ones if you were doing a literature review it 
would come up, but actually it’s not true, it’s some sort of relatively kind of lone researcher 
(type of study).” 
 
A place for publication of PFS 
Methodologists unanimously agreed that PFS should be published and/or the 
results made publicly available, even if the results show that a main trial is not 
feasible. Publication of PFS was regarded as important for preventing the research 
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being repeated unnecessarily thereby preventing research waste, for allowing 
others to learn from previous work, and for developing ideas for future research.   
019 (CTU Director/Funder): “They absolutely should be published. The two reasons are, one it 
stops somebody else wasting their time unnecessarily, repeating what you’ve done and the 
second one is, if someone can spot a way in which they can improve on what you’ve done, it 
gives them an opportunity to build on it, so they really should be published.” 
Methodologists also felt that if the work had been publicly funded, publication 
was obligatory from a standpoint of good research practice. 
017 (CTU Director/Funder): “They’ve been publicly funded so why wouldn’t they [be 
published] …that’s the slightly bureaucratic reason for doing it, it’s important but the purpose 
behind it is that other people can learn from it.” 
However, most methodologists noted that despite many PFS being funded from 
the public purse, public reporting of PFS is not a requirement of all funders.  
016 (Methodologist/Funder): “I suppose there’s probably a cost argument to it, because I’m sure 
that the HTA’s staff incur a cost for the editorial process so there’s the back and forth and 
there’s obviously the big unpaid reviewing that goes on of reports as well for HTA. So, there 
needs to be a whole mechanism behind it to make peer reviewed [articles] publicly available from 
the reports, for RfPB in the same way as the HTA. But I would have thought that that was 
worth investing in because… not everyone will publish their feasibility study in ‘Trials’ or 
somewhere else in ‘BMC’ or ‘BMJ Open’ or something like that. Some just will never see the 
light of day.” 
Some funders defended this position, stating that the infrastructure for the smaller 
funding streams did not lend itself to peer-review publication, despite agreeing 
that there should be a principle of publication.   
017 (CTU Director/Funder): “The HTA is a large well-funded programme, so there was a 
requirement if we’re gonna spend a million, two million on a trial, it jolly well ought to be out 
there and that’s it, that’s where publishing is brilliant. But RfPB was always was light touch… 
but in general you want at least some kind of report somewhere…” 
In addition to funders not always requiring publication, methodologists also noted 
challenges with journal editors and academic institutions not prioritising or 
valuing PFS, as they perceived them to have a low impact overall in not offering 
definitive practice-changing results.  
009 (CTU Director/Funder): “And regrettably the university won’t see this as being an 
important paper because, nobody’s going to see it as being three or four star […] it ends up in a 
low key journal, they look at it, you haven’t collected any data, you haven’t got really hard 
outcomes other than saying it can’t be done or it can be done, we’re not interested, where’s the 
main data?” 
Some methodologists further illustrated how the value of PFS had been 
undermined because of many funded projects not progressing beyond the pilot 
phase historically and subsequently not being reported. These PFS were felt by 
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methodologists to be widely perceived as standalone projects with little purpose 
or value, which for inexperienced trialists, may diminish reasons for performing 
them.  
019 (CTU Director): I do think there are probably some people out there who spend their career 
doing pilots and don’t move forward into doing the definitive trial which is harder’ 
However, some methodologists also lamented that it was difficult for trial teams 
to be motivated to write up the work for publication, particularly if it was 
‘negative’ in that it demonstrated a definitive study was not possible.  
009 (CTU Director): ‘Well actually the biggest problem, biggest bias in getting this stuff 
published is getting the team to get their backsides in gear to write the paper. If you do the 
feasibility study and you demonstrate, it’s not feasible, that’s a really important finding. And 
there’s a whole lot of experience to go into that. You do the pilot study and you decide you can’t 
do it that should be written up. But they lose enthusiasm.” 
 
019 (CTU Director): “It’s less exciting, I guess, to write up a study where the pilot showed 
something couldn’t be done. I guess some people might view it as embarrassing I wouldn’t […] 
we saved the HTA programme 1½ million pounds, which they can now spend on something 
else, I can see it’s slightly embarrassing, but I don’t see there’s any good reason not to report 
it.”  
In addition, several methodologists perceived that whilst PFS contained much of 
the methodologically important material transferable to other studies, if neither 
study teams, journal editors or universities valued this, the cycle of 
misunderstanding and devaluation would continue. 
009 (CTU Director): “All the science, all the clever stuff is in the protocol paper, which counts 
for nothing. And actually, in the feasibility work, because it’s all the positive feasibility work 
that got you to the point that you could do the main study. It’s where all the clever stuff is. The 
wonderfully concise paper in ‘The Lancet’ says, we tested it, we found a load of people with 
whatever it is they’ve got, we gave them whatever these two interventions were and either it 
worked, or it didn’t. I mean there’s nothing scientific about that.” 
Considering all these barriers to the publication of PFS, several methodologists 
welcomed and cited the introduction of The Journal of Pilot and Feasibility Studies 133 
stating how important it was for there to be a place where PFS were accepted and 
made widely available in the published literature 
020 (CTU Director/Funder): “The new journal of pilot and feasibility studies is really, really, 
really important because it gives an opportunity, an outlet to get these things published and 
they may well be very highly cited ultimately, because they’re telling us things that don’t come 
out through the big all singing, all dancing study.” 
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5.6 C) Solutions to optimise the design and 
conduct of pilot and feasibility studies for 
surgical trials 
As detailed above, participants identified many challenges around the design, 
conduct and completion of PFS. Adding to problems with variable understanding 
of the purpose and scope of PFS amongst the wider surgical community, these 
challenges were perceived to result in confusion, undervaluation, and under-
utilisation of PFS in surgery. Several solutions to optimise future PFS for surgical 
trials were, however, proposed. 
5.6.1 Education  
Several elements of education were perceived by participants as important 
solutions to improving PFS. These included; the education of surgeons more 
broadly in trials methodology (both undergraduate  and postgraduate research 
training); the development of accessible guidance for surgeons; complementary 
(not contrasting) endorsed guidance from funding and other regulatory bodies; 
and finally ‘on-the-job’ education through surgeons working collaboratively with 
methodologists within trial teams. 
 Education of surgeons in trial methodology 
The education of surgeons in trials methodology was proposed by methodologists 
as necessary to improving understanding of the nature and value of PFS amongst 
the surgical community. 
025 (CTU Director/Funder): “I think it’s just by slow drip, drip process of taking it out there to 
people.” 
 
020 (CTU Director/Funder): “Because of the nature of their work being quick decision making 
and trials are very pedantic and take a long time to set up, so I think there’s an element of 
frustration sometimes in appreciating all of the regulation around trials.” 
Methodologists also felt that, whilst the education of surgeons was important to 
improve understanding, journal editors and reviewers might also benefit from 
such education to improve the perceived value of PFS by breaking the cycle of 
publishing small underpowered RCTs labelled as PFS in surgical journals. 
014 (Methodologist): “Show them some of these small mini-randomised controlled trials that 
they do, show them the bad examples, not saying that they are bad examples, and point out why 
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they shouldn’t have just concluded there’s no difference between these two techniques because 
they didn’t see a significant p value… If they still get accepted in their journals then, they think 
they’re okay.” 
Most participants believed that the RCSEng Surgical Trials Initiative 196 and the 
nationwide surgical trainee collaboratives had made an important contribution to 
improving the surgical research infrastructure through helping to raise the profile 
of surgical research and improving surgeon participation in trials. However, 
uncertainty about the genuine ability of these groups to deliver trials was 
highlighted by some funders, who felt methodological research into how and 
when surgical trainee collaboratives are successful, would be useful. 
011 (Funder): “Sometimes we get proposals for surgical trials where they seem to be quite light 
on the clinical trials unit support, heavily reliant on the [trainee] network and we don’t know 
well is this gonna be one where the network is enthusiastic and it takes off and it really works 
or, is it gonna be one that falls through. Whereas, if you’ve got a professional CTRU clinical 
trials unit then you can say, ‘well ok, they should be able to deliver this’, but it does add another 
layer of uncertainty to things. And working out how and why and when it works would be very 
interesting.” 
 Accessible guidance  
Both surgeons and methodologists considered the available theoretical and/or 
conceptual literature as poorly understood and inaccessible to the wider surgical 
community. It was proposed that accessible guidance, which serves to 
operationalise the key concepts into practical recommendations for undertaking 
PFS and trials, would be beneficial.  
021 (Surgeon): “It’s one of the areas that I’m not aware of any guidance, so some guidance 
would be sensible, just sensible guidance along the lines we’ve been talking about what to look 
out for, to highlight the areas of concern, how to set it up, who to talk to and when, I think it 
would be valuable.” 
 
015 (Methodologist/Funder): “My sense is that the solution would be better guidance from, well 
better guidance full stop, which is very clear and very practical, better guidance from the 
funders […] I think we could give much clearer guidance and actually it keeps coming up and 
we… nobody ever has the time to do it […] so there might be different versions of it so if you 
think of it like layers of guidance.” 
Methodologists perceived that developing guidance to transcend the interface 
between surgeons and methodologists was, therefore, a key solution to improve 
PFS in surgery. 
025 (CTU Director/Funder): “I think that one of the key things is providing this kind of 
guidance which sits at the interface between the real methodology and the clinician and that I 
think is the important thing because there is stuff out there but some of it is a bit too specific or 
a bit too technical […] so I think there’s a huge amount to do on that interface between 
clinicians and methodologists.” 
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Methodologists felt that in addition to distilling and operationalising the most 
important messages, new guidance may also signpost surgeons to some of the 
conceptual and theoretical guidance documents, such as the CONSORT reporting 
framework for PFS 79, in order to complement and enhance surgeon’s 
understanding. 
020 (CTU Director/Funder): “If that guidance only brings forward the fact, that puts the 
reporting into a framework for people to look at when they’re designing [PFS], they’re more 
likely to look at it in that sense. I’m not sure clinicians will automatically go to the reporting 
literature when thinking about designing something.” 
 
014: “I don’t think the reporting guidelines have got through to people in other countries yet, so 
until we point out; ‘you might find it helpful to look at this’, they may not have come across 
them.” 
In addition, methodologists perceived it to be important, that any guidance 
developed, would advertise and encourage the use of existing methodological 
resources, for example, the NIHR Research and Design Service. 
019 (CTU Director/Funder): “I think the best guidance I ever give the surgeons, so surgeons 
who are comparatively research naïve and they want to do research, is to go and talk to their 
research design service, if they’re in England anyway. So, I think that’s a great resource and I 
think if you need a bit of guidance at this end of the project, you shouldn’t be doing it on your 
own.” 
All participants agreed that any new guidance, should be simple, including some 
key recommendations, and encourage consideration of individual study 
uncertainties, rather than didactically listing certain issues to explore in PFS. 
022 (Surgeon/Funder): “As long as they’re not didactic because they need flexibility around 
different kinds of trials, but yes it would be very useful.” 
 
017 (CTU Director/Funder): “I think something in which you say the principles and why we do 
them, what’s in it for the investigators, what’s in it for the funders, some things to think about 
have you got your questions straight, does it need to be internal or is it standalone to answer 
them […] something that gives us a sort of framework. I mean they’re all very different so that’s 
why I wouldn’t want it say you must have this; you must have that.” 
Methodologists also felt that examples of how PFS have been designed to inform 
main trials in surgery would assist in informing better understanding about PFS 
design amongst surgeons. 
025 (CTU Director/Funder): “I think people need to start engaging with what’s out there, and 
we need to find some good examples of how that’s helped people.” 
 
017 (CTU Director/Funder): “In your area from surgery, saying this is where a feasibility 
study was done, this is how it informed the main study, this is how a pilot was done and either 
it stopped or it went on, so some concrete examples so they can get their heads round what the 
variety is. A lot of people learn by example anyway so I think that’s particularly true in areas 
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like surgery […] a high-level check list that should apply to everything but with concrete 
examples and making it clear that it’s not a kind of a recipe, it’s a thing to think about.” 
 
020 (CTU Director/Funder): “I’m thinking you know really focus your examples on the 
challenges and feasibility around surgery.” 
Some methodologists felt that layers of guidance, starting with key points that 
always need to be considered for PFS, and developing this with layers of 
complexity for different end users would be helpful. This approach was 
analogised to a detailed appliance manual with a point of reference page at the 
front signposting the absolute requirements for safety before use. 
015 (Methodologist/Funder): “So there might be different versions of it, so if you think of layers 
of guidance so something which is widely readable, if you like, in a sense that this is meant for 
the widest possible audience and gets across key messages so if you see nothing else or take 
onboard nothing else these are the things you really need to think about. And then for those who 
are more interested, whose job it is perhaps to be working with trial teams to do this on a day to 
day basis across many trials, something a bit more detailed I think would be appropriate and 
there might be a third layer where it’s very very detailed and this is what a trial methodologist 
or a CTU ought to be looking at.” 
 Content of accessible guidance for surgeons 
Methodologists and surgeons illustrated some items they felt to be fundamental 
for inclusion in a list of key recommendations within guidance for surgical PFS. 
Considering specific uncertainties of the research question 
Methodologists were very clear throughout the interviews that it was paramount 
to consider all uncertainties relating to the research question in PFS, and that those 
uncertainties will be different for different studies. A criticism of some current 
guidance documents was that offering lists of issues to consider as examples, led 
researchers to believe they are the only items to explore in PFS. 
026 (CTU Director/Funder): “That’s the danger of saying; these are always the things that you 
should look at in feasibility, that people stop thinking. Actually, you need to think about the 
context, you need to think about the question that you’re wanting to answer, the big question. 
And then what is it that you need to be able to show to convince people that that main question 
is answerable.” 
As addressed, within the previous theme (Section 5.5 Challenges of PFS for 
surgical trials), considering uncertainties around the intervention was perceived as 
fundamental for surgical trials.  Exploring the uncertainty around surgical 
interventions would need emphasising in any guidance, given that surgeons were 
less explicit about this, tending to focus on recruitment. 
 
 142 
Selecting a PFS design 
Methodologists felt guidance on what type of PFS to perform and in which 
circumstances, would be particularly useful. It was perceived that the type of PFS 
would need to be considered in the context of the research question, the types and 
number of uncertainties and the experience of the trial team. 
018 (CTU Director): “Some kind of uncertainty index […] a short questionnaire, ten items or 
fewer, that people could answer, possibly a scale on each question and I could see you’d have like 
three cut-points, one where you probably didn’t need a pilot, one where you probably needed a 
pilot, one where you probably needed a feasibility, of increasing uncertainty. I’m sure if you did 
something like that it would be well cited because I think a lot of people, well certainly 
applications for pilot/feasibility studies, people would probably use it for that, to justify why 
they wanted a pilot or didn’t want a pilot for that matter.” 
In contrast, and illustrating the urgency felt by surgeons to move on quickly to a 
main trial, surgeons perceived that considering when you didn’t need a PFS was 
particularly useful to include in guidance on PFS.  
021 (Surgeon): “So maybe the most important part of your piece of advice would be what is the 
information you need before you start a trial, to mean that you don’t need to do a pilot 
feasibility study, that might be the way around looking at it.” 
Early planning for the main trial 
Methodologists and surgeons perceived that having clear intentions to undertake 
a main trial and, therefore, justifying the importance of the research question that 
the main trial will ultimately answer, was fundamental to the design and conduct 
of PFS.  
019 (CTU Director/Funder): “So you must know what the main trial you want to do looks like.  
You might not have the detail […] but I think you need to write down, and certainly if you’re 
applying for funding, your funder will want to see an idea of what you’re working towards, and 
that helps you both justify and think through what the unknowns are that’s stopping you doing 
it right now.” 
 
010 (Methodologist/Funder): “I think that you do have to have the main trial in sight because, if 
you don’t, why are you doing the pilot anyway […] it’s a waste of resources.” 
 
002 (Surgeon): “You’ve got to have a big picture first, and then decide do you need a pilot 
study. You can’t do one without the other can you really […] you’ve got to know where you 
want to be and where you’re going first.” 
 
023 (Surgeon/Funder): “I don’t think you should be running a pilot or feasibility unless you 
can see the full practice- changing trial at the end of it. I mean what are you doing, you’re just 
playing around. […] it’s irresponsible of anyone to be funding you if you can’t demonstrate 
what the whole game is.” 
Handling clinical outcomes measured in PFS 
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The ongoing practices of publishing underpowered RCTs labelled as PFS, and of 
undertaking formal hypothesis testing on PFS data were highlighted in Section 
5.5.5 (Challenges of reporting and interpreting PFS). Methodologists perceived it 
was important, therefore, for any guidance to explain and demonstrate the issues 
around outcome analysis for PFS. 
025 (CTU Director/Funder): “I think what you do with clinical outcomes is another area 
because a lot of people want to analyse those just to say we’re doing a main trial.” 
5.6.1.4 Complementary guidance and endorsement from 
funding and regulatory bodies 
As explained in section 5.4 (Differential understanding of PFS), funder guidance 
was perceived as limited in offering operationalised detail for designing and 
conducting PFS in practice. Whilst most funders offer some guidance on their 
websites, this is mainly limited to brief definitions of PFS, which often differ 
between funders. Methodologists and surgeons felt, therefore, that consistent 
guidance for designing and conducting PFS across funders and other regulating 
bodies, such as the Royal College of Surgeons, would be key to encourage better 
practice.  
015 (Methodologist/Funder): “I think it would be important for funders to effectively endorse it 
[…] I think that would be really nice and if the funders put it up, the funders clearly have the 
stick where the other organisations don’t. They hold the money, and so if the funders have asked 
me to do it I think you’re much more likely to do it and if you don’t do it, it makes it easier to 
reject it.” 
 
007: “I think it’s important for the… you can try and preach to the individuals but ultimately, 
it’s down to the associations and to the colleges to try to come out with guidance of what is 
acceptable behaviour and what isn’t.” 
In addition, participants felt that endorsement of guidance for the design and 
conduct of PFS from all the major funders and relevant journals would also be 
beneficial. 
022 (Surgeon/Funder): “I think the major funders are going to be paying for it so it would be 
good if, not just NIHR, but all the major funders will endorse it. Say if you are gonna run a 
feasibility or a pilot study, this is how we’d expect you to go about it and of course it would be 
nice if some of the journals…” 
However, some methodologists suggested that whilst formal endorsement of 
guidance would be advantageous, it would be unusual for this to come from 
funders.  
016 (Methodologist/Funder): “It would be quite unusual wouldn’t it to endorse guidance for 
how to go about designing a pilot or feasibility study […] I think that it should, endorsement 
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would help because then it would hopefully make people take notice of it, but I’m not sure 
where’s the best place to actually get that from.” 
 
027 (Funder): “I think there’s always a case for something like that [endorsed guidance], but 
whether that’s the NIHR’s business, certainly it’s the Research Design Services’, they should 
have it all nailed down as to what kind of [PFS to perform]. My experience of the RDS is people 
don’t use them sufficiently.” 
Another difficulty surrounding the endorsement of guidance highlighted by some 
methodologists was reaching agreement across different funding bodies, given 
that not all funding bodies currently agree on the role and purpose of PFS. 
024 (CTU Director/Funder): “If you’ve got two funding bodies that are actually coming at it 
from very different angles, then it may not be very helpful to have broad guidance, it’s about 
what your target funding agency is thinking about. So, if you’ve applied to CRUK then you 
need to know what the CRUK rules are for feasibility, if you’re applying to NIHR you need to 
know their rules. So, maybe there’s a space for funding bodies to discuss this, and if there is a 
lining up of view then it could be useful to generate something generic.” 
5.6.2 Collaboration  
Methodologists and more methodologically experienced surgeons perceived that 
collaboration between clinical groups and methodologists/trialists would aid 
more efficient design and conduct of PFS whilst simultaneously contributing to 
educating the surgical community (see also section 5.6.1). Improving surgeon 
collaboration and engagement with methodologists and CTUs was therefore seen 
as a key solution to optimise PFS. 
026 (CTU Director/Funder): “And so a trial unit might not be involved necessarily in running 
the feasibility due to expense or capacity or something, but they have to be involved in designing 
it, because you’ve got to think of the design of the main trial. You can’t think about feasibility in 
isolation, so it’s absolutely crucial that you get on well with them.” 
 
018 (CTU Director): “I think you’ll probably need a methodologist involved […] even if it’s just 
the pilot and you’re going to throw all the data away and start again. You don’t want to learn a 
lesson that someone who runs loads of trials knew beforehand.” 
 
019 (CTU Director/Funder): “You probably do need some CTU advice because if you’re a 
clinician who’s not done a lot of trial work, you probably don’t know what you don’t know. You 
know all the clinical uncertainties, but you don’t know the methodological uncertainties.” 
Additionally, methodologists perceived how working collaboratively with 
surgeons might be mutually beneficial and that improving surgeons’ perceptions 
of the value of methodological expertise would enable better collaborative 
working. 
010 (Methodologist/Funder): “I mean it’s always lovely if you’ve got an experienced CI but 
more importantly it’s lovely if you’ve got a CI who’s able to not think that their job is to know it 
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all and who is able to take direction and listen to and act on advice […] responsive to the fact 
that you’re bringing your expertise in and they’ve got theirs and it is that blending of it.” 
 
012 (CTU Director): “It’s just when busy clinicians try to do everything it seems really 
difficult for them and that’s where I just think a trials unit helps because you get the database 
done and tested, you get someone taking care of all the documents […] some of the big units 
don’t, but we’re kind of helpful to our local investigators.” 
Both methodologists and methodologically experienced surgeons understood that 
collaborating with a fit-for-purpose trial team with the necessary expertise to 
consider the research question fully, was important for improving PFS. 
008 (Surgeon/Funder): “You need the right team but […] the constituents of the right team 
depend on what elements of the feasibility you’re addressing.” 
 
004 (Surgeon): “If you’ve got a good team they recruit well, work together […] and they enjoy 
it and therefore it all gets better and better […] relationships and teamwork is fundamental 
across trials actually.” 
Methodologists also perceived that the PFS team might require broader types of 
expertise than the main trial team. 
020 (CTU Director/Funder): “I think the team is potentially wider in a feasibility study than it 
would be in the main trial because there are so many uncertainties. You need to engage 
probably in a more diverse group of people.” 
Collaborating with patient and public involvement groups as early as the PFS 
stage, was also perceived by methodologists as key to improving the design of 
surgical PFS. 
024 (CTU Director/Funder): “I think probably patient groups are even more important, because 
a lot of the time the feasibility fails because the investigators haven’t worked out what are the 
patient centred issues.” 
 
016 (Methodologist/Funder): “Patient input I think is essential, not just token patient input, 
but having patients who are engaged and can be co-applicants and can offer proper input rather 
than token input. Because again from a patient’s point of view if you’re proposing things in a 
study that patients are just not going to do, then you need to know that quite early on, so that 
you design your study in a different way.” 
5.6.3 Efficient funding infrastructure  
Surgeons were less explicit in considering education about research methodology 
a fundamental necessity to improve PFS. Instead, surgeons focused more 
generally on the current research infrastructure being too inefficient to allow 
thorough and timely evaluation of surgical interventions. This was considered 
particularly relevant to surgical research where new technologies and techniques 
are often introduced quickly and without the same level of regulation as, for 
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example, the pharmaceutical industry. Improvements in surgical research 
infrastructure were perceived, therefore, as a key solution to improve PFS by 
surgeons. 
023 (Surgeon): “I think we probably need to look at more efficient approaches, and I think that 
the current trials structure is very inefficient and is probably not fit for purpose for new 
technologies in the future because they’re coming through so quickly and so fast we have to be 
able to evaluate them in a much more efficient manner, and discard ones that aren’t working. At 
the moment, our structures are completely hopeless for that.” 
Methodologists also supported improvements to the research infrastructure but 
were much more specific in how they thought it could be improved to allow PFS 
studies to be undertaken more efficiently. Some funders, for example, described 
how there should be caveats where an external pilot can run seamlessly into a 
main trial if, the outcome data has not been analysed, the pilot and main trial are 
not too dissimilar, and the PFS shows that the main trial is feasible. 
008 (Surgeon/Funder): “If you’ve not analysed that data and you’ve just stood it alone and set 
it aside until you get funding for the major study, then personally, on a funding panel, I 
wouldn’t have a problem with that. In fact you just saved me an X amount of pounds cos you’ve 
already got 100 patients […] the reality is that we’ve got to run these things efficiently, so to 
discard 100, 200 patients within a study that seems ridiculous if you don’t change the 
interventions.” 
 
015 (Methodologist/Funder): “So perhaps the cleanest thing would be, which might address 
both funders’ needs and researchers’ needs, is that there’s one proposal which includes an 
external pilot and there’s the progression criteria and if the external pilot is fine then the 
remaining 3 million is released.” 
However, this approach still incurs a lag time between the pilot work and the 
definitive study, and most funders felt that this was the clear disadvantage of a 
standalone (external) PFS design.  
010 (Methodologist/Funder): “I think you have to understand the pace of research and the 
clinical area as well, to determine whether or not it’s achievable or reasonable to do the external 
pilot.” 
Many methodologists felt that, whilst applicants should not waste time designing 
a main trial if there was still considerable uncertainty, if the question was 
sufficiently important, then funding for a main trial should be planned as a staged 
approach.  
017 (CTU Director/Funder): “With commissions somewhere we’ve said maybe this should be a 
pilot, a standalone pilot and we say; ‘well they know what they’re doing, if they can’t recruit 
then that will stop’. It maybe harsh but it will stop at the pilot stage, and that always feels nasty 
cos you feel you’ve had a big grant snatched away from you. But if it is going to work that 
would be a much better model, cos everything will be set up and they can roll in to it, rather 




027 (Funder): “I think some flexibility. Sometimes you’ll know in advance whether it’s going to 
be an external pilot or, an external feasibility study and, sometimes you won’t. There should be 
enough leeway in judgement at the point of having finished the feasibility study or the pilot to 
say, actually this isn’t going to change and therefore the data can be used as an internal pilot.” 
 
011 (Funder): “If you’re convinced there’s a case that we need a trial to answer it, and that 
we’re pretty clear about what the patients, the intervention, the control and the outcome should 
be then it should be an internal pilot, but with perhaps phased funding to allow withdrawal of 
funding if it’s not feasible.” 
Conversely, some funders perceived inevitable limitations with this approach, 
explaining how funding can’t be entirely open-ended without the definitive study 
being fully costed. Furthermore, funding bodies were regarded as not currently set 
up to make quick decisions on large sums of money. 
019 (CTU Director/Funder): “If you’re in that position so you’ve got an external pilot which 
has gone nicely and you want to roll straight through but...so currently funders are not set up 
to make quick decisions about large amounts of money, so if you come along asking for another 
million pounds, the chances that that’s gonna go through on a nod are pretty low.” 
In addition, one funder perceived that standalone PFS should be reported and 
made publicly available, from a standpoint of probity and good ethical practice, 
before further funding is released. 
011 (Funder): “There’s an issue of probity that if you funded the standalone…you’re committed 
then, to wanting the standalone pilot to be written up, be reviewed and made publicly available 
before you fund anything else, because you’ve committed public funding to that and we have a 
right to know what the pilot study shows and that’s a slow process.” 
However, overall, funders recognised that modifications to the current system of 
funding PFS, both to improve efficiency and reduce waste, were necessary and 
possible. For example, many funders felt a more formal and linked funding set-up 
between different funding streams within the same funding body, would offer a 
solution to improve the efficiency of funding infrastructure. This approach is more 
in line with the model used in the NIHR Programme Grants for Applied Research 
(PGfAR) funding stream. Funders felt this approach would help to prevent the 
funding of PFS that are unlikely to be sufficiently important to warrant major 
investment in a definitive study. Consequently, it was felt this would improve the 
efficient progression of standalone PFS to feasible main trials, and therefore 
prevent the waste of valuable funding resources.  
027 (Funder): “I think it’s one of the major advantages of programmatic funding is that you can 




025 (CTU Director/Funder): “I think that there is an argument for doing something that’s a bit 
more joined up. I mean the programme grants I think are really good because they do allow 
people to go through those stages […] I think that’s a really helpful model and in some ways it 
would be better if everything went under that model.” 
5.6.4 Wider dissemination of pilot and feasibility 
studies 
As illustrated in section 5.5.5 (Challenges of reporting and interpreting PFS), the 
methodologists identified that dissemination of PFS results and reports was 
currently limited and sub-standard. This was perceived to be due, in part, to a lack 
of requirement by all funders to release the report into the public domain, and also 
due to variable understanding of journal editors regarding the purpose and value 
of PFS. As solutions to this problem, methodologists described how threaded 
publications and open access online repositories for all documents relating to a 
research study, not just the primary journal publication, would be beneficial. 
017 (CTU Director/Funder): “They can certainly publish a register of studies, they could 
certainly publish the protocols easily on line so and whether there could be some grossly light 
touch way, even if people were uploading their own report. So yea, something so fit for purpose 
and proportionality.” 
 
027: (Funder): “I think digital publication is, and the idea of threaded publications, so you go to 
an online site where there’s the original protocol, there’s all the referees comments, there’s the 
revised protocol, here’s the feasibility study protocol, there’s the main trial protocol following 
the feasibility study and then all the publications are threaded, attached to that.” 
Methodologists also perceived that, as part of any grant requirements, there 
should be greater emphasis from funders on incentivising and prioritising 
reporting of PFS. 
017 (CTU Director/Funder): “[for most funders] you give the funder a report for internal 
purposes but then you publish it separately. But in general you want at least some kind of 
report somewhere and again how you do that is the whole question of open publishing and 
making data available but in principle absolutely […] they should be in the public domain, and 
exactly how that should be done, I guess it’s an infrastructure thing, but I think now more are 
being exclusively funded that…it follows on from that.” 
Methodologists, therefore, felt that improved dissemination of PFS would 
augment the recognised value of PFS through providing learning opportunities 
across clinical areas, avoiding repetition of failed ideas and, consequently, 
reducing research waste.  
014: (Methodologist): “Well, so that people can learn from each other […] so that people don’t 
keep re-inventing the same wheel. People can learn, but you learn across disciplines as well […] 




027: (Funder): “Whether that’s via the report in the journal’s library or whether it’s via papers 
and journals to some extent doesn’t matter. My point is that the aim should be 100% of publicly 
funded research does get an airing so that people can learn.” 
5.7 Summary 
The PEPSTAR study has further identified and expanded on exactly what the key 
challenges are for the design and conduct of surgical PFS, why these challenges 
and barriers to optimal practice exist, and what solutions might be necessary to 
improve future practice in this area. The findings build on knowledge and 
understanding of the issues affecting surgical trials more widely, to understand 
specifically, from the perspective of all key stakeholders, why research practice 
around surgical PFS is perceived as difficult and therefore not currently 
optimised.  
The findings of the PEPSTAR qualitative interview study (phase two), and the 
targeted review and systematic analysis of NIHR funded surgical PFS (phase one), 
were synthesised and interpreted, as described in chapter three, to produce 
detailed recommendations from this work for how to optimise future PFS in 
surgery (phase three). The next chapter (Chapter six) will describe and explain the 
results of this synthesis process, and present detailed recommendations for 
improving research practice more widely amongst all key stakeholder groups and 
a ‘Top Tips’ tool to operationalise these recommendations for practical use by 





A synthesis and interpretation of the 
findings in this thesis to inform 
recommendations for the optimisation 
of pilot and feasibility studies in 
surgery 
6.1 Introduction 
This chapter provides a complete written account describing and illustrating the 
results of phase three of this work. Objectives one and two of this thesis were 
completed through phases one and two of this work. The objectives of phase three 
of this work were, therefore: 
Objective 3 To synthesise and interpret the findings of the targeted review and 
systematic analysis of protocols of pilot and feasibility studies funded by the 
NIHR and the in-depth qualitative interview findings, in light of the 
methodological and theoretical literature around pilot and feasibility studies 
(as reviewed in chapter one and two) and;  
Objective 4 To develop recommendations from this work for all key 
stakeholders and, specifically, accessible and practical top tips for surgeons to 
optimise the design and conduct of pilot and feasibility studies to inform main 
trials in surgery.  
This chapter will be divided into two parts. The first part of this chapter will 
address objective three and present the synthesis and interpretation of the findings 
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from phases one and two. The second part of this chapter will focus on objective 
four to present the recommendations from this work.  
For clarity and ease of use, the diagram illustrating the process of data collection 
and analysis leading to the synthesis and interpretation of the findings in phase 3 























Figure 3c Process of data collection and analysis in this thesis (repeated from chapter 3). 
The key findings from phase one (Chapter 4) and phase two (Chapter 5) of this 
thesis are summarised and illustrated in Figure 6a. All the findings from this work 
were interpreted whilst also considering the existing methodological concepts 
surrounding PFS and the background literature and knowledge in this area, which 
has evolved over the course of this thesis. Figure 6a below therefore maps onto 
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surrounding PFS generally, and the guidance documents relevant to PFS in 
surgery, are made in this chapter where appropriate. This is because the synthesis 
process occurred within the context of these documents and the evolving concepts 




Figure 6a Summary of the key findings from phase I and II of this thesis, interpreted in 
light of the known methodological and theoretical literature. 
6.2 Part 1: Results from a synthesis and 
interpretation of the findings in this thesis  
6.2.1 Defining a cyclical problem surrounding the 
conduct of surgical pilot and feasibility studies 
During the synthesis and interpretation of the findings from phases one and two 
of the research, a cyclical model linking a variety of sub-optimal research practices 
around the design and conduct of surgical PFS emerged and is illustrated in 
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Figure 6b. This model comprises four root causes of why surgical PFS are not 
currently optimised, which are: 1) A differential appreciation and /or 
misunderstanding of the breadth and scope for PFS to inform main trials in 
surgery (‘not optimally understood’); 2) Consequently, surgical PFS are potentially 
not optimally designed or conducted, or not perceived as valuable to complete at 
all (‘not optimally conducted’); 3) Many surgical PFS that are done, are not 
reported or reported incorrectly (‘not optimally reported’) and; 4) This leads to 
PFS being undervalued by surgeons, journal editors, academic institutions and 
potentially funders .  
In addition to the root causes identified for why surgical PFS are not currently 
optimised, there are also compounding factors, which are linked to both the root 
causes and to each other. These compounding factors are: 1) The challenges 
relating to current guidance and; 2) The challenges relating to the cultural issues 
surrounding both surgical research in general and surgical PFS more specifically. 
These challenges can variably impact at different and multiple points in the cycle 












Figure 6b Cyclical model of sub-optimisation of PFS illustrating the linked and co-influential 
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Recognition of the root cause problems and the compounding challenges causing 
sub-optimal design and conduct of surgical PFS, and how they interact and 
influence each other, offers insight into what solutions are needed to improve 
research practice in this area. Each of the components in the cyclical model will 
now be discussed in turn, with consideration of how the components interact and 
influence each other. Throughout, how the different data sources compared, 
converged, or complemented each other in a process of triangulation, to form the 
cyclical model, will be highlighted and discussed.  
6.2.2 A) Root causes of why surgical pilot and 
feasibility studies are not optimised 
Surgical PFS are not optimally understood 
Differential and problematic understanding of the purpose and scope of PFS 
amongst the surgical research community was a finding that converged from all 
data sources. For example, the targeted review and systematic analysis of NIHR 
funded PFS protocols, demonstrated that nearly a quarter of PFS studies planned 
to conduct formal hypothesis testing. This finding converges with that of the 
PEPSTAR interviews, which found that many surgeons still perceive PFS as small 
underpowered RCTs, designed and reported with statistically tested outcome 
measures of safety and effectiveness. Hypothesis testing is, therefore, still 
commonly done in PFS, and held up as evidence of effectiveness of interventions 
in the published literature.  
Even the more methodological experienced surgeons in the PEPSTAR interviews, 
viewed PFS in more pragmatic terms, as a tick box exercise or steppingstone to 
achieving main trial funding. Whilst not incorrect, this purely practical application 
of PFS potentially limits their optimal use. These findings converged with the 
findings from phase one, where exploitation of the full potential of PFS to explore 
all relevant uncertainties to the research question was not observed. 
These differences and difficulties around understanding PFS could be described as 
a limited understanding amongst surgeons, but this would be too simplistic. From 
the PEPSTAR study, understanding seems to be intrinsically related to both 
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experience and professional roles within research and clinically, and in particular 
to roles relating to clinical trials. However, the majority of surgeons in the UK do 
not have significant methodological experience as a major part of their 
professional role. The PEPSTAR study showed that whilst methodologists had a 
more complete and accurate understanding of the principal purpose of PFS in 
optimising the main trial, in general most surgeons, lacked a basic understanding 
of what PFS are, and how they should be utilised.  
Surgical PFS are not optimally conducted 
If there is misunderstanding of what PFS are and why they should be done, this 
will impact on the range of issues that surgeons will seek to explore in PFS, 
meaning PFS are not optimally conducted. Sub-optimal conduct of surgical PFS 
was demonstrated in the targeted review and systematic analysis of NIHR funded 
surgical PFS protocols. A tendency to focus on issues in surgical PFS that are 
generic to all trials, such as recruitment, was observed rather than considering the 
breadth of uncertainty that is of specific importance to trials of surgical 
interventions. This finding converged with data from the PEPSTAR interviews, 
with methodologists perceiving that there was a propensity for clinical and 
inexperienced applicants, to follow ‘example’ lists provided by funders, of what to 
consider in PFS, rather than thinking more widely and specifically as to the 
individual study needs. 
More specifically, complementarity was demonstrated between the quantitative 
and qualitative findings, of an under appreciation of the importance of exploring 
the intervention in PFS in surgery. The findings in phase one illustrated that only a 
quarter of PFS sought to explore uncertainties specific to the surgical intervention. 
This was complemented by findings in the PEPSTAR study, where the full range 
of, and reasons for, the many challenges facing trials of surgical interventions, 
were not always recognised by surgeons. More importantly, the potential for 
using PFS to explore the unique challenges of surgical trials was generally not 
fully appreciated by surgeons. 
Surgical PFS are not optimally reported  
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The findings from phases one and two converged in agreement that surgical PFS 
are currently not optimally reported. The data from the targeted review and 
systematic analysis of NIHR funded surgical PFS illustrates categorically, that PFS 
in surgery are frequently under reported with only two thirds publishing the 
results to date. Complementary to this finding, the continued practice of 
inappropriate publication of PFS masquerading as RCTs and/or underpowered 
RCTs being badged as PFS a posteriori, was identified in the PEPSTAR study. The 
PEPSTAR data also demonstrated that there were several cultural barriers 
impacting on the publication and appropriate interpretation of surgical PFS, 
resulting in suboptimal reporting of such studies (see section 6.2.3). 
Surgical PFS are undervalued 
The findings from the targeted review and systematic analysis of NIHR funded 
PFS protocols demonstrated that PFS are sub-optimally conducted and reported. 
The PEPSTAR study complemented these findings by illustrating the 
undervaluation of PFS by all key stakeholder groups, which leads to suboptimal 
conduct and reporting of PFS. Funders for example, perceived that many PFS had 
historically been conducted as standalone pieces of work with no intention of the 
study team, funders or both to progress to a main trial. PFS were consequently 
undervalued as being ineffectual and not worth investment. Similarly, academic 
institutions were perceived to undervalue PFS, considering them low impact 
studies, which do not contribute significantly to the Research Excellence 
Framework (REF) as three- or four-star papers, and often have no outputs at all. 
This is in part, perpetuated because journal editors undervalue PFS as not offering 
definitive practice changing results, and therefore are of limited interest to the 
readership and clinical/research community. This perception means PFS are often 
challenging to publish, meaning authors don’t attempt to publish them. Finally, 
surgeons perceived PFS to lengthen the process of trials research, meaning 
answers to important questions took longer to attain. Consequently, the research 
question may become obsolete in fast moving clinical areas like surgery, before the 
research was finished. Undervaluation of PFS by all key stakeholders therefore 
perpetuates the cyclical model of sub-optimal design and conduct of such studies.  
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6.2.3 B) Challenges compounding the cyclical model 
of sub-optimisation of surgical pilot and 
feasibility studies 
The synthesis and interpretation of findings from phases one and two of this work 
has produced a cyclical model of sub-optimisation of PFS which links the issues 
underpinning why surgical PFS are sub-optimally designed and conducted (see 
Figure 6b). There were two key compounding factors identified from this 
synthesis for the perpetual sub-optimisation of surgical PFS. The first is the 
variability and inconsistency of both the guidance available from funders, and the 
guidance available in the published literature. It is important to note, however that 
the guidance available relevant to surgical PFS has changed and evolved during 
the course of this thesis (see chapter 7 for full discussion of this). The second is the 
cultural challenges surrounding surgical trials more generally which also impact 
on surgical PFS, and the challenges of PFS more specifically. The next sections will 
discuss the compounding challenges identified from this synthesis, contributing to 
why surgical PFS are sub-optimally designed and conducted. 
GUIDANCE CHALLENGES 
Funder guidance 
The PEPSTAR study findings highlighted that funder guidance was perceived to 
be limited to brief and variable definitions of PFS, which are not the same and/or 
complimentary to the definitions given in the theoretical and conceptual guidance. 
The NIHR glossary definitions 77, 78 of PFS were, for example, until recently the 
only guidance offered by the NIHR on conducting PFS. These NIHR definitions of 
PFS were perceived by the PEPSTAR participants as both linear and succinct but 
lacking any detailed explanation of when to choose different PFS designs. Whilst 
some methodologists and trialists quoted the definitions given by the NIHR as 
‘guidance’ during the PEPSTAR interviews, there was acceptance that ongoing 
confusion exists in the wider surgical research community. Using the terms ‘pilot’ 
and ‘feasibility’ interchangeably may seemingly cause little harm. However, 
underlying the interchangeable use of terms by surgeons applying for PFS 
funding is a fundamental misunderstanding of the full purpose, value and 
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potential of pre-trial work and how it applies to the individual research area as 
demonstrated in phase one of this work. This results in using the nuances of 
different definitions to design studies which may not be fit for purpose, so PFS 
will consequently continue to be sub-optimally designed and conducted. 
Theoretical/conceptual guidance 
The PEPSTAR data illustrated that whilst most methodologists recognise the 
extensive work already done to conceptualise the types, purpose and reporting of 
PFS 71, 79-81, 90, 132, many felt this work to be inaccessible and poorly disseminated to 
surgeons. There was limited awareness of its existence amongst surgeons, and the 
few surgeons who did mention the conceptual work, felt that it was mostly 
theoretical and generic, making it largely unhelpful. This finding indicates that the 
conceptual work is poorly understood and not widely acknowledged beyond the 
methodological community. Indeed, the newest NIHR guidance published in 2019 
197, does not quote any of the theoretical/conceptual work as further information 
on best practice in this area. Even the IDEAL guidance 9, 100, which is the 
conceptual work most aligned with surgeons and surgical trials, was not 
perceived in the PEPSTAR study, to be widely accepted or utilised amongst 
surgeons.  
If available guidance is inaccessible, not publicised and/or not endorsed by 
funders and research design services, it will not be pragmatically incorporated in 
research practice. The PEPSTAR interviews perceived that amongst those without, 
or not incorporated within groups with, methodological expertise, the available 
theoretical/conceptual guidance on the design and conduct of PFS was both 
inaccessible and/or often unheard of. Furthermore, there was a perception that the 
available guidance (including the IDEAL guidance) is too generic for surgeons to 
operationalise.  
In summary, if none of the available guidance is operationalised specifically so 
that it is of practical use by surgeons, its inaccessibility is compounded, further 
adding to confusion so that it is consequently misunderstood or ignored. The cycle 
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of misunderstanding and undervaluation of surgical PFS is, therefore, 
perpetuated, by a lack of consistent, accessible and operationalised guidance. 
CULTURAL CHALLENGES 
Surgical trials 
The PEPSTAR findings showed that many of the existing challenges for surgical 
trials, also impact on PFS, and in doing so, make PFS even more important in 
surgery. In addition, the findings in the PEPSTAR study emphasised the 
blossoming culture of surgical research in recent years, through the formation of 
nationwide surgical trainee research collaboratives and the RCSEng Surgical Trials 
Initiative, for example. These newer developments have undoubtedly contributed 
significantly to raising the profile of surgical research and, more specifically 
collaboratively conducting trials in surgery. However, the methodological 
robustness of some research performed by surgical trainee collaboratives was 
highlighted as potentially problematic by some PEPSTAR participants. 
Furthermore, findings in both phases one and two, suggest there is some way to 
go before methodologically sound surgical trials are the domain of the majority 
rather than the interested few. 
Reporting of surgical PFS 
Inappropriate reporting of PFS was identified as a root cause of suboptimal 
research practice in this area, as illustrated in Figure 6b. However, there are also 
cultural influences on the reporting of PFS. The PEPSTAR findings demonstrated 
ongoing misunderstanding even amongst surgical journal editors, some of whom 
desire only to publish definitive results and therefore request that these are 
included for the publication of a PFS. This editorial practice will consequently 
perpetuate the cycle of misunderstanding; if definitive results are requested, 
authors may feel compelled to produce them in order to achieve publication. In 
addition, the findings from phases one and two converged in confirming that 
variable funder policy on public reporting of PFS, impacts on the dissemination 
and perceived value of PFS. Whilst there is now a journal dedicated to the 
reporting and publication of PFS (The Journal of Pilot and Feasibility Studies 134), 
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without investment of journal editors, academic institutions and funders to drive 
the importance of publishing pre-trial work, the cycle of sub-optimisation of PFS 
will continue.  
Funding surgical PFS 
The targeted review and systematic analysis of NIHR funded PFS studies 
demonstrated that almost four years beyond the end of the funding period (2015) 
for included studies, only three PFS (3/35, 8.6%), have progressed with certainty 
to a main trial, with at least a third (11/35, 31.4%) falling into relative obscurity. 
This finding was complemented by the PEPSTAR study findings, where it was 
perceived that standalone PFS had historically been funded, completed (or not) 
and reported (or not) but importantly, without any intention of funders, study 
teams or both, of progressing to a main trial. Whilst this practice, was perceived in 
the PEPSTAR interviews to now be less common in recognition of this issue, the 
structure of many funding streams remains unchanged. Most funders still offer 
uncoupled funding where a PFS may be funded initially, without firm promise of 
main trial funding.  
The inefficiencies in the current funding structure were demonstrated by the 
convergence of findings from phases one and two of this work. Phase one showed 
that PFS are sub-optimally reported and rarely progress to a main trial despite 
demonstrating feasibility. The PEPSTAR study illustrated that the additional time 
and resources needed to perform standalone pre-trial work, represents a major 
barrier to completing them. In addition, there was scepticism demonstrated in the 
PEPSTAR study, over whether PFS (especially standalone/external studies) make 
enough difference to main trial success and/or preventing research waste to 
justify the time and additional resources necessary to complete them properly and 
effectively. The benefits of pre-trial work in avoiding failed main trials, may 
therefore be far less valuable, if the pre-trial work adds so much time to the 
research pathway, that the question and interventions being studied become 
outdated and irrelevant before definitive answers are acquired. 
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6.2.4 Summary of the synthesis to produce a cyclical 
model of sub-optimisation of pilot and 
feasibility studies 
Overall, the synthesis and interpretation of phases one and two of this work, 
produced a cyclical model explaining the sub-optimisation of surgical PFS. The 
root causes of sub-optimisation of surgical PFS were identified, along with the 
compounding challenges. The root causes and compounding challenges were 
shown to interact and impact on each other in a cyclical and thus co-influential 
way. Each of the root causes and compounding challenges have been discussed 
above in terms of how the concepts were derived in light of the findings of this 
work. The cyclical model was then used, in the context of the methodological or 
theoretical literature and the available guidance in this area, to produce 
recommendations for all key stakeholders for optimising the design and conduct 
of PFS to inform main trials in surgery. 
6.3 Part 2: Recommendations from this work for 
optimising the design and conduct of surgical 
pilot and feasibility studies 
The recommendations from this work to improve research practice around the 
design and conduct of surgical PFS are described in the second part of this 
chapter. Firstly, recommendations are made for changes to wider research 
practice. These broad recommendations are followed by the presentation of a ‘top 
tips’ guidance tool for surgeons to specifically operationalise these 
recommendations and disseminate them to the wider surgical community. 
The key recommendations derived from this work for how to optimise future 
surgical PFS, and which phase of the work contributed to each recommendation, 
are outlined in Table 6.1. These recommendations identify four key areas for 
improvement to research practice necessary to optimise future PFS in surgery, 
termed education, collaboration, funding and dissemination. Each of these areas 
will now be discussed in turn, including how they relate to and address the 
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Table 6.1 Recommendations derived from this work to optimise surgical pilot and feasibility studies 
 
KEY: CTUs Clinical Trials Units, PFS Pilot and Feasibility Studies, PGfAR Programme grants for Applied Research, RCTs Randomised Controlled Trials 
 Recommendation Further detail Issues to consider Informed by 








 Improved guidance on designing and conducting PFS Consensus based guidance endorsed by regulatory bodies, 
funders and journals. 
 
Theoretical/conceptual guidance operationalised 
specifically for application by surgeons in practice. X X 
Grass roots training for surgeons from earlier in career Training in trials methodology through courses, conferences, 
publication and guidelines.  
 













 Collaboration of surgeons with methodologists & CTUs Working closely with methodologists and CTUs from earlier in 
the research process to ensure the future main trial is in sight. 
 
 
Practicalities of funding collaborations. 
 X 
Accessibility of CTUs & methodology support Highlight where to go/who to ask for assistance in the new 
guidance. 
 
Consensus process should consider what level of 







Improved efficiency of funding structure PFS should only be funded if main trial would be funded (i.e. 
important enough research question) so PFS are not wasteful. 
More joined up funding so no lag time between successful PFS 
and main trial. 
 
More programmes offering staged funding like NIHR 
PGfAR to improve efficiency and reduce waste. 
X X 
Raising the profile of the importance of funding surgical 
studies  
To achieve proportional funding. 
More surgeons on funding panels. 
Regulatory requirements for industry to contribute to surgical 
research. 
 
How to promote surgical involvement on funding 
panels. 











Funder requirement to publish PFS 
 
Publication in journals and/or through publicly available funder 
reports. 
 
How to fund process of publication. 
X X 
Journal editors stop publishing underpowered RCTs as PFS 
or PFS as underpowered RCTs  
 
Both wrong! Educate through guidance. Involve editors of surgical journals specifically in the 
consensus process for guidance. X X 
Academic institutions to value PFS as potentially essential 
for main trial development 
 
May not be 3 or 4* alone but need to have improved value for 
the often essential role they play in the success of the main 
trial. If academic institutions don’t value PFS, researchers will 
not value disseminating their findings. 
 
How to engage academic institutions in considering 
the value of PFS 




The first recommendation identified from this work to improve the design and 
conduct of PFS for surgical trials is enhancing education which can be done in 
several ways.  
Improved guidance on designing and conducting PFS 
The cyclical model of sub-optimisation established evidence that the available 
guidance around the design and conduct of PFS in surgery, is considered by 
surgeons and other key stakeholders, to be largely generic, theoretical and as such 
inaccessible. New guidance is needed which crosses the interface between practice 
(surgeons) and theory (methodologists). Such guidance would incorporate the 
extensive methodological work already performed but importantly, build on this 
to operationalise it for surgeons and those with less methodological expertise.  
New guidance should ideally be endorsed by funders, journal editors and other 
regulatory bodies such as the Royal College of Surgeons in order that it is 
incorporated fully into research practice. 
Grass roots training for surgeons from earlier in career  
A need for more ‘grass roots’ education of surgeons from earlier in their careers, is 
also identified from this work. This would mean educating the surgical 
community about methodological research practice through courses, conferences, 
relevant publications and finally, again, accessible guidance. There are steps being 
taken to achieve this educational strategy nationally, as already discussed in 
chapter one of this thesis, through the RCSEng Surgical Trials Initiative and the 
surgical trainee research collaboratives. In addition, courses such as the Bristol 
Oxford Surgical Trials Course (BOSTiC): Making trials stick 198 and GRANULE 
(GeneRAtiNg StUdent Recruiters for Surgical TriaLs) 199 are reaching out to 
trainees and medical students, through education in an area that is currently not 
taught elsewhere in the surgical training pathway. Whilst such courses are not yet 
mandatory across all surgical training programmes, there is certainly an argument 
for this, so that all surgeons are educated in trials methodology as part of their 
training programme 200. In addition, the research requirements for surgeons in 
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training would be far more usefully focused on collaborative trial involvement 
and training in recruitment, rather than the number of first author publications. 
This ‘publish or perish’ phenomenon, potentially only perpetuates poor surgical 
research, for trainees with neither the time, resources or access to methodological 
expertise to perform high quality, meaningful studies. Surgeons will also become 
more educated in research methodology through collaboration with 
methodologists, and this is the second key recommendation identified for 
optimising future surgical PFS and is discussed below. 
6.3.2 Collaboration 
Improved collaboration between methodologists and surgeons is the second area 
of recommendation made from this work, both for improving the design and 
efficient conduct of PFS, but also to enhance the education of surgeons through 
learning from working with expert trial teams. Those surgeons interviewed in the 
PEPSTAR study who had worked closely with methodological experts on surgical 
trials, recognised the essentiality of this approach. However, many surgeons ‘on 
the outside’ of Clinical Trials Units, found accessing such support difficult and 
sometimes obstructive. This may be due to the relatively limited funding packages 
available for PFS and the time and input that is still required by methodologists 
with inexperienced clinical teams. Some methodologist participants however, 
recognised that the responsibility might lie with the methodological community to 
translate and transcend this interface, to at the very least provide accessible 
guidance for PFS. Future consensus-based guidelines should consider the 
importance and proportionality of methodological expertise for PFS design and 
conduct. This should particularly consider funder requirements for 
methodological input, and how this might be achieved within the limited funding 
parameters of PFS grants. 
6.3.3 Funding 
A third key area of recommendation identified with the potential to optimise PFS 
in surgery, was improvements to current funding practices and infrastructure.  
Improved efficiency of funding structure 
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These improvements included a more cohesive approach between funders and 
funding streams, at the point of a PFS design and funding application. Here, 
consideration of the importance of the research question overall, should have 
more impact on whether a PFS is funded as the initial step. Funders need to 
consider, whether a main trial would be funded in the future, and whether the 
study applicants are appropriately supported by the necessary expertise enabling 
continuation to a main trial. Certainly, this advice has now appeared in the most 
recent NIHR RfPB guidance on the NIHR website, where an outline of the main 
trial is requested as part of the PFS application and, if the main trial is proved 
feasible it is expected the application for the main trial will be submitted in the 
timeframe of the PFS 197. In addition, more opportunities for staged funding, like 
the NIHR PGfAR funding stream may be beneficial to improve the value and 
efficiency of PFS for surgical trials. A key recommendation from this thesis is, 
therefore, that PFS are, essential to optimising surgical trials, but more efficient 
ways to fund them need to be found. An improved funding structure for PFS, 
would allow progress to a main trial, if the PFS shows one is possible, to be 
seamless. This would reduce the additional time added by a PFS in getting to a 
definitive answer, thus avoiding waste through trials becoming obsolete before 
finishing, and improving the perceived value of PFS overall. 
Raising the profile of the importance of funding surgical studies 
A related issue to improving the funding structure for PFS, is the fact that funding 
for surgical studies is known to be proportionately underrepresented. The 
findings in phase one, demonstrated that of all clinical research funded by the 
NIHR HTA and RfPB programmes from 2005-2015, only 10.4% (140/1341) were 
studies of surgery as the main intervention, and of these just a quarter were PFS 
(35/140, 25%). This converged with findings in the PEPSTAR study, where 
surgeon applicants felt disadvantaged in the funding process. However, whilst the 
qualitative work did consider the views of a wide variety of funders from different 
UK funding bodies, this thesis did not quantitatively examine the proportion of 
surgical research funded by other funding bodies. Nevertheless, this work 
suggests that some funding bodies do not currently prioritise surgical research, 
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though some of these findings may also be explained by fewer surgical studies 
seeking funding, than other clinical areas. Another explanation could be that 
applications for surgical studies are of poorer quality and are therefore not passing 
the peer review process. 
Certainly, it is apparent that there is under representation by surgeons on funding 
panels. This is likely due to the evolving culture of research amongst surgeons and 
should change as interest and involvement in surgical trials by surgeons continues 
to grow. Funding bodies could advertise specifically for members in 
underrepresented areas, like surgery, and employers should recognise this as a 
meaningful use of surgeons’ time.  
In addition, surgical trials have historically, and probably often still are, being 
dismissed as too difficult or risky to perform, because of the many challenges of 
surgical trials identified and explored in the context of PFS in this thesis. Unlike 
pharmaceutical trials, there is no industry infrastructure around trials of surgical 
interventions, and no regulatory requirement for the device and implant industry 
to perform trials, meaning sources of funding are limited. These are all cultural 
challenges representing barriers to completing surgical trials research in general, 
therefore equally affecting PFS. Addressing these challenges is not 
straightforward, and the identified problems represent the need for a cultural shift 
amongst all key stakeholders in surgical research including funders, regulatory 
bodies such as the RCSEng, industry, academic institutions and surgeons.  
6.3.4 Dissemination 
Finally, the fourth recommendation identified from this work is the wider 
dissemination of PFS results. The findings from phase one demonstrated that PFS 
are sub-optimally reported, with an ongoing propensity for hypothesis testing and 
that funders have variable requirements on the publication of PFS. Improved 
dissemination would happen through improvements to funder policies and 
practices on the mandatory publication of PFS, and journal editorial practice being 
open to the publication of ‘true’ PFS. These changes were perceived as essential in 
the PEPSTAR study for improving understanding of the purpose and value of 
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PFS, allowing cross disciplinary learning, and consequently breaking the 
identified cyclical process of sub-optimisation of PFS. Wider and required 
dissemination of PFS, should subsequently increase their perceived value and 
importance, thereby cultivating improvements in the quality of design and 
conduct of such studies. 
In addition, academic institutions need to shift their appreciation of the value of 
PFS. Without this, even researchers who understand the purpose and importance 
of PFS, will continue to undervalue the dissemination of PFS. It will be important 
in any consensus process to include academic institution leaders, so that the value 
of publishing PFS to the Research Excellence Framework (REF) can be 
reconsidered. For example, instead of measuring the worth of PFS in terms of 3* or 
4* outputs and publications, the value of PFS in terms of its impact on reducing 
waste could be considered, for instance where a main trial is shown to not be 
possible. The impact of PFS could also be measured in terms of successful 
optimisation of a main trial where the PFS substantially contributed to main trial 
design, and ultimately trial conduct and successful completion. 
Finally, journal editors need to publish the results of PFS correctly, by recognising 
their true value and importance and understanding the damaging consequences of 
publishing underpowered RCTs as PFS or PFS as underpowered RCTs. This shift 
in practice would be achieved via education from accessible and endorsed 
guidance, as described earlier (see section 6.3.1). 
6.4 Top Tips for surgeons designing and 
conducting surgical pilot and feasibility 
studies 
Practical and accessible guidance that serves to operationalise and bridge the gap 
between recommendations produced in this thesis and surgeons involved in 
designing and conducting surgical PFS,  is something that this work has identified 
as acutely necessary in parallel to the wider recommendations for research 
practice presented in the previous section. The following ‘Top Tips’ tool illustrated 
in Figure 6c, is a brief and simplified summary of the key findings and practical 
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recommendations from this work. The purpose of this diagram is to condense the 
findings of this work into an accessible tool for those surgeons who are 
considering or involved with participating in surgical PFS but who may have 
minimal methodological expertise. This tool was created as a direct result of the 
work in this thesis but should undergo assessment and validation as part of a 
future consensus process to produce formal guidelines for PFS in surgery (see 



































PFS are  
• Any work done to inform the 
design and/or conduct of a main 
trial. 
• Have multiple design types and 
may be randomised or not. 
• Done to assess or build towards 
assessing the feasibility of a 
definitive study.  
• Done with the intention of 
proceeding to a main trial, if the 




PFS should address uncertainty about 
the research question, trial design, 
and/or the research team & resources 
needed. 
• What is stopping you doing the 
main trial now?  
• What are the specific 
uncertainties of your study? 
 
In surgery, uncertainties around the 
intervention are key: 
• Is it novel/new? 
• Is it stable? 
• Is it standardised? 
• Is there a learning curve? 
• Is there equipoise? 
 
ENGAGE 
Collaborate with methodologists at 
the outset. 
Resources:  
• NIHR Research & Design Service 
• Clinical Trials Units 
Consider: 
• Type of PFS needed 
• Feasibility outcomes (not main 
trial outcomes) 
• What will the MT look like 
• Collaborate early and widely 




Report and publish all PFS. 
Do not report significance testing or 
offer definitive reporting of 
outcomes. 
Consider: 
• Is a main trial feasible? 
• If not, why not – what are the 
learning points? 
If a main trial is feasible: 
• Design it and do it, or justify why 
not! 
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6.5 Dissemination of the findings and 
recommendations from this doctoral thesis 
Outputs relating to Phase I of the work in this thesis 
Work from Phase 1 of this thesis, relating to the background literature review 
and the targeted review and systematic analysis of NIHR funded PFS, has 
already been presented and disseminated in several formats. 
Publication in a peer-reviewed journal:  
Fairhurst K, Blazeby JM, Potter S, Gamble C, Rowlands C, Avery KNL. Value of 
surgical pilot and feasibility study protocols. Br J Surg. 2019;106(8):968-978 
This work was published in the British Journal of Surgery 201, with the specific aim 
of disseminating best research practice in this area to a surgical audience. 
Conference contributions: 
1) Katherine Fairhurst, Jane Blazeby, Ceri Rowlands, Shelley Potter, Carrol 
Gamble, Kerry Avery. A systematic analysis of UK nationally funded 
surgical pilot and feasibility study protocols from the last 10 years to 
inform and optimise future surgical trials. Clinical Trials 2018; 15(S2): 118 
(A82) 
Oral presentation at the Society of Clinical Trials (SCT), Portland Oregon 
(international). May 2018. (NB Given on my behalf by Kerry Avery as on 
maternity leave) 
2) Katherine Fairhurst, Jane Blazeby, Shelley Potter, Amanda Blatch-Jones, Ceri 
Rowlands, Carrol Gamble, Kerry Avery. Key design features of pilot and 
feasibility studies to inform successful surgical trials: A systematic analysis 
of funded studies. Trials 2017; 18(Suppl 1):P16  
Poster presented at 4th International Clinical Trials Methodology 
Conference (ICTMC) & 38thAnnual meeting of the Society of Clinical Trials 
(SCT), Liverpool (international). May 2017. 
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3) Katherine Fairhurst, Kerry Avery, Elaine O’Connell Francischetto, Chris 
Metcalfe, Jane Blazeby. How can pilot work optimally inform surgical 
RCTs? A review of current evidence. Trials 2015; 16(Suppl 2):P17  
Poster presented at 3rd International Clinical Trials Methodology 
Conference (ICTMC), Glasgow, (international). October 2015 
Outputs relating to phases II and III of the work in this thesis 
Conference contributions: 
1) Katherine Fairhurst, Shelley Potter, Jane Blazeby, Carrol Gamble, Kerry 
Avery. Unique challenges and proposed solutions for designing and 
conducting pilot and feasibility work to optimise surgical trials. Trials 2019; 
20(Suppl 1):PS9D-O5 
Poster presented at 5th International Clinical Trials Methodology 
Conference (ICTMC), Brighton, (international). October 2019. 
2) Katherine Fairhurst, Kerry Avery, Alicia O’Cathain, Pat Hoddinott, Jane. 
When to do an external or internal pilot study: Findings from an interview 
study with research. Trials 2019; 20(Suppl 1):PS5A-O1  
Poster presented at 5th International Clinical Trials Methodology 
Conference (ICTMC), Brighton, (international). October 2019. 
 
The PEPSTAR qualitative interview study was presented at the 5th International 
Clinical Trials Methodology Conference (ICTMC) in October 2019. There are 
plans for further dissemination of the work in this thesis, and specifically the key 
messages for surgeons, at surgical conferences later this academic year (for 
example at Association of Surgeons of Great Britain and Ireland, ASGBI; 
Association of Surgeons in Training, ASiT; Association of Breast Surgery, ABS). 
With this in mind, the ‘top tips’ tool (see section 6.4) will present the key 
messages regarding designing and conducting PFS in an accessible and 
operationalised format for surgeons to use. The aim is to also publish the results 
of the PEPSTAR study (Phase II), and the synthesis and interpretation of the 
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findings (Phase III) including the ‘top tips’ tool for surgeons, in a surgical journal, 
to disseminate this work through publication. 
6.6 Summary 
The next and final chapter of this thesis will discuss and critique the key findings 
of this work both in the context of other published literature and guidance 
documents in this area, and its strengths and limitations. Consideration of how 
this work adds to the field of research will be made, and proposals for future 






This chapter will discuss the key findings from this work and how they enhance 
understanding of the potential for PFS to optimise future surgical trials. In 
addition, how these findings contribute and relate to the research field in the 
context of other work, and in particular other relevant published guidance in this 
area, will be critiqued and discussed. Strengths and limitations for each phase of 
the work will be considered, and an appraisal made of the applicability and 
generalisability of the findings to different audiences and current research 
practice. Finally, proposals for future work building on the findings in this thesis 
will be presented. 
7.2 Key findings from this work 
This work used an interpretative process to synthesise the findings from a 
targeted review and systematic analysis of NIHR funded PFS protocols, and a 
qualitative interview study with key stakeholders to produce a cyclical model 
illustrating why the design and conduct of surgical PFS is currently sub-optimal. 
This model delineates the cyclical relationship between misunderstanding of the 
purpose, scope and different PFS design types in the context of surgical trials and 
the sub-optimal design, conduct and reporting of PFS, and how this continues to 
perpetuate undervaluation and dismissal or disregard of PFS by surgeons, 
journal editors, academic institutions, and sometimes funders. The root causes 
outlined in the model are compounded by additional challenges relating to 
inconsistent and dense, inaccessible guidance and the cultural challenges 
inherent to the surgical community. The cyclical model developed in this thesis 
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was used to inform the development of key recommendations for surgeons and 
study teams for how to improve research practice. 
The recommendations from the work in this thesis, intended to comprehensively 
address the cyclical model illustrating why surgical PFS are sub-optimised. This 
is achieved by ensuring that the recommendations incorporate necessary and 
achievable changes to current research practice. The premise at the outset of this 
thesis was: ‘If we could just change the way surgeons think and behave 
regarding surgical research, everything would be much improved!’ However, 
during the course of the research, it became apparent that not all the challenges 
identified in this work, are entirely rectifiable by changes to surgeons’ behaviour 
and practice, as initially hypothesised. Much of what is recommended by this 
work, in fact, requires a wider cultural shift in research practice amongst funders, 
academic institutions, regulatory bodies and journal editors, as well as amongst 
surgeons.  
The justification for why PFS might be key for optimising trials more generally, 
has been well described and considered by others, as explored in chapter two of 
this thesis. These works include the published methodological work on the 
definitions, study types and reporting of PFS in general, 71, 79-81, 90, 132, the MRC 
guidance document on developing and evaluating complex interventions in 
general 13 and the IDEAL guidance on the development and evaluation of 
surgical interventions specifically 101, 102.  This guidance discusses PFS more 
generally, but to date no work has specifically considered the value and scope of 
PFS in surgery. As explained and illustrated in the introductory chapters, when 
compared to other clinical areas, surgical trials face unique challenges meaning 
pre-trial work to explore challenges and uncertainties may be even more 
necessary.  
Perhaps in recognition of the limitations of the guidance already available on the 
design and conduct of PFS, further guidance has evolved during the course of 
this thesis. These new guidance documents will be critiqued in terms of how they 




To reiterate, the IDEAL framework 144 is the currently available guidance most 
specific to surgery, and describes a pathway for new surgical interventions from 
the initial Idea (Stage 1) to Development (Stage 2a)/Exploration (Stage 2b), 
Assessment (Stage 3) and Long-term monitoring (Stage 4). Within this 
framework, PFS are considered as stage 2a/2b studies, aiming to explore 
uncertainties before a stage 3 assessment in a definitive RCT. The recently 
updated IDEAL recommendations were published in print in 2019 102. This is 
four years after the final studies in the targeted review and systematic analysis of 
NIHR funded protocols were funded, and 14 months after the PEPSTAR 
qualitative interviews were completed. The updated guidance does provide 
some clarification and examples of what to consider when designing PFS. In 
particular, several feasibility issues are suggested for consideration in stage 
2a/2b studies including: Estimating effect size (though importantly, what is 
meant by this this is not clarified in this guidance); defining intervention quality 
and standards; evaluating learning curves; exploring subgroup differences; 
eliciting key stakeholder values and preferences and analysis of adverse events. 
However, as demonstrated in this thesis, this is far from an exhaustive list. In 
addition, such example lists were perceived in the PEPSTAR study as limiting 
PFS study applicants into thinking the listed items are the only uncertainties to 
consider, rather than thinking more laterally about uncertainty specific to the 
study and research question, and the potential for PFS to explore these 
uncertainties. In addition, offering ‘estimating effect size’ as a use of PFS without 
any clarification, is potentially incorrect and misleading (see next section on 
hypothesis testing in PFS guidance). 
The perception that the IDEAL guidance is not widely accepted or utilised was 
explicitly highlighted in this work, and further corroborated recently, by a 
publication in The Lancet from the IDEAL collaboration in 2019. This study 
analysed how surgical research has changed since the first IDEAL 
recommendations were published in 2009. Random samples of n=25 studies 
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published in the general literature in the periods 2000-2004 and 2010-2014 were 
compared 103. The study found that explanation of modifications of IDEAL 2a 
studies had not changed over this 10-year period (4/25, 16%), though the use of 
prospective cohort studies had slightly improved (5/25, 20% to 9/25, 36%). 
However, the mention of PFS to prepare for an RCT had, at best, not improved at 
all over this time (2/25, 4% to 1/25, 1%) 103. The authors also note, that statistical 
testing was still being employed inappropriately in pre-trial studies 103. This 
work from the IDEAL group suggests that the original IDEAL guidance, has had 
little impact on the design and conduct of surgical PFS over the time period 
(2005-2015) of the PFS analysed in this thesis. 
It would be reasonable to surmise, therefore, that the IDEAL guidance is 
currently not adequate in terms of operationalised detail for surgeons to improve 
the design and conduct of surgical PFS specifically. 
Guidance on hypothesis testing in PFS  
There has been ongoing and evolving contention during the course of this thesis 
regarding if and how hypothesis testing should be performed in PFS. This issue 
permeates through multiple components of the cyclical model of sub-
optimisation, and consideration of this issue is, therefore, discussed here in terms 
of published guidance and debate of this issue. 
Phase II studies are usually defined as early phase pharmaceutical trials, and 
have been methodologically established for longer, with very different feasibility 
issues from studies of complex interventions. In the context of pharmaceutical 
trials, a Phase II study could be regarded as synonymous with doing a PFS and 
means specifically testing for signs of ‘promise’, typically an early signal of safety 
(e.g. toxicity) and effectiveness (e.g. reduction in a viral count). It is possible, 
therefore, that because of the more established methodology for Phase II trials, 
with the defined purpose of demonstrating preliminary evidence of efficacy, this 
has influenced the perceived purpose of PFS for complex clinical interventions. It 
is evident, from the work in this thesis, that understanding around when, how 
and if to use hypothesis testing in PFS has not yet become widespread. In 
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addition, whilst some might argue that the same rationale of seeking early signs 
of promise can be applied to PFS of surgical interventions, there are challenges 
with taking this approach.  
Firstly, safety is always reported as part of an adverse event profile in any 
surgical trial, including a PFS. Unacceptable death or major complication rates 
would be monitored by the Data Monitoring Committee (DMC) and cause a PFS 
or trial to be reviewed and/or stopped by the Trial Steering Committee (TSC). 
However, the measurement of clinically important outcomes in surgical trials 
may have extrapolated endpoints, for example, recurrence of cancer or quality of 
life assessments, meaning effectiveness may be difficult to determine in the 
timescale of a PFS. In addition, surrogate outcomes for surgical trials may be 
difficult to establish 202. Short-term outcomes such as in-hospital or 30-day 
mortality, may, therefore, have limited value in determining a signal of promise 
for the true safety or effectiveness of surgical interventions. 
Secondly, safety and effectiveness data from a PFS reported without any warning 
or caveat, may be accepted for publication as the definitive result, when the PFS 
is not powered to assess such outcomes. Because of this, it is advised that 
outcomes from PFS should either not be analysed at all, or if a suggestion of 
promise is sought, this should only be analysed and reported with a very clear 
caveat that the study was underpowered to test for significance. Not analysing 
PFS data may be especially important if there are plans for, or the potential to 
proceed to a main trial, as any analysis of outcomes may bias the results. 
Unfortunately, as is evident from the work in this thesis, there are ongoing issues 
with the definitive reporting of outcomes of surgical PFS, without appropriate 
caution during interpretation of results. 
Whist there has been general acceptance in the literature for some time that any 
suggestion of promise or significance should be reported with caution, given the 
underpowered sample size of most PFS 72, 75, 92, 124, 125, it is important to note that 
historically, it has been justified as appropriate to use PFS efficacy data for 
assisting the calculation of a sample size for the main trial 82, 203. In addition, 
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estimates of effect derived from PFS data have been used as a criterion to assess 
progression to a main trial 204. More recently it has been explicitly proposed that 
estimating efficacy outcomes in PFS is inappropriate, as the sample size is rarely 
large enough to support or adequately refute a hypothesis 205.  Some propose that 
using estimates of effect from pilot and feasibility study data might, therefore, do 
more to “mislead than to enlighten” 205 , and should not be used in such important 
decisions as whether or not to proceed to a main trial 206, unless perhaps 
combined with more statistically robust evidence such as from a Bayesian 
decision model 207 . 
Reporting results from a PFS as significant or definitive is, therefore, potentially 
inaccurate and misleading, both statistically and from inappropriate 
interpretation, because of misunderstanding about PFS more generally. It could 
be argued, therefore, that publicly reporting any suggestion of promise from a 
PFS is inappropriate, and new guidance must seek to fully clarify the appropriate 
handling of hypothesis testing in surgical PFS. 
NIHR Guidance 
Perhaps in recognition of limitations of the existing advice from the NIHR on 
PFS, a guidance document was published 197 online on 18th June 2019  (after the 
data analysis for phases one and two of this work were complete). This relatively 
brief guidance offers applicants more information on designing PFS. The original 
NIHR definitions are included and concise guidance on which NIHR funding 
stream to apply to, both in terms of PFS grant size and how likely a definitive 
trial is in the immediate future.  The guidance also stipulates that PFS should be 
distinguished from Phase II trials, as described above. However, whilst this more 
recent NIHR guidance 197, states that Phase II trials are different from PFS, it does 
not clarify why, and if and /or how any suggestion of promise of safety or 
effectiveness should be appropriately handled. 
The most recent NIHR guidance 197, also offers advice on specifically applying to 
the RfPB funding stream for a PFS. Examples of key design parameters that a PFS 
may consider are listed, and it is stipulated that an outline of the proposed main 
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trial should be included. As part of the full trial proposal within the PFS 
application, applicants are requested to outline progression criteria. If the main 
trial is deemed feasible the guidance states applicants will be expected to write 
the main trial proposal within the timeframe of the PFS. Only three references on 
best practice for designing and conducting PFS are given 72, 74, 208 and these are all 
earlier references in the evolution of PFS methodology (published 9-14 years 
ago). Notably, this new NIHR guidance does not include reference to any of the 
more recent conceptual work 71, 132 or the complex interventions guidance from 
the MRC 13.  
In addition, this guidance is only relevant for NIHR funding applications. The 
work in this thesis highlighted that if different funders adopt different 
definitions and guidance, this results in mixed messages and further confusion 
for study applicants. This variable and inconsistent message, consequently, 
serves to restrict applicants to fitting their study into a specific funder definition. 
As demonstrated, this further perpetuates the cycle of sub-optimisation, meaning 
PFS are not designed and conducted to optimally explore all the issues relevant 
to a specific study question. 
In terms of the existing funding structure for surgical PFS, the NIHR have also 
published data on how this may be a barrier to completing PFS. Work conducted 
by the NIHR assessing the value of PFS was published in 2018 209. This work 
sought to identify the outcome of 89 completed RfPB funded feasibility studies 
(in all specialties) by sending questionnaires to the Principal Investigator of each 
study. The authors identified a mean time trajectory of 8 years from the start of 
the PFS to the completion of a main trial and definitive results, meaning that a 
PFS adds on average three years to achieving a definitive answer to a research 
question through a main trial. In fast moving clinical areas such as surgery, this 
represents another barrier to completing PFS, as an intervention may become 
obsolete before trials are complete, meaning PFS are avoided by surgeon trialists. 
The authors concluded 209 that whilst PFS may be avoiding waste through fewer 
trials failing secondary to poor research questions and trial design as previously 
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described 105, the failure of feasibility studies to progress to definitive studies in a 
time efficient manner, therefore, represents an alternative source of waste 209. 
The study also considered the financial value of PFS in terms of saving monetary 
resources. Of the 89 feasibility studies, funded by the NIHR RfPB funding stream 
that had completed by May 2016, 57 studies judged the main trial feasible, 20 
were deemed unfeasible and 12 had uncertain feasibility. The authors conclude 
that these 32 studies had saved in the region of £20-30 million of funding (the 
12/89 studies that went on to achieve main trial funding had an average 
awarded grant of just over £1m per trial: mean £1,163,966, range £321,403 to 
£2,099,813). However, of the 57 studies that were judged feasible, 15 had secured 
further funding, 17 had been unsuccessful in securing further funding and 17 
had not yet applied for further funding. So, whilst just over half of the successful 
feasibility studies had applied for further funding, less than half of these had 
secured it. Another key finding in this paper, therefore, is that an alternative 
source of research waste exists, when PFS show that a main trial is feasible, but 
fail to progress to a main trial. This could, therefore, be considered a fault of the 
current funding structure, and corroborates the findings in this thesis. However, 
one contradictory finding in the PEPSTAR study was that funders perceive PFS 
as a way of researching high-risk questions or clinical areas, of which surgery 
was perceived to be one in the PEPSTAR study. It may be challenging therefore, 
to alter the funding structure for research questions perceived to be high-risk, 
such as in surgery. 
A summary of the key recommendations from this work 
Underpinning all the recommendations made from this work, is the urgent need 
for accessible and operationalised guidance for surgeons on the design and 
conduct of PFS. The creation of clear guidance, endorsed across funding and 
regulatory bodies and journals, would drive up the quality of PFS in surgery. 
Consequently, improved PFS, would lead a mechanism for change to a more 
efficient and thriving research structure and culture around surgical trials. The 
development of targeted and accessible guidance will bring key stakeholders 
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together to consider, and come to consensus, over what guidance is needed and 
how this should be delivered and endorsed to greatest effect.  
The strengths and limitations of this work will now be discussed, followed by 
plans for future work to build on the findings in this thesis.  
7.3 Strengths of this work 
7.3.1 A novel contribution to the field of pilot and 
feasibility study methodology in the context of 
surgical trials 
This is the first work to specifically consider the current research practice for PFS 
in surgery and the explicit challenges and barriers preventing optimal conduct of 
PFS in surgery. Producing surgery-specific recommendations for the optimal 
design and conduct of surgical PFS is also entirely novel. 
A key strength of this project is the incorporation of a variety of different 
research methods to understand the potential for PFS to optimise future surgical 
trials. The rationale for this mixed methods approach was thoroughly described 
and justified in Chapter 3 (sections 3.10-3.12). Each component of this project 
involved researching a novel area of research practice, and sometimes used 
techniques that had not been employed previously. The targeted review and 
systematic analysis of NIHR funded PFS protocols, for example, was an 
innovative method for exploring current research practice and seeking out 
detailed understanding of how and why PFS are currently designed.  Reviewing 
and analysing surgical PFS protocols, offered insights into research practice that 
could not have been achieved with a more traditional systematic or narrative 
review of the literature.  
The PEPSTAR study involved the purposive sampling of participants, to 
consider the perceptions, experiences, views and opinions of key stakeholders 
involved in the design, conduct and funding of PFS in surgery.  The in-depth 
qualitative interviews included participant surgeons, funders, trial 
methodologists and journal editors with the aim of maximum variation sampling 
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to consider the breadth of participant perspectives, experience, and research 
practice amongst different key stakeholder groups. The perspectives of these 
stakeholders have not been previously explored in the context of the design, 
conduct and funding of surgical PFS. 
The synthesis and interpretation of the findings from the different phases of 
research, enhanced the breadth and strength of understanding regarding the 
difficulties facing PFS in surgery. The mixed methods approach therefore 
increased the validity and applicability of the results of this work. In addition, 
whilst surgical PFS are a relatively niche area in the broader realms of trials 
research, the results are likely to be more widely generalisable, further enhancing 
their impact, which is discussed next. 
7.3.2 Applicability of the recommendations of this 
work to current practice and different audiences  
Surgical trials have long been recognised as a challenging area of research and 
many of the unique and complex challenges of surgical research have been 
further highlighted and explored within the context of PFS for this thesis. The 
work to explore and understand how surgical PFS might be optimised in the 
future has been performed within the context of surgery, and the 
recommendations from this work are, therefore, specific to surgery. Whilst the 
recommendations from this work are focused on PFS in surgery, many may be 
relevant to the wider context of complex interventions as a whole. As part of a 
future consensus process (see section 7.5), this question could be addressed, 
especially in light of other similar work going on in other areas 210 (see also 
section 7.4.3 for details of this work). Most methodologists and funders have 
been and are involved in a wide range of clinical areas and are well placed to 
assess the potential for cross-pollination of useful strategies. 
Examining the literature, it seems PFS may be less commonly done in countries 
outside the UK. A systematic review by the methodology group who produced 
the conceptual framework of the definitions of PFS, looked at the quality of 
reporting of 18 pilot and feasibility cluster randomised trials conducted 
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published between 2011 and 2014 211. This study found that half (56%) were set in 
the UK, with all other studies represented only once, apart from Canada (three 
studies) and the USA (two studies). In addition, it was noted in the PEPSTAR 
study, that the UK produced methodological guidance 71, 79 was perceived to 
have not been incorporated into practice by authors from overseas yet. 
Whilst the focus of this work was entirely on research and funding practice in the 
UK, it is perhaps reasonable to tentatively conclude, that the UK is ahead of the 
curve in terms of methodological developments for the design and conduct of 
PFS, and that with further exploration and collaboration, the findings of this 
research could well be relevant to researchers in other countries. 
7.4 Limitations of this work 
7.4.1 Phase 1: A targeted review and systematic 
analysis of NIHR funded surgical pilot and 
feasibility studies 
This targeted review and systematic analysis demonstrated some key limitations 
of PFS in surgery but focused solely on studies funded by the NIHR HTA and 
RfPB funding streams. While these represent two of the major funding bodies for 
surgical PFS in the UK, they do not include all possible funders of such work. 
Analysing PFS funded by NIHR funding streams, other than HTA and RfPB 
were considered initially. However, these other funders were excluded early on, 
as they fund surgical research far less commonly. To illustrate, the 2012 NIHR 
call for surgical research resulted in a number of ‘surgical’ studies being funded 
through a variety of NIHR funding streams 212. A total of n=25 studies were 
funded as a result of this call: 
EME (Efficacy and Mechanism Evaluation), which predominantly funds 
translational research: (n=1/25); 
HS&DR (Health Services and Delivery Research), which funds research to 
produce evidence to impact on the quality, accessibility and organisation of 
health and social care services: (n=4/25); 
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HTA (Health Technology Assessment): (n=11/25) 
RfPB (Research for Patient Benefit): (n=10/25); 
i4i (Invention for Innovation), which is a translational funding scheme aimed for 
an advanced or clinically validated prototype medical device, technology or 
intervention: (n=3/25) 
PGfAR (Programme Grants for Applied Research): Open to applications for 
surgical research but has predominantly funded applications relating to primary 
care historically: (n=0/25). 
A review of these studies against the inclusion criteria for phase one of this work, 
showed that n=20/25 were not PFS, n=1 was not primarily surgical (assessing 
surgical outcomes for osteoarthritis of the knee following a short-term 
psychological intervention), leaving n=4/25 which are studies of surgical 
interventions and PFS, all of which were funded by RfPB, and all were included 
in our study. 
Whilst the NIHR HTA and RfPB research programmes are the major funders of 
studies of surgical interventions in the UK, it is accepted there are other funders, 
for example the British Heart Foundation (BHF) and Arthritis UK (ARUK), which 
may also consider and fund such work. However, including work from other 
funders would have been logistically challenging, given that very few funders 
make study protocols publicly available. Another potential limitation of this 
work is that NIHR funded protocols, are likely to be of relatively high quality so 
may provide an overly positive perception of the quality of PFS performed in 
surgery more generally. 
This work also focused only on so-called external PFS.  It would also be 
informative to review internal PFS, but as stated in the methods (Chapter 3), trial 
experts are increasingly agreeing that internal pilots should not be termed ‘pilot’ 
studies at all, being so intrinsically part of the main trial, in terms of design, 
funding and outcome analysis. In addition, external PFS were considered to yield 
more relevant information for this thesis as this design is typically chosen when 
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there is greater uncertainty about main trial design and conduct.  Despite these 
recognised limitations, this work provided valuable insights through identifying 
several challenges and areas of difficulty with surgical PFS design and conduct, 
which warranted further exploration. 
Ideally, it would be useful to compare the findings of this work regarding PFS 
exploring surgical interventions, with those of non-surgical complex 
interventions. This comparison would give further insight into the differences in 
approach between these research areas and allow for cross specialty learning. 
Unfortunately, this was not feasible within the time limitations of this project but 
could be considered for future work.  
7.4.2 Phase 2: The PEPSTAR Study 
Seniority of participants in the PEPSTAR qualitative interviews was deemed 
important to ensure extensive experience in the area of PFS design and conduct, 
to allow the extraction of information about the challenges and barriers to 
conducting pre-trial research from those with the most extensive experience. 
However, a limitation of this study is in not also sampling less senior surgeons, 
for example, those leading the trainee surgical collaboratives. This group might 
have given different views of the current difficulties facing PFS in surgery.  
Another limitation of the sampling strategy might have been in not sampling 
research-naïve surgeons for a comparison of knowledge, understanding and 
perceptions of the challenges in this area. However, throughout this thesis the 
long-standing issues with inappropriate reporting of both underpowered RCTs 
as PFS, and vice versa has been emphasised, indicating a widespread 
misunderstanding of the value and purpose of PFS in surgery. It was therefore, 
felt most important within the time and resource limitations of this PhD thesis, to 
concentrate on extracting data from the most experienced and data-rich sources. 
This stance was taken for both the targeted review and systematic analysis of 
NIHR funded PFS (as opposed to performing a traditional systematic or 
narrative literature review) and the PEPSTAR interviews (where the most senior 
and experienced participants were sampled).  
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Another limitation of this work might have been in considering only UK based 
participants for the interview study. It would certainly have added a further 
dimension to the qualitative work, to consider stakeholder participants from 
outside the UK. However, including participants in the PEPSTAR study from 
outside of the UK, might have added additional complexity to an already poorly 
understood area. Further complexity would potentially be created by the 
relatively different funding systems outside the UK, as well as a potential 
language barrier with participants at interview. Certainly, considering research 
practices around pre-trial work outside of the UK, might be an area for future 
work and collaboration. 
7.4.3 Phase 3: A synthesis and interpretation of the 
findings in this thesis to inform 
recommendations for the optimisation of pilot 
and feasibility studies in surgery 
There was not time within the scope and timeframes of this thesis to derive 
consensus-based recommendations, though this is considered for future work 
(see next section 7.5). This was partly because considerably more preparatory 
work was necessary to arrive at the recommendations presented in Chapter six 
than originally thought. As the work progressed, therefore, it became apparent 
that a consensus-based process to produce recommendations, would be out of 
the scope of this project, both in terms of time and resources.  
This is a complex and contentious area of research methodology. The 
methodological research already performed to derive guidelines on the reporting 
PFS 79 and a conceptual framework of the definitions of PFS 71 took five years and 
a whole team of methodological experts. Similarly, in public health the GUEST 
(GUidance for Exploratory STudies of complex public health interventions) 
study funded by the MRC/NIHR Methodology Research Programme, aims to 
develop guidance on the design and conduct of PFS (termed exploratory studies) 
in complex public health interventions (Grant: MR/N015843/1, £246,955, 
awarded 2015/2016) 213. Specifically, the research team planned a systematic 
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review of current guidance, an audit of current practice, a web based DELPHI 
exercise to identify expert consensus on the design and conduct of PFS studies 
and a horizon scan to identify approaches to intervention optimisation and PFS 
design from other contexts within and outside health care research. The 
systematic review from this work has now been published, concluding that 
existing guidance was inconsistent with little evidence available to inform when 
to proceed to a main trial 214. The Delphi study has also completed 210, but 
guidance is not yet published. The GUEST study is another example of the work 
and resources needed to create guidance in a similar area of complex healthcare 
to surgery, and why creating consensus-based guidance for PFS in surgery was, 
therefore, outside the realms of possibility within this PhD. 
However, the work in this thesis has concluded with a clear list of 
recommendations for how to take the findings forward. The planned 
dissemination pathway of this work and the recommendations produced from it, 
were discussed at the end of chapter six (section 6.5). The next section will 
discuss further work proposed to build on the recommendations from the work 
in this thesis.  
7.5 Proposals for further work to implement the 
key recommendations from this thesis 
7.5.1 New guidance 
Ultimately, consensus-based recommendations are needed to allow this work to 
be incorporated into clear, operationalised guidelines, which would ideally be 
endorsed by major funders, journals and regulatory bodies. A consensus process 
would need to include representation from all key stakeholder groups including 
funders, methodologists/clinical trials units, journal editors, the IDEAL 
collaboration and surgeons.  
Improved, accessible and operationalised guidance for surgeons and those 
applying for surgical PFS funding is recognised as key to improving surgical 
PFS. The new guidance needs to consider the methodological work done by 
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others, but most importantly this needs distilling and shaping into 
operationalised content for study applicants. Some key considerations around 
the content and processes for producing guidance in this area have been 
highlighted in this work. 
Key Stakeholders 
To be implemented fully into practice, guidance needs to be derived from a 
consensus-based process including all key stakeholders. A list of key 
stakeholders to consider for inclusion at a consensus process are: 
Funders: The NIHR RfPB and HTA funding programme are the major funders of 
surgical research in the UK. Representatives from these funding streams are 
essential. It would also be relevant to invite representatives from the PGfAR 
funding stream, as this is a funding stream that may become more relevant for a 
streamlined approach to conducting PFS. Other charity funders should be 
considered, though they fund PFS less commonly;  
Methodologists: To include CTU directors, senior statisticians and those with an 
interest in surgical research and/or PFS; 
Pilot and Feasibility Studies Collaboration: The group who produced the 
CONSORT extension for reporting PFS 79; 
NIHR Research Design Service (RDS): The RDS will be pivotal in dissemination 
and uptake of new guidance, so senior representation from this group is 
necessary at a consensus process to determine the level to pitch guidance at and 
what might be included; 
Journal editors: Representation from journals who publish PFS and/or surgical 
studies for example, Trials, Pilot and Feasibility Studies, and British Journal of 
Surgery; 
Surgeons: Particularly methodologically experienced surgeons (both junior and 
senior) for example those leading the RCS Surgical Trial Initiative, RCS Surgical 
Specialty Leads, Trainee Collaborative Leads, NIHR Surgical Clinician Scientists; 
 
 190 
IDEAL collaboration: Senior representation from this group to make sure 
complementary messages are filtered through into other guidance documents. 
Endorsement 
Endorsement by funders and relevant journals and regulatory bodies is vital to 
optimise future research practice in this area. Funders are key in producing and 
endorsing this guidance, as they drive the format and selection of research 
projects for funding. The current RfPB guidance 197 was written by the RfPB 
programme director, as a ‘top tips’ type of guide, with the NIHR definitions of 
PFS agreed across certain NIHR funding programmes (HTA, RfPB, EME, PHR). 
However, there was no input or consensus from other key stakeholders, and a 
need is identified to bring these groups together to produce accessible, accurate 
and operationalised guidance in order to improve pre-trial surgical research.  
Some PEPSTAR participants highlighted potential problems with achieving 
funder-endorsed guidance, given that funding bodies do not currently agree on 
the role and purpose of PFS.  A consensus process amongst all key stakeholders, 
including representatives from all major funders, journals and regulatory bodies 
would be paramount to overcoming this obstacle. This would probably also 
mean that the guidance would need to be broad and accessible to research 
practice across all specialties, but with specifics as necessary for areas such as 
surgery that have unique challenges. 
Key questions to consider in a consensus process to produce guidance 
This work identified several important questions that should be considered as 
part of a consensus process to produce operationalised guidance for performing 
PFS in surgery. These are: 
1) Methodological input to PFS design and conduct: This is clearly needed as 
part of PFS study design as a minimum. Consideration is also necessary 
for what this may consist of within the realms of PFS funding, and indeed 
for creating a funding application. The NIHR Research and Design Service 
(RDS) are well placed to assist at the initial stages of PFS design, but 
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appropriate input from methodological teams/Clinical Trials Units needs 
to be determined. 
2) Funding structure: A need was identified for a more efficient and 
streamlined funding structure and the reality of creating this will be an 
important discussion point for the key stakeholders. 
3) Publication and dissemination of PFS: The consensus-based process to 
produce guidance also needs to consider how to encourage improved 
rates of appropriate publication of PFS. The CONSORT extension to PFS 
offer comprehensive guidance on the appropriate reporting of PFS, but 
there is also a need for funders to require publication, perhaps as an 
incentive to receiving grant instalments. This may be as a publicly 
available report, or as a journal publication. With journal editors present 
as part of the stakeholder group, this will allow channels of 
communication for how PFS can be appropriately and consistently 
published and disseminated. 
7.5.2 Education & training 
Whilst improved consensus based guidance, incorporating the input of all key 
stakeholders is shown to be necessary from the work in this thesis, there is also 
an identified need to engage and educate the surgical community on the use of 
PFS in surgical research. The PEPSTAR study demonstrated that there had been 
relatively little engagement with the currently available guidance, such as the 
IDEAL framework. Mandatory training as part of surgical training pathways 
would assist with early collaborative engagement with surgical trials and allow 
those with a specific interest to develop their skills appropriately. Existing 
courses designed to engage both medical students and surgical trainees were 
discussed in section 6.3.1. As such courses are already in existence, further work 
would involve advocating for the mandatory training status of these courses, 
through engagement and collaboration with the Royal College of Surgeons and 
the Joint Committee on Surgical Training (JCST). In particular, involvement with 
surgical trials in terms of recruitment for example, rather than first author 
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publication in quantity rather than quality, should become the primary focus of 
research training for surgeons. 
7.5.3 Wider collaboration 
Improved collaborative practice between surgeons and methodologists/CTUs 
was given as one of four key recommendations for improving research practice 
around PFS in surgery (see section 6.3.2). Publishing these recommendations and 
highlighting the need for improved collaboration alone as is planned (see section 
6.5), will not suffice to improve practice. The practicalities of improving 
collaboration dictate that further work is needed to showcase the available 
methodological support and opportunities to surgeons interested in trials, and 
better collaborative models of working need to be developed. These might 
include, for example, the Royal College of Surgeons Surgical Specialty Lead 
roles, being mutually beneficial and collaborative positions between surgeons 
and methodologists.  
This work was presented and well received at ICTMC (see section 6.5), where a 
collaboration lead by the RfPB to produce guidance for the design and conduct of 
PFS more generally was formed and instigated. The challenge for this future 
work is to advocate for the nuances and specific needs of surgical research and 
ensure that the surgical ‘voice’ is not lost.  
7.6 Conclusion 
It is increasingly acknowledged that PFS are a methodological solution that can 
be utilised to explore, and address uncertainties surrounding the design and 
conduct of a future main trial. The unique and complex challenges that have 
been proven to obstruct the conduct and completion of surgical trials may, 
therefore, be usefully explored in PFS, to increase the chances of main trial 
success. This work has addressed a gap in the clinical trials research field, by 
providing a detailed understanding of the potential for PFS to optimise future 




The mixed methods approach taken to achieve the objectives of this work, 
allowed comprehensive exploration of the challenges and barriers obstructing 
the optimal design and conduct of PFS in surgery. A synthesis and interpretation 
of quantitative and qualitative findings from the first two phases of work 
revealed that misunderstanding, sub-optimal design, conduct, reporting and 
consequent devaluation of PFS are perpetuated in a cyclical model of sub-
optimal practice amongst the surgical research community. The members of this 
surgical research community include methodologists, funders, academic 
institutions, journal editors and surgeons. Confounding issues further preventing 
optimal surgical PFS design and conduct, include the cultural challenges 
inherently surrounding surgical trials and a lack of targeted and accessible 
guidance. 
To address this model of sub-optimisation of PFS, a set of recommendations 
relevant to all key stakeholders was produced delineating the key approaches to 
optimise the design and conduct of future PFS. In addition, to operationalise 
these recommendations, a ‘Top Tips’ tool was developed for use by surgeons 
designing and conducting surgical PFS. At the foundation of all the 
recommendations made from this work, is the need for guidance that is 
specifically operationalised and accessible to surgery as an area of research with 
known complexity and challenges.  
This work has demonstrated that well-performed PFS, as part of a more 
streamlined and efficient research process, will enhance the success of surgical 
main trials and optimise the use of limited funding resources, therefore 
providing a solid foundation for the high-quality evidence base necessary to 
inform future surgical practice. Future work is directed towards developing 
consensus-based operationalised guidance for surgeons designing and 
conducting PFS, recognising that this guidance could also be more widely 
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Appendix II: Pilot and feasibility studies of surgical interventions funded by NIHR HTA and RfPB programmes between 2005 and 2015 details and outputs. 
 
NIHR project ID 
& CI 
Date funded to 
projected study end 
date 





















Oesophageal squamous cell cancer: chemoradiotherapy versus chemotherapy and surgery  
- a feasibility study 








A pilot randomised controlled single-blind trial of a collagen implant for the prevention of 
sternal wound infection in cardiac surgery. 








Optimum care for non-morbidly obese patients with type 2 diabetes: the perspectives of 
patients and clinicians on the role of bariatric surgery. 
✓   ✓  N/A  






Barts Health NHS 
Trust 
A randomised mixed methods pilot (phase II exploratory trial) of sacral and percutaneous 
tibial nerve stimulation for faecal incontinence ✓  
 






of North Midlands 
NHS Trust 
Perineal re-suturing versus expectant management following vaginal delivery 
complicated by a dehisced wound (PREVIEW): A pilot randomised controlled study. 





County Durham and 
Darlington NHS 
Foundation Trust 
Biodegradable stent in benign oesophageal stricture compared to standard balloon 
dilatation treatment 
✓   ✓  N/A ✓   




North Bristol NHS 
Trust 
A feasibility study for a randomised controlled trial to measure the impact of frenotomy in 





South Tees Hospitals 
NHS Foundation 
Trust 
A multicentre randomised controlled trial of spinal cord stimulation plus usual care vs. 
usual care alone in the management of refractory angina: A feasibility & pilot study. 






Royal Devon and 
Exeter NHS 
Foundation Trust 
Pilot investigation on the effect of the Memokath® 028 prostatic stent on Quality of Life in 
patients with urethral obstruction – a comparison with long term catheter 
✓    N/A ✓   








SHOULDER ARTHROPLASTY TRIAL A Randomised Controlled Trial of Total 
Resurfacing Versus Hemi Resurfacing in the Treatment of Primary arthritis of the 
Shoulder ✓  
  N/A 







of Leicester NHS 
Trust 
BRIDE (Barrett’s Randomised Intervention for Dysplasia by Endoscopy) - a feasibility 
study  
✓   ✓  N/A ✓  Qualitative interviews 








A pilot randomised controlled trial to compare the costs and effects of Conventional 
Implants with Mini Implants used to retain full lower DENTures (CIMI-DENT trial)  






Hospitals NHS Trust 
Randomised Controlled Trial of Pringle Manoeuvre versus Portal Vein Clamping in 
Patients undergoing Liver Resection for Colorectal Liver Metastasis – A Pilot Study ✓  
  N/A 








The feasibility of undertaking Appendicectomy to impact upon the Clinical Course of 
UlceRativE Colitis- The ACCURE Trial Feasibility study 









Onabotulinum toxin-A versus extended release tolterodine in the management of 
idiopathic overactive bladder in children: A pilot randomised controlled trial  








The Royal Marsden 
NHS Foundation 
Trust 
A phase II randomised feasibility study of Chemoresection and surgical management in 
Low rIsk non muscle invasive Bladder cancER (CALIBER) 






Hospitals NHS Trust 
A study to determine the feasibility and acceptability of conducting a phase III 
randomised controlled trial comparing   Stereotactic Ablative Radiotherapy (SABR) with 
surgery in patients with peripheral stage I non-small cell lung cancer (NSCLC) considered 
higher risk of complications from surgical resection. 
✓  ✓   N/A ✓   







Three-arm randomised trial of Arabin pessary, cervical cerclage and progesterone to 
prevent spontaneous preterm birth in an asymptomatic high risk cohort: a feasibility study 







A feasibility study with a crossover design to assess the diagnostic accuracy of acetic acid 
targeted biopsies versus non targeted biopsies (current practice) for detection of dysplasia 
during Barrett's surveillance: The ABBA study 









Does Laryngeal Reinnervation or Type I Thyroplasty give better voice results for patients 
with Unilateral Vocal Fold Paralysis (VOCALIST): a feasibility study 








The iBRA (implant Breast Reconstruction evAluation) study – A prospective multicentre 
cohort study to inform the feasibility and conduct a pragmatic randomised clinical trial 
comparing new techniques of implant-based breast beconstruction. 











Needle fasciotomy versus limited fasciectomy for the treatment of Dupuytren’s 
contractures of the fingers: a study which investigates the feasibility, acceptability and 
design of a multicentre randomised trial. 








KFORT – Knee Fix or Replacement Trial. A feasibility study comparing fixation vs 
replacement in elderly patients sustaining a distal femoral fracture 





Brighton and Sussex 
University Hospitals 
NHS Trust 
Palliative long-term abdominal drains versus repeated drainage in individuals with 
untreatable ascites due to advanced cirrhosis: a feasibility randomised controlled trial  









A phase II trial of endoscopic ultrasound-guided radiofrequency ablation of cystic 
tumours of the pancreas (RADIOCYST) 









University Court of 
the University of 
Aberdeen 
Effectiveness and cost-effectiveness of arthroscopic lavage in the treatment of 
osteoarthritis of the knee: a mixed methods study of the feasibility of conducting a surgical 
placebo controlled trial (the KORAL study) 







An External Pilot Study to test the Feasibility of a Randomised Controlled Trial comparing 
Eye Muscle Surgery against Active Monitoring for Childhood Intermittent Distance 
Exotropia 









The management of Otitis Media with Effusion in children with cleft palate (mOMEnt) 





The University of 
Nottingham 
Assessment of the feasibility and clinical value of further research to evaluate the 
management options for children with Down syndrome and otitis media 
✓    ✓   
Questionnaires 
Qualitative interviews, 










Feasibility study for a randomised controlled trial comparing hip arthroscopy with best 
conservative care for patients with femoro-acetabular impingement (UK FASHIoN) 











The relationship between refluxing pelvic veins and chronic pelvic pain in women 







University of Bristol Randomised Oesophagectomy: Minimally Invasive or Open, a feasibility study. The 













The Newcastle upon 
Tyne Hospitals NHS 
Trust 
A feasibility randomised controlled trial of pre-treatment gastrostomy tube versus oral 
feeding plus as-needed nasogastric tube feeding in patients undergoing chemoradiation 
for head and neck cancer (TUBE trial) 







The Newcastle upon 
Tyne Hospitals NHS 
Trust 
Willingness of clinicians and patients to randomise into a study comparing radio 
frequency ablation (RFA) with active surveillance, in the management of incidentally 
diagnosed small renal tumours: a feasibility study 





University of Oxford A randomised controlled trial of Partial prostate Ablation versus Radical prosTatectomy 
(PART) in intermediate risk unilateral clinically localised prostate cancer – a feasibility 
study 
✓    ✓  ✓  Qualitative 
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        Centre for Surgical Research 
University of Bristol 
School of Social and Community Medicine 
Canynge Hall 1.13, 39 Whatley Road, 
Clifton, Bristol. BS8 2PS 
Phone: 0117 92 87386 
Email: katherine.fairhurst@bristol.ac.uk 
 
29th August 2017 
 




We write to invite you to take part in our research study and enclose details of this 
in the participant information sheet.  The study forms part of Katherine Fairhurst’s 
PhD thesis titled ‘Optimising the design and evaluation of pilot work to inform 
more efficient RCTs in surgery’ and supervised by Dr Kerry Avery and Professor 
Jane Blazeby.   
The study aims to explore the experience and opinions of individuals working in 
the field of designing, conducting or funding pilot and feasibility work for surgical 
trials and to ultimately make recommendations for the optimal use of such pilot 
work.  Given your experience and expertise, we would hugely value your 
participation in this study and hope that you will agree to take part. 




Miss Katherine Fairhurst   Professor Jane Blazeby   Dr Kerry Avery 
MRC Clinical Research Training Fellow  Professor of Surgery   Research Fellow 
MRC ConDucT - II Hub PhD Student  Director of the MRC ConDucT II Hub 
Specialist Training Registrar General Surgery  Director of the Bristol RCS Trials Centre 
 












Appendix 3: Participant Information Sheet A 
 




We would like to invite you to take part in our research study as titled above. Before you decide we would 
like you to understand why the research is being done and what it would involve for you. Please feel free to 
talk to others about the study if you wish and/or ask us if there is anything that is not clear.  
 
What is the purpose of the study?  
We wish to explore opinions, perceptions, experiences and attitudes of individuals involved the field of 
designing, conducting or funding pilot and feasibility work for surgical trials.  The ultimate aim is to form 
recommendations for the optimal use of such pilot and feasibility work. 
 
Why have I been invited?  
You are being asked to participate because you have experience in the field of designing, conducting or 
funding pilot and feasibility work for surgical trials and we would value your expert opinion and 
contribution. 
 
Do I have to take part?  
Taking part in this study is entirely voluntary.  This information sheet describes the study and what it 
involves.  If you are interested in participating in this study please get in touch via the contact details at the 
end of this information sheet.  We may contact you again if we don’t hear from you to follow up on whether 
you wish to participate.  If you agree to take part, we will ask you to sign a consent form.  You are free to 
withdraw at any time, without giving a reason. 
 
What will happen to me if I take part and what will I have to do?  
The initial part of the study involves an interview with the researcher (lasting 30-60 minutes).  The interview 
will be audio recorded and you will be asked questions about your experience with surgical pilot and 
feasibility work and your opinions about its conduct.  The researcher will travel to meet you at convenient 
location to conduct this interview.  We may then invite you to take part in a consensus process and/or 
meeting.  We will give you plenty of notice about timings for this.  If you take part in the consensus process, 
this may include, for example, questionnaires, surveys and group discussions to contribute to forming 
consensus recommendations for the design of pilot and feasibility work for surgical trials. 
 
Expenses and payments 
The researcher will make arrangements to travel to meet/speak with you at a convenient time and location to 
conduct the interview. Travel expenses incurred getting to a consensus meeting will be payable following 
attendance and refreshments will be provided. 
 
What are the possible disadvantages and risks of taking part? 
There are no anticipated risks associated with taking part in this study. 
 
What are the possible benefits of taking part?  
We hope that the results of this study will guide the future design and conduct of pilot and feasibility work 
for surgical trials.  This will benefit the surgical trials community as a whole, and will ultimately also benefit 
patients. 
 
What will happen if I don’t want to carry on with the study?  
You are free to withdraw from participating in the study without giving a reason.  If the consensus meeting 
has taken place, we may be unable to remove you voice from the tape, but we will remove any data deduced 





Will my taking part in this study be kept confidential?  
Data will be collected through audio-recordings and notes taken during the interviews.  All data will be 
stored under the provisions of the National Data Protection Regulations and the University of Bristol 
requirements. Participants’ contact details will be stored securely in a restricted access folder on password 
protected computers at the School of Social and Community Medicine, University of Bristol. The audio-
recordings and interview data will be created using an encrypted digital recorder and the raw data will only 
be available to members of the study team. Interview data will be stored using coded study numbers to 
ensure that individuals cannot be identified from the file name alone. The hard copies of the consent forms 
and audio-recordings will be kept securely by the University of Bristol in a locked filing cabinet. They will be 
kept up to 10 years after termination of the study and then disposed of securely.  Access to all data will be 
restricted to the project lead (Katherine Fairhurst) and the supervisors (Dr Kerry Avery, Professor Jane 
Blazeby, Miss Shelley Potter, Professor Carrol Gamble). Data from the study, excluding any personal data, 
may be seen and used by other researchers, for ethically approved research projects, on the understanding 
that confidentiality will be maintained. 
 
What will happen to the results of the research study? 
The results of the study will be disseminated through the resulting PhD thesis and via normal academic 
channels including for example, journal publication, presentation at scientific/academic 
meetings/conferences and talks to academic/research audiences.  Participants will be anonymised and every 
effort made to ensure they will not be identifiable in any written or verbal reports from the research. In 
situations where participants may potentially be identifiable, their agreement will be gained for their data to 
be used in publication/presentation. When disseminating findings, no names of individuals or places will 
appear in any form of publication.  
 
Who is organising and funding the research?  
Katherine Fairhurst is the lead researcher who is an MRC Clinical Research Fellow.  This research forms part 
of a PhD thesis, supervised by Dr Kerry Avery, Professor Jane Blazeby, Miss Shelley Potter and Professor 
Carrol Gamble at the University of Bristol.  The research is funded by the MRC Network of Hubs for Trials 
Methodology Research (MRC HTMR). 
 
Who has reviewed the study? 
The Faculty of Health Sciences Research Ethics Committee at the University of Bristol has reviewed and 
approved this research. 
 
If you would like to take part in this study, have any further questions or require further information 
please do not hesitate to contact: 
 
Miss Katherine Fairhurst 
MRC Clinical Research Fellow, MRC ConDuCT-II Hub PhD Student, General Surgery Registrar 
Centre for Surgical Research, School of Social and Community Medicine, University of Bristol, Room 1.13, 
Canynge Hall, 39 Whatley Road, Bristol, BS8 2PS. 
Tel: 0117 92 87386 
Email: katherine.fairhurst@bristol.ac.uk  
 










Participant ID Number: 
Appendix 1: Semi structured interview topic guide 
Exploring Perceptions and Experiences of Pilot work for Surgical Trials: A Qualitative Research Study 
(PEPSTAR) 
 
1. Introduction     2. General Information 
Your name & role     Current & previous roles 
Purpose and aims of the study   e.g. surgeon, university, editor, funder, REC, trial team etc 
Test audio recorder   Specific areas of research interest 
Explain will record interview 
Written consent 
 
3. Topic areas (Introduce each area as necessary) 
A) General        B) Importance 
What is (you/in general) pilot work (PW)?  How important is PW? 
What is (you/in general) feasibility work (FW)?  Why is it important? 
What role does it have?  Any examples of how/why important 
What should its role be?    
What issues should PW/FW consider? 
Generic? (E.g. recruitment, retention, eligibility, protocol adherence, outcome assessment – selection/data 
collection & quality) 
Specific to surgery? (E.g. developing innovation, standardisation, leaning curves, quality assurance, co–
interventions, preferences/acceptability, blinding) 
When would you do internal/external pilot?   
 
C) Experience      E) Challenges/difficulties  
Examples of specific studies    What challenges in general with PW/FW?  
Why i.e. purpose/rationale    Why are they challenges?   
Objectives at start – did they change?  Examples of specific challenges/difficulties   
Why internal/external/both?    What were these? 
Participant’s role      Why did they occur?    
Design       How dealt with? 
 How design decided? By who?    Learning points? 
 Did design change?      Do anything differently? 
  How? Why?     Any remaining uncertainties about a main trial? 
Conduct          
Discussions with funders    F) Essential components 
 When? Why? Outcome?   Any key components to the design? 
        Progression criteria?   
D) Impact      Any key processes for conduct?  
On the main trial      Who needs to be involved?  
Design/Conduct/Funding            
              
 
4. Closing the interview 
Thank them for their time - Any further questions/comments? 








▪ What do you/other people think PW/FW is?  
▪ Can you expand on the meanings of the terms IP/EP and NRFW? 
▪ What role should PW/FW have in the context of trial design? 
▪ What role does PW/FW actually have currently? 
▪ What sort of questions (about whether a MT is possible) should PW/FW be answering? 
OR 
▪ What is important for PW/FW to show before you go ahead with a MT? 
▪ How would you choose when to do an internal or external pilot? 
B) Importance 
▪ Do you think it is important to always do PW/FW before a MT? 
o Why do you think it is important? 
o Do you have any examples of when PW/FW might not be necessary? 
▪ Are you able to give any examples of how important PW/FW is from your own/others work? 
C) Experience 
▪ Could we talk about some of your own experiences of designing/conducting/funding PW/FW? 
o What was the rationale for doing X study? 
o Why was it important to do a pilot/feasibility study? 
o Why did you choose to do an internal/external pilot? 
▪ How was the design of X study decided? 
o Who was involved in the design? 
o Did the design change in the course of the study? 
o What happened? 
o Why did the design change? 
▪ Could you describe any positive or negative experiences you had with funding bodies in the 
context of pilot/feasibility studies? 
o Any difficulties getting funding for X study? 
o Why do you think there were difficulties? 
D) Impact 
▪ How did the PW (IP/EP)/FW impact on the design of the MT? 
▪ How did the PW (IP/EP)/FW impact on the conduct of the MT? 
▪ Did the PW (IP/EP)/FW have any impact on getting/not getting funding for the MT? 
E) Challenges 
▪ We have discussed some of these already, but could you summarise in your opinion, what you 
think the main challenges of doing (designing/conducting) PW/FW are? 
o Why do you think there are these challenges? 
o How did you/the trial team deal with these challenges? 
o Would you do anything differently if you were planning the PW/FW study again? 
▪ Were there any remaining uncertainties about the MT once the PW/FW was completed? 
 
F) Essential components 
▪ Again we have talked about some important components to PW/FW already, but could you 
summarise/comment on what in your opinion, you think the key components to designing 
successful pilot/feasibility studies are? 
▪ Do you have any experience of determining progression criteria for PW? 
o What do you think these should be? What are their purpose? 
o How should they be decided? How are they decided in your experience? 
o Do you have examples where an IP has progressed to a MT with PC being met/not 
met? 
o Do you think there are any specific challenges around selecting and using PC for IP 
studies? 









Participant ID Number: 
Appendix 1: Semi structured interview topic guide 
Exploring Perceptions and Experiences of Pilot work for Surgical Trials: A Qualitative Research Study 
(PEPSTAR) 
 
1. Introduction     2. General Information 
Your name & role     Current & previous roles 
Purpose and aims of the study   e.g. surgeon, university, editor, funder, REC, trial team etc 
Test audio recorder    Specific areas of research interest 
Explain will record interview 
Written consent 
 
3. Topic areas (Introduce each area as necessary) 
A) General       B) Importance 
What is (you/in general) PW/FW?   How important is PW? 
What is (you/in general) IP/EP/NRFW?  Why is it important? 
When would you do internal/external pilot?  Any examples of how/why important 
What role does it have? How impacts on design/conduct/funding 
What should its role be?    
What issues should PW/FW consider? 
Generic? (E.g. recruitment, retention, eligibility, protocol adherence, outcome assessment – selection/data collection & 
quality) 
Specific to surgery? (E.g. developing innovation, standardisation, leaning curves, quality assurance, co–interventions, 
preferences/acceptability, blinding) 
Progression criteria? 
What/how decided/always met?/challenges 
 
C) Experience     D) Challenges/difficulties  
Examples of specific studies   What challenges in general with PW/FW? 
Why i.e. purpose/rationale   Why are they challenges?  
Objectives at start – did they change? Examples of specific challenges/difficulties 
Why internal/external/both?   What were these? Methodological/cultural? 
Participant’s role     Why did they occur?    
Design      How dealt with? 
 How design decided? By who?   Learning points? 
 Did design change?     Do anything differently? 
  How? Why?    Any remaining uncertainties about a main trial? 
Conduct          
Discussions with funders   E) Essential components 
 When? Why? Outcome?  Any key components to the design? (Cost effectiveness?) 
      Any key processes for conduct?  
      Who needs to be involved?      
  
4. Closing the interview 
Thank them for their time - Any further questions/comments? 









▪ What do you/other people think PW/FW is?  
▪ Can you expand on the meanings of the terms IP/EP and NRFW? 
▪ How would you choose when to do an internal or external pilot? 
▪ What role should PW/FW have in the context of trial design? 
▪ What role does PW/FW have currently? 
▪ What are the reasons for doing PW/FW? 
OR What is important for PW/FW to show before you go ahead with a MT? 
OR What sort of questions (about whether a MT is possible) should PW/FW be answering? 
▪ Where does your understanding of PAFS come from? 
▪ Are you aware of any guidance on the design and conduct of PAFS? 
o What guidance would you find helpful? Who should create/endorse that guidance? 
▪ Do you have any experience of determining progression criteria for PW? 
o What do you think these should be? What are their purpose? 
o How should they be decided? How are they decided in your experience? 
o Do you have examples where an IP has progressed to a MT with PC being met/not 
met? 
o Do you think there are any specific challenges around selecting and using PC for IP 
studies? 
 
G) Importance & Impact 
▪ Do you think it is important to always do PW/FW before a MT? 
o Why do you think it is important? Examples of importance is from your own/others 
work? 
o When might PW/FW might not be necessary? Examples? 
o Do you think a PW/FW showing a MT is not viable is valuable? 
▪ How does PW/FW impact on MT design/conduct/funding? 
▪ Should PAFS be published? Why? 
 
H) Experience 
▪ Could we talk about some of your own experiences of designing/conducting/funding PW/FW? 
o What was the rationale for doing X study? 
o Why did you choose to do an internal/external pilot? 
▪ How was the design of X study decided? 
o Who was involved in the design? 
o Did the design change during the study? Why? 
▪ Could you describe any positive or negative experiences you had with funding bodies in the 
context of pilot/feasibility studies? 
o Any difficulties getting funding for X study? 
o Why do you think there were difficulties? 
 
I) Challenges 
▪ We have discussed some of these already, but could you summarise in your opinion, what you 
think the main challenges of doing (designing/conducting) PW/FW are? 
o Methodological/cultural? 
o Why do you think there are these challenges? 
o How did you/the trial team deal with these challenges? 
o Would you do anything differently if you were planning the PW/FW study again? 
▪ Were there any remaining uncertainties about the MT once the PW/FW was completed? 
 
J) Essential components 
▪ We have talked about some important components to PW/FW already, but could you 
summarise/comment on what in your opinion, you think the key components to designing 
successful pilot/feasibility studies are?  
▪ Do you think it is important to consider cost effectiveness in PW/FW? 
▪ Do you think there are any key processes/personnel for the conduct of PW/FW? 
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Participant ID Number: 
Appendix 6: CONSENT FORM A for study participants 
Exploring Perceptions and Experiences of Pilot work for Surgical Trials: A Qualitative Research Study 
(PEPSTAR) 
 
Name of Researcher: Katherine Fairhurst 
Contact details: katherine.fairhurst@bristol.ac.uk, 0117 92 87386  
Please initial all 
boxes 
1. I confirm that I have read and understand the participant information sheet A dated August 2016 
version 1.0 for the above study.  I have had the opportunity to consider the information, ask questions 
and have had these answered satisfactorily.   
2. I understand that my participation is voluntary and that I am free to withdraw at any time without 
giving any reason. I understand that I can decline from answering a question during the interview and 
that I am free to withdraw my consent for data to be used at a later date if I wish. 
3. I understand that I will be interviewed, that the interview will be audio-recorded and that notes will be 
documented by the researcher.  
4. I understand that all audio recordings, transcripts and copies of study documents will be stored on a 
secure computer and/or in a locked filing cabinet at the University of Bristol.  
5. I understand that all data collected will be treated as confidential and that where possible I will be 
anonymous in written reports from the research.  In situations where I might potentially be identified, 
the research team will contact me to secure my agreement for a data extract (e.g. a verbatim quote) to be 
used. 
6. I understand that only members of the research team will have access to my personal data and that data 
from the study, excluding my personal data, may be seen and used by other researchers, for ethically 
approved research projects, on the understanding that confidentiality will be maintained. 
 
7. I agree to take part in the above study. 
 
8. I agree to being contacted about my participation in a consensus process in the future.   
 
 
            
Name of participant  Date    Signature 
 
            
Name of person taking consent Date    Signature  
 
 239 
Appendix VIII Published paper in the British Journal of Surgery 
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